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Abstract 
G protein-coupled receptors (GPCRs) are often described as ‘gate-keepers’ of the 
eukaryotic cell and their roles primarily involve translating extra-cellular stimuli via G-
protein coupling and intracellular signalling to govern various physiological responses.  
These functional parameters are wide ranging and include the modulation of visual 
sensory organs, to the control of vasoreactivity and heart rate. Importantly, their flexible 
architecture can facilitate small molecule interaction within a ‘binding-pocket’ and GPCR 
research often focuses on this relationship to identify and design novel and effective 
ligands to manipulate GPCR activation and signalling.  
GPR35 is a poorly characterised, Class A GPCR and despite reports of two potential 
endogenous activators; kynurenic acid (KYNA) and lysophosphatidic acid (LPA) in recent 
years, it is still widely acknowledged as an ‘orphaned’ GPCR. This is reflected by the 
propensity of its ligands, both endogenous and synthetic, to demonstrate extreme species 
orthologue-selective properties.  Despite this, investigators have highlighted various roles 
for GPR35 relating to pain, inflammation, hypertension and heart failure, and 
investigations have suggested that activation of GPR35 leads to a selective coupling of 
Gα13, a G-protein understood to mediate Rho A and ROCK 1/2 signalling. However, a lack 
of functional ligand pairs has hampered further research to examine a role for GPR35 and 
subsequent Gα13 signalling in these disease models. In this study, we have characterised 
a series of highly-potent, synthetic ligands at human, rat and mouse orthologues of 
GPR35, revealing that GPR35 agonist, pamoic acid and antagonists, CID-2745687 and 
ML-145, are highly potent and selective for the human orthologue of GPR35. This has 
provided us with the opportunity to assess a functional role for GPR35 within a 
cardiovascular disease setting using functional ligand pairs in cells of a human origin, for 
the first time.  
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Vascular smooth muscle cell (VSMC) migration and proliferation are central to neointima 
formation in vein graft failure. Despite a detailed understanding of VSMC migration and 
proliferation mechanisms, there are no pharmacological interventions which effectively 
prevent vein graft failure through intimal occlusion. In this study, we demonstrated that 
primary vascular cells expressed robustly detectable levels of GPR35, and these were 
comparable to those demonstrated in the colon, which has been previously reported to 
highly express GPR35. Human GPR35 is potently activated by the selective agonist 
pamoic acid and reference ligand zaprinast and blocked by antagonists CID-2745687 and 
ML-145. Following exposure of VSMC to pamoic acid or zaprinast, cell migration was 
enhanced and these effects were blocked by co-incubation with CID-2745687 or ML-145. 
Pamoic acid induced HSV SMC migration was also blocked in the presence of two distinct 
Rho A pathway inhibitors, Y-16 and Y-27632. Activation of this pathway was also reflected 
by remodelling of the cytoskeletal architecture in HSV SMCs to significantly elongate the 
cell and promote a contractile, migratory phenotype following pamoic acid stimulation and 
this effect was also blocked following co-administration with either antagonist. Additionally, 
we also demonstrated that following exposure to pamoic acid or zaprinast, human 
saphenous vein endothelial cell (HSV EC) integrity and proliferation were significantly 
improved and this was blocked following co-administration with either antagonist, 
suggesting a protective role for GPR35 in the vascular endothelium.  
Results from a previous study demonstrated that lack of GPR35 expression resulted in an 
elevation in systolic blood pressure (SBP) by up to 37.5mmHg in mice. The recent 
identification of mast-cell stabilising compounds as highly potent agonists at GPR35 
provided the opportunity to pharmacologically target GPR35 within a rodent model of 
hypertension. Therefore, we also aimed to test if pharmacological manipulation of GPR35 
via stimulation with the novel, rodent selective agonist amlexanox, modulated blood 
pressure and end-organ related damage in 6-12 weeks of age stroke prone 
spontaneously hypertensive rats (SHRSPs). Radiotelemetry acquisition of haemodynamic 
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properties highlighted that pharmacological agonism of GPR35 exacerbated hypertension 
and end-organ damage in the SHRSP and this was evident following an elevation in SBP 
by 20mmHg throughout the trial.  Moreover, quantification of heart mass and 
cardiomyocyte size revealed that GPR35 agonism induced cardiac hypertrophy.  Collagen 
staining revealed enhanced renal fibrosis in both the interstitial and perivascular regions of 
the kidney from amlexanox treated animals, compared to vehicle controls.  Additionally, 
large vessel myography highlighted that endothelium-dependent vasorelaxation was 
reduced by 20% in amlexanox treated SHRSPs.  Fundamentally, these results suggest 
that GPR35 is involved in regulating vascular tone and we hypothesise that this may 
involve the Gα13-Rho A-ROCK1/2 signalling pathway demonstrated to mediate a 
contractile, migratory phenotype in human primary VSMCs. 
Taking these data together, the results suggest that GPR35 antagonists might be of 
clinical use to therapeutically target and inhibit activation of GPR35 in the setting of 
vascular remodelling during acute vascular injury, and hypertension and its related end-
organ damage.  
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1 Introduction 
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1.1 G Protein-Coupled Receptors 
Since their discovery in the early twentieth century, G protein-coupled receptors (GPCRs) 
have become the most extensively studied class of cellular receptors.  Comprising a 
‘super-family’ with an extensive array of sub-classifications, all GPCRs share a common 
single polypeptide, seven-transmembrane domain structure and are therefore also termed 
seven-transmembrane domain receptors (7TMRs).  Often described as ‘gate-keepers’ of 
the eukaryotic cell, members of the GPCR superfamily are activated by a diverse range of 
endogenous ligands which include neurotransmitters, hormones, and environmental 
stimuli such as light, smell and taste as well as synthetic small molecules (Kenakin, 2004).   
Upon activation, the GPCR-ligand binding complex undergoes marked conformational 
changes to facilitate coupling to a heterotrimeric G-protein, which in turn, produces 
physiological effects via regulation of a broad group of intracellular signalling pathways. 
Pharmacological manipulation of GPCRs can provide the means to alter GPCR 
regulation, activation and downstream signalling in health and disease and, consequently, 
these receptors are widely considered as excellent therapeutic targets in a variety of 
pathological conditions.  It is, therefore, unsurprising that GPCR research remains an 
integral aspect of efforts in translational medicine and, to this end, there are many 
examples of ‘druggable’ GPCRs for which ligands that either block or activate the receptor 
are widely used in clinical medicine. Examples of these include valsartan, an antagonist of 
the angiotensin II-type 1 receptor (AT1R) which is utilised in the treatment of hypertension, 
coronary artery disease and heart failure and a range of β2-adrenoceptor (β2AR) ligands 
with broad application including relieving acute symptoms of asthma and chronic 
obstructive pulmonary disease as well as heart failure (DeWire and Violin, 2011).   
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1.1.1 GPCR structure 
In their inactive state GPCRs are routinely situated within the lipid-rich plasma membrane 
and span the surface of virtually all eukaryotic cells.  These surroundings provide 
structural stability for the relatively hydrophobic transmembrane domains (TMDs) of 
GPCRs. The seven helices are linked via extra and intra-cellular loops (E/ ICL) spanning 
the cell membrane and both the extracellular domains and the architectural organisation 
of the transmembrane helices provide flexible pockets into which GPCR ligands can bind 
(Kobilka, 2007).   
The core domain of the seven transmembrane helices and linking intra- and extra-cellular 
loops is flanked by an extracellular amino (N)-terminus and an intracellular carboxyl (C)-
terminus.  Sequence alignments show the third intracellular loop between the fifth and 
sixth TMDs, along with the C and N-termini, are the most variable regions (Kobilka, 2007). 
GPCR termini can vary in both length and function and are often indicative of their GPCR 
classification, as discussed later.   
Analysis of GPCR protein structure has also highlighted a number of highly conserved 
regions within the TMDs and, as anticipated from such conservation, these regions play 
key roles in receptor structure and function (Teller et al., 2001). Perhaps the best known 
of these is the key ‘DRY’ motif. This amino acid sequence, which consists of glutamic 
acid/aspartic acid–arginine–tyrosine (i.e. E/DRY), is located at the interface between the 
bottom of the third TMD and second ICL of the ‘rhodopsin-like’ family of GPCRs 
(Ballesteros et al., 1998).  Due to its highly conserved nature, researchers have examined 
its structural and functional role within GPCRs and evidence is strongly suggestive of 
critical involvement in the governance of conformational stability, constitutive activity and 
G-protein coupling profiles (Alewijnse et al., 2000, Rovati et al., 2007).  In recent years 
rapid advances in the ability to stabilise and obtain atomic level X-ray structures of 
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individual GPCRs has resulted in a previously unimaginable increase in understanding of 
the organisational structure of members of the GPCR family (see later). 
1.1.2 GPCR classification 
GPCRs are the largest family of cell surface receptors, with more than 800 identified 
following the completion of the human genome project in 2003 (Fredriksson et al., 2003).  
Based on homology and potential ligand groups, they are organised into 5 broad sub-
families, ‘Rhodopsin-like/ Class A’, ‘Secretin’, ‘Glutamate’, ‘Adhesion’ and ‘Frizzled’ 
(Fredriksson et al., 2003, Krishnan et al., 2012) – please see Figure 1-1 for a 
representative diagram of the 5 sub-families and a range of representative GPCRs which 
have been clinically targeted or where atomic level structures have been solved. 
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Figure 1-1. The human GPCR superfamily. 
Representative diagram based upon the phylogenetic analysis of the broad superfamily of 
GPCRs which are sub-divided into 5 distinct categories relating to their homogeneity 
within the 7TMD region.  The grey branch represents the ‘Rhodopsin-like/ Class A family’, 
composed of 701 GPCRs it is further categorised into 4 groups; α, β, γ and δ.  The yellow 
branch relates to the 15 ‘Secretin/ Class B’ receptors.  The ‘Glutamate/ Class C’ receptors 
constitute a family of 15 which are denoted by the blue tree branches.  The orange tree 
branch relates to the ‘Adhesion’ receptors, of which there are 24 and finally, the ‘Frizzled’ 
family of 24 are represented by the yellow branches.  Exemplar receptors are highlighted; 
GPR35, GPR55, Bal 1-3 - brain-specific angiogenesis inhibitor 1-3, EMR 1-4 - EGF-like 
module-containing mucin-like hormone receptor 1-4, GHRHR - growth-hormone-releasing 
hormone receptor, GLP1R/2R - glucagon-like peptide 1/2 receptor, mGluR1-8 - 
metabotropic glutamate receptor 1-8 and FZD1-10 – frizzled receptor 1-10. GPCRs 
highlighted in pink are exemplar GPCRs with atomically solved structures; βAR1/ βAR2 – 
β1/ β2 adronergic receptor, RHO – rhodopsin receptor, A2aR – adenosine A2a receptor, H1R 
– histamine1 receptor, CXCR4 – CXC chemokine receptor-4 and S1P-1 - sphingosine-
1-phosphate receptor 1 (Diagram adapted from (Stevens et al., 2013)). 
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The ‘rhodopsin-like/ class A’ GPCRs comprise the largest family (87.6%) and have varied 
agonists and physiological roles (Fredriksson et al., 2003). This family is readily 
identifiable via their short extracellular N-termini and ligand binding pockets that lie 
predominantly within the TMD regions (Nordstrom et al., 2009).  Due to the large number 
of members, the rhodopsin-like family are further sub-categorised into 4 distinct groups; α, 
β, γ and δ, based upon phylogenetic similarities. The second group of receptors constitute 
the ‘secretin’ or ‘class B’ receptors and comprise a small family of some 15 members. 
Secretin family receptors are regulated primarily by large peptide hormones which 
interact, at least in substantial part, with the extracellular N-terminal domain and 
importantly, contain hormone binding domains (HBD) (Nordstrom et al., 2009).  In recent 
times, the first atomic level structures of class B receptor family members have been 
described (Hollenstein et al., 2013, Siu et al., 2013), providing a much more detailed 
insight into the basis of recognition of such peptide hormone ligands. This includes the 
identification of novel orthosteric binding pockets located deep within TMD regions 
(Hollenstein et al., 2014).  Of a similar size to the ‘secretin’ receptor family, the ‘glutamate’ 
or ‘class C’ receptors also constitute a small group of some 15 members. Unlike the class 
A receptors, the N-terminal domain of members of this group consists of a large ‘venus 
flytrap’ region, and the members of the family exist as constitutive dimers, an 
organisational feature which is intrinsic to their function. Although to date no atomic level 
structure of a full length ‘class C’ receptor has been reported this has been achieved  
individually for both the extracellular domain (Kunishima et al., 2000, Muto et al., 2007) 
and the 7TMD  segments (Wu et al., 2014) and, by linking these, models of the mode of 
ligand activation are well established (Chun et al., 2012, Yin and Niswender, 2014).  The 
‘Adhesion’ receptors are a family of 24 members, and hence they constitute the second 
largest family of GPCRs (Yona et al., 2008).  Although similar to the ‘Secretin’ family, they 
are distinguished by markedly extended N-termini which can be structurally diverse 
(Lagerstrom and Schioth, 2008).  However, they often containing common structural 
domains which are involved in cellular adhesion and protein interactions for downstream 
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signalling; these are present in epidermal growth factor (EGF)-like, lectin-like and 
immunoglobulin (Ig) secretin GPCRs (Yona et al., 2008). Finally, the ‘Frizzled’ sub-
category is also a family of some 20 receptors.  These are primarily activated by Wnt 
glycoproteins which bind to cysteine-rich, extracellular domains on the GPCR (Bjarnadottir 
et al., 2006).  
This method of comparative sequence homology is widely employed.  However, recent 
protocols to classify GPCR sub-families have taken other approaches.  For example, 
when categorising receptor families, some approaches have begun to consider a 
combination of structural homology, ligand specificity and physiochemical hierarchy 
(Klabunde, 2007, Gao et al., 2013). The integration of these approaches may be useful in 
exploring the evolutionary history and conserved nature of ancient receptors and 
successive relatives (Nordstrom et al., 2009, Krishnan et al., 2012).  Indeed, the quest for 
an accurate system to define the molecular signatures of GPCR families is becoming 
more evident, particularly as the structural details of a greater number of GPCRs becomes 
available (Venkatakrishnan et al., 2013). 
 
1.1.3 GPCR crystallisation 
In order to better understand GPCR structure-function relationships, immense efforts have 
focused upon obtaining atomic level structures of GPCRs in both inactive (R) and active 
(R*) states. These structures provide a wealth of information relating to the key residues 
which are involved in mediating GPCR flexibility and thereby facilitate the conformational 
changes which occur during ligand binding, receptor activation and subsequent G-protein 
coupling (Nakamura et al., 2013).   
The first GPCR crystal structure, bovine Rhodopsin, was solved over a decade ago 
(Palczewski et al., 2000) and following this an increasing stream of structural information 
has become available for class A receptors (Stevens et al., 2013).  This includes the high 
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resolution structural identity of the β2AR in 2007 and the chemokine receptor, CXCR4 in 
2010 (Rasmussen et al., 2007, Wu et al., 2010).  
Despite this progress, the conformational instability of an activated GPCR within a lipid 
rich, hydrophobic membrane hindered many early attempts to capture the GPCR in an 
active form (Kobilka, 2007, Kobilka and Schertler, 2008). This improved following 
development of highly specific antibodies and GPCR stabilising ligands (Maeda and 
Schertler, 2013).  In 2011, details of the β2AR, A2A-adenosine and rhodopsin receptors in 
agonist-bound, active states were published, the first such descriptions (Rasmussen et al., 
2011, Xu et al., 2011, Standfuss et al., 2011).  These data provided much sought after 
comparative structural insights relating to the basal conformational status, ligand 
specificity and conserved domains which are essential in potentiating the R* state of 
rhodopsin-like/ class A GPCRs (Maeda and Schertler, 2013, Costanzi, 2013). Most 
notably, the leading collaborators in this field - Professors Brian Kobilka and Robert 
Lefkowitz, were jointly awarded the Nobel Prize in Chemistry in 2012 for their outstanding 
contributions to GPCR research.  
 
1.2 GPCR signalling 
1.2.1 G-proteins  
The fundamental roles of GPCRs are to regulate various physiological signalling 
processes involved in maintaining homeostasis and to mobilise responses to pathological 
stimuli within the extracellular environment. Following ligand binding, GPCRs undergo 
unique conformational changes which promote their coupling to heterotrimeric guanine 
nucleotide binding proteins (G-proteins) and it is by these means that they can regulate 
intracellular signalling pathways in canonical fashion (Milligan and Kostenis, 2006).    
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G-proteins are freely distributed across eukaryotic cell membranes and may be 
preferentially expressed within cells and tissues depending upon their physiological 
relevance and functional role (Wettschureck and Offermanns, 2005).  For effective 
activation by GPCRs, they are required to be closely anchored to the plasma membrane 
and this is facilitated via covalent lipid modifications and additional plasma membrane 
targeting factors, including palmitoylation and/or myristoylation (Marrari et al., 2007).  In 
an inactive state, G-proteins exist as a single, heterotrimeric unit comprising three sub-
components; Gα, Gβ and Gγ (Milligan and Kostenis, 2006).  It is well established that 
upon GPCR coupling and activation, the newly GTP bound Gα subunit dissociates from 
the Gβγ complex following the release of guanosine diphosphate (GDP) and its exchange 
for guanosine triphosphate (GTP).  This activation process is accelerated by guanine 
nucleotide exchange factors (GEFs), with GPCRs being key examples of such GEFs, and 
decelerated by GTPase activating proteins (GAPs) such as Regulators of G-protein 
signalling (RGS) proteins (Suzuki et al., 2009). Inactivation is associated with hydrolysis of 
the terminal phosphate of GTP, catalysed by the GTPase activity intrinsic to the Gα 
subunit and this allows re-association with the Gβγ complex. Figure 1-2 displays a 
schematic representation of GPCR activation and G-protein coupling mechanisms. 
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1. A GPCR and a heterotrimeric G-protein unit in the inactive state with bound GDP and 
anchored to the lipid plasma membrane. 2. GPCR and G-protein complexes in the active 
state.  Guanine nucleotide exchange factors (GEF) promote the dissociation of GDP.  
Following receptor activation, conformational changes couple a select Gα subunit; Gα12/13, 
Gαq/11, Gαi/o or Gαs.  The newly GTP bound Gα subunit dissociates from the Gβγ complex, 
by exchanging guanosine diphosphate (GDP) for guanosine triphosphate (GTP).  Gα and 
Gβγ complexes may then initiate distinct, intracellular signalling pathways. Two enzymes 
frequently linked to Gβγ-mediated control of activity are phosphatidylinositol-3 kinase 
(PI3K) and various isoforms of phospholipase-C β (PLCβ).  This process is terminated via 
the GTPase activating proteins (GAP) which serve to promote the hydrolysis of the active 
GTP-Gα subunit. 
Figure 1-2. GPCR-G-protein coupling and activation.  
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1.2.1.1 G-protein families 
In a similar fashion to GPCRs, G-proteins also comprise a collection of families and sub-
families.  In mammals, Gα proteins are encoded by 21 genes, categorised within 4 broad 
signalling families primarily based upon their sequence homology and central functional 
roles (Cabrera-Vera et al., 2003). Collectively, Gα
 
protein signalling families have been 
well characterised, consisting of; Gαs (Gs(S) aα, Gs(L)aα and Golf α), Gαi/o (Gi1-3 α, GoA/Baα, Gz 
α, Gt1/2 α and Gg α), Gαq/11 (Gq α, G11 α, G14 α and G15/16 α) and Gα12/13  (G12 α and G13 α) 
(Cabrera-Vera et al., 2003, Kostenis et al., 2005).   
There are 5 genes which code for Gβ subunits 1-5,
 
and with the exception of Gβ5, these 
subtypes share close homology, ranging between 79-90% (Khan et al., 2013). 
Contrastingly, Gγ subunits are more diverse in sequence and are coded by 12 genes, 
Gγ(1-12).  The role of specific isoforms in ‘active’ Gβγ complexes is comparatively less well 
understood than the Gα family.  However, the diverse range of Gβγ subunits is also highly 
conserved amongst species (Khan et al., 2013) and research in this area of G-protein 
signalling is steadily progressing (Garland, 2013). 
1.2.1.1.1 The Gαs family 
The Gs family of α-subunits are, with the exception of Golf,  ubiquitously expressed within 
human tissue (Offermanns, 2003).  Their central role and effectors are well characterised, 
given that the nomenclature of the Gs family signifies their ability to stimulate adenylyl 
cyclases – a family of enzymes responsible for catalysing production of 3’5’ cyclic-AMP 
from ATP (Kostenis et al., 2005).  Hence, via activation of isoforms of protein kinase A 
(PKA) or EPAC (exchange proteins activated by cAMP), a vast range of proteins are 
phosphorylated or transcriptionally regulated, respectively (McCormick and Baillie, 2014).  
These actions range from the regulation of endothelial gap-junctions in the maintenance 
of vascular permeability and integrity via EPAC-induced Rap signalling and subsequent E-
cadherin regulation (Gloerich and Bos, 2010), to the control of voltage gated Ca2+ 
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sensitive Ryanodine receptors (RyR) via PKA phosphorylation in excitation-contraction 
coupling in functional cardiomyocytes (Marx et al., 2000). 
Many class A GPCRs expressed within cardiac tissue, including the β-adrenoceptors and 
histamine receptor subtypes couple to this pathway (Tang and Insel, 2004).  Notably, the 
Gs subunit recently became the first G-protein to be successfully crystallised in an 
activated and GPCR-coupled state; a highly anticipated development in the field of GPCR 
research which provided insights into the marked displacement in the proximities of 
binding domains; Ras (αRas) and α-helical (αAH) (Rasmussen et al., 2011), which is 
important for the efficiency of nucleotide binding pockets following activation and coupling 
to the β-adrenoceptor (Rasmussen et al., 2011).    
1.2.1.1.2 The Gαi/o family 
The role of the Gi/o family of G-proteins is, in many aspects, to counter that of the Gs family 
in that they are generally viewed as direct inhibitors of adenylyl cyclase isoforms (Neves 
et al., 2002).  Although ubiquitously expressed within human tissue, many of the individual 
Gi/o family members including Gz and Gtd-1, are preferentially expressed in neuronal tissue 
and retinal rods and cones (Offermanns, 2003). For example, Gtd-1 acts to link opsins to 
the regulation of a cGMP phosphodiesterase and therefore acts to control levels of the 
secondary messenger cGMP (Tsang et al., 1998).
 
  
The GPCR coupling profile and physiological roles of the Gi/o family are very well 
characterised in health and disease. In large part this has been facilitated by the 
sensitivity of most members of the family to pertussis toxin (PTX) (Katada and Ui, 1982), a 
bacterial toxin produced by Bordetella pertussis which has the ability to catalyse the 
addition of ADP-ribose to the Gi subunit and thus prevent dissociation and downstream 
signalling (Kostenis et al., 2005).  
Further to its direct Gα subunit signalling pathway, the Gi/o family are also understood to 
promote the dissociation and thus signalling of the Gβγ complex to a higher degree than 
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others; leading to direct interactions with other signalling pathways, including the 
regulation of phosphodiesterases (PDEs) and potassium channel activation 
(Wettschureck and Offermanns, 2005, Leaney and Tinker, 2000). 
1.2.1.1.3 The Gαq/11 family  
The Gq/11 family comprises four distinct α-subunits that are best known for their ability to 
couple GPCRs to the β1-isoform of phospholipase-C (PLC-β), an enzyme which promotes 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) at the plasma membrane, 
generating the second messengers inositol 1,4,5-trisphosphate (IP3) and sn-1,2 diacyl 
glycerol (DAG) (McCudden et al., 2005). Unlike the Gi/o family of proteins, this family is not 
PTX sensitive and, therefore, characterisation of this pathway has involved the use of 
assays which target downstream signalling proteins.  The second messengers IP3 and 
DAG collectively stimulate the mobilisation of intracellular calcium (Ca2+) and activate 
protein kinase C (PKC) isoforms, leading to diverse signalling properties and functional 
outcomes in a variety of cells including regulation of the actin cytoskeleton, gene 
transcription and cell proliferation (Kostenis et al., 2005, Hubbard and Hepler, 2006). 
The Gq and G11 subunits are widely expressed within human tissue.  However, expression 
of the other family members G14 and G15/16, is limited to lung, kidney and hematopoietic 
cells (Offermanns, 2003).  Surprisingly, any distinct variations in the activation of signalling 
pathways or functional role of alternative subunits in the Gq/11 family remain to be 
elucidated despite significant sequence variations in the N-terminal regions of G14 and 
G15/16, in comparison to Gq (65% and 35%, respectively) (Hubbard and Hepler, 2006).   
1.2.1.1.4 The Gα12/13 family 
The final G-protein family, identified in 1991, is the G12/13 family of proteins and for a 
variety of reasons, these remain the least well understood (Strathmann and Simon, 1991).  
Primarily, the absence of tools, such as bacterial toxins, which directly interact or interfere 
with the G12/13 family – has hampered efforts to differentiate G12/13 signalling from that of 
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other G-protein families. Furthermore, the downstream small monomeric GTP-bound Rho 
proteins which are activated via the G12/13 pathway are particularly difficult to quantify 
efficiently or accurately (Maguire and Davenport, 2005).  These initial drawbacks are 
further hampered by the limited means available to discriminate between endogenous G12 
and G13 signalling, particularly in vivo and, therefore, their differential actions also remain 
poorly understood (Worzfeld et al., 2008). Lastly, it is well understood that GPCRs 
coupling to this family of G proteins often simultaneously couple to Gq/11 and in some 
cases to Gi/o (Siehler, 2009), albeit at different efficiencies (Riobo and Manning, 2005).  
Taken together, it is understandable that the process of characterising the G12/13 family 
has been extremely difficult (Wettschureck and Offermanns, 2005). 
As with many other G-proteins, G12/13 family members are ubiquitously expressed within 
human tissues. They are classically reported to mediate formation of actin stress fibres 
and activation of serum response factor (SRF) in cells (Worzfeld et al., 2008). 
Consequently, this pathway has been implicated in the proliferation and survival in cells 
overexpressing sphingosine kinase type-1 (Olivera et al., 2003), the migration of an 
ovarian cancer cell line, SK-OV3, following LPA stimulation and subsequent activation of 
the Gα12/13/Rho A axis (Bian et al., 2006), and finally transcriptional regulation via 
ROCK1/2 activation and subsequent engagement with the SRF (Siehler, 2009). 
Interestingly, G12/13 double-knockout mice are subject to embryonic lethality, and this is 
primarily attributed to the underdeveloped nature of both neural and vascular networks, 
suggestive of a pertinent role for G12/13 in vascular and cardiac development (Offermanns 
et al., 1997).     
1.2.2 Gβγ signalling 
The Gβγ complex is an essential signalling component of G-protein: receptor interactions 
and is activated simultaneously with the classical Gα pathway (Hamm, 1998).  Despite its 
importance, the Gβγ complex was initially dismissed as a passive regulator of G-protein 
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signalling, in which isoprenylation modifications on the Gγ
 
subunit merely facilitated a 
close proximity to the plasma membrane (Johnston and Siderovski, 2007).  It was also 
thought that this proximity promoted the re-association of the heterotrimeric unit and in 
turn, readied Gα
 
for more cycles of receptor-mediated activation.  However, in 1987, 
following the infusion of purified Gβγ protein into embryonic atrial cells, it was first 
discovered that the Gβγ
 
complex interacted directly with Kir3 channels to promote inward 
potassium (K+) movement (Logothetis et al., 1987).  Following this, it was also 
demonstrated that Gβγ interacted directly with a number of effector molecules to promote 
downstream signalling pathways closely linked to the MAPK signalling cascade including 
PI-3 kinase (PI3K) (Stephens et al., 1994) and PLC-β2 (Hawes et al., 1996), as well as 
alternative pathway initiators such as adenylyl cyclases (AC) (reviewed in (Khan et al., 
2013)).  Interestingly, research also suggests a role for Gβγ in structural protein trafficking 
(Dupre et al., 2009) and endosomal sorting (Hynes et al., 2004).  However, these roles 
are currently less well established.  
Unlike the specific nature of Gα isoforms, it is still unclear if the combination of Gβ and Gγ 
isoforms to form functional complexes are highly specific in relation to their roles or cell 
types (Dupre et al., 2009). However, an early characterisation study demonstrated this 
may be the case, as evidence suggested the Gγ1 isoform is highly expressed within retinal 
rod cells and, following the activation of the rhodopsin receptor within these cells, Gγ1 was 
shown to preferentially promote Gβγ1 signalling (Kisselev and Gautam, 1993).  Isoform 
selectivity was further highlighted in a study which demonstrated that the Gγ1 isoform is 
favoured over Gγ5 for efficient trafficking of the Gβγ complex to the Golgi network 
following receptor internalisation (Akgoz et al., 2004).  Initially, the authors related this 
finding to differing lipid modifications amongst isoforms.  However, subsequent mutational 
analysis suggested that phosphorylation sites located on the c-terminus were the 
influencing factor (Akgoz et al., 2004). Taking these findings together, future research 
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relating to the selectivity of the Gβγ isoform may provide further insight in relation to the 
functional consequences of targeting individual Gβγ subunits. 
1.2.3 GPCR desensitisation, internalisation and trafficking 
Following the activation of a GPCR, multiple molecular mechanisms are in place to 
terminate the signalling process. Firstly, the GPCR must be uncoupled from the Gα 
subunit to become desensitised, internalised and trafficked into endosomal compartments 
for recycling, or become lysosome-bound for degradation (Magalhaes et al., 2012). This 
process is vital for sustained sensitivity in GPCR signalling and there are several key 
molecular facilitators, primarily initiated via the activity of GPCR kinases (GRKs) 
(Magalhaes et al., 2012). There are only seven members of the GRK family (1-7) and, 
considering the uneven ratio of GRKs to GPCRs, it is anticipated that each isoform has 
the ability to bind numerous GPCR subtypes - although their specificity for receptor 
families remains poorly understood (Gurevich et al., 2012).  The majority of GRK isoforms 
are localised to the plasma membrane via their interactions with the Gβγ complex or 
phospholipids such as phosphatidylinositol 4,5-bisphosphate (PIP2), whereas others, 
specifically GRK 5 and 6, are targeted there via palmitoylation (Gurevich et al., 2012). 
When GPCRs are activated, changes in the conformational state present the opportunity 
for GRKs to recognise and rapidly phosphorylate the c-terminal tail and/ or third 
intracellular loop of the GPCR (Shenoy and Lefkowitz, 2011) (Ribas et al., 2007).  
Following phosphorylation by GRKs, the GPCR is rapidly recognised by a family of cytosol 
localised arrestin proteins; of which arrestin 2 and arrestin 3 (often still designated β-
arrestin 1 and 2) are the predominant forms and are expressed widely (Walther and 
Ferguson, 2013).  Sharing 78% sequence homology, the arrestin isoforms are thought to 
be relatively interchangeable in their roles, which involves GPCR binding, an event that is 
enhanced by GRK mediated receptor phosphorylation (Walther and Ferguson, 2013).  By 
so doing this, blocks access of the Gα subunit and thus prevents further G protein-
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mediated signalling (DeWire et al., 2007).  The stability of the bound β-arrestin-GPCR 
complex can be indicative of the speed and outcome of the internalisation and recycling 
process (Shukla et al., 2011) and research suggests that this stability is variable amongst 
individual GPCR subtypes, for example, Class A GPCRs have been shown to bind 
transiently to β-arrestin and are recycled rapidly whereas, Class B GPCRs are more firmly 
bound and thus the process is comparatively slower (Oakley et al., 2000). Following 
recruitment of a β-arrestin, receptor endocytosis is stimulated by attracting clathrin, 
various adapter proteins (e.g. AP-2) and dynamin - molecules responsible for the 
development of clathrin coated pits (CCPs) and molecular trafficking of GPCRs (Jean-
Alphonse and Hanyaloglu, 2011).  A further role of β-arrestins is to recruit the small 
GTPases required for intracellular trafficking of the receptor; these include Rab 4, 5, 7 and 
11 – the specificity of which is determined by the fate of the receptor in relation to whether 
it will be recycled back to the membrane or become degraded (Moore et al., 2007). 
 
1.2.4 The role of β-arrestin in cell signalling 
Interestingly, in addition to their roles in GPCR desensitisation and internalisation, in 
recent years it has come to light that β-arrestins can also promote signalling via alternative 
pathways, facilitated by their role as scaffolding and adapter molecules for other proteins 
and hence, other signalling pathways (Shukla et al., 2011).  Essentially, this function is 
non-canonical and G-protein independent and can span multiple molecular pathways, 
many of which are linked to the MAPK-mediated signalling cascades; c-Src, c-Jun and 
ERK1/2 (Luttrell et al., 1999). Collectively, c-Src, c-Jun and ERK1/2 are understood to 
recruit β-arrestins as chaperone complexes for the regulation of cellular mitogenesis 
(Reiter and Lefkowitz, 2006).  Furthermore, research has also demonstrated that β-
arrestins can enhance the process of GPCR ubiquitination and, in the first such instance, 
β-arrestin was shown to facilitate targeting of the β-2AR for degradation by acting as an 
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adapter molecule for an E3 ubiquitin ligase (Shenoy et al., 2001). Interestingly, for the β-
2AR, ubiquitination was specifically mediated via β-arrestin-2, rather than β-arrestin-1, 
and this may be suggestive of preferential roles for specific isoforms, an aspect of β-
arrestin research which remains poorly understood in relation to internalisation and 
trafficking (Shenoy et al., 2001, Shukla et al., 2011).   
The therapeutic potential of ‘biased’ GPCR ligands, which preferentially signal via β-
arrestin controlled pathways, has become an increasingly important aspect of recent 
research and the actions of many GPCR targeted ligands or medicines, are being 
reconsidered in this respect (Reiter et al., 2012).  For example, it has been demonstrated 
that TRV120023, a β-arrestin biased agonist at the angiotensin type-I receptor (AT1R), 
stimulates cell survival following ischemic injury in cardiomyocytes via the promotion of 
MAPK signalling in the setting of congestive heart failure (Kim et al., 2012).  Most 
astonishingly, TRV120023 proved more effective than losartan in protecting 
cardiomyocytes from ischemic injury in vitro. This is a valuable finding, given that losartan 
is a gold standard antagonist at the AT1R and is used to prevent cardiac remodelling in 
heart failure, as well as vascular remodelling in the treatment of hypertension and diabetic 
neuropathy (Kim et al., 2012, Violin et al., 2013).  Taking this evidence alongside two 
recent reports which detail the atomic level structures of β-arrestins in their active 
confirmation it is evident that the future of β-arrestin research is promising (Borshchevskiy 
and Buldt, 2013).   
 
1.3 G protein-coupled receptor 35 
G protein-coupled receptor 35 (GPR35) is a member of the ‘rhodopsin-like’ family of 
GPCRs discovered more than 15 years ago (O'Dowd et al., 1998). It remains poorly 
characterised in relation to the identification of its endogenous activator, its downstream 
role in signalling and thus, its wider physiological function in health and disease.   
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GPR35 was first identified within an intronless open reading frame (ORF) corresponding 
to 309 amino acids, located on chromosome 2, region q37.3 in human genomic DNA 
(O'Dowd et al., 1998).  In the following six years, it was discovered that GPR35 also 
produced an alternatively spliced version in humans, for which there was an extended N-
terminus of 31AA - although the TMD and C-terminal tail were identical (Okumura et al., 
2004). Referring to the short version as GPR35a and the extended version as GPR35b, 
this initial report suggested that GPR35b was preferentially expressed in both healthy 
gastric mucosa tissue and in NIH3T3 fibroblasts which exhibited transforming capabilities 
(Okumura et al., 2004).  This report was the first to propose a functional role for GPR35 
and, although evidence suggests that there may be an affiliation between GPR35 isoform 
expression and gastric tumour progression, the significance of the N-terminal extension 
remains unresolved in relation to the pathophysiology of tumour progression, ligand 
recognition or GPR35 function (Guo et al., 2008, Mackenzie et al., 2014). 
Ultimately, deciphering the roles for GPR35 has been hampered by limited knowledge of 
the endogenous ligand(s). Although a number of potent synthetic ligands have been 
identified which include pamoic acid (Zhao et al., 2010), amlexanox and lodoximide 
(Mackenzie et al., 2014), GPR35 displays very marked differences in ligand pharmacology 
between species (Milligan, 2011).  Moreover, as noted above, the true endogenous 
ligand(s) of GPR35 remains uncertain.  Whilst some reports argue that it should still be 
considered as an ‘orphan’ receptor, at least in man (Milligan, 2011), others have proposed 
two possible endogenous ligands; kynurenic acid (KYNA) and 2-acyl lysophophatidic acid 
(2-acyl LPA) (Wang et al., 2006a, Oka et al., 2010). Regardless of these issues and 
limitations, continued efforts to identify novel, surrogate agonists which activate or block 
GPR35 have provided investigators with the tools to question its physiological function 
and possible roles in disease, albeit to a limited extent.  Current evidence, derived from 
mouse knock-out  models and studies utilising synthetic ligands, strongly suggests a role 
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for GPR35 in a range of diseases including heart failure, inflammation and nociception 
(Mackenzie et al., 2011). 
 
1.3.1 GPR35 expression 
In addition to the initial discovery of GPR35 in 1998 – O’Dowd and colleagues were also 
first to report endogenous RNA expression of GPR35 within a range of healthy tissues 
(O'Dowd et al., 1998). Using northern blot RNA analysis, robustly detected levels were 
shown to be present only in the small intestine of the rat, with negligible levels in the 
lungs, liver, heart, spleen and kidney (O'Dowd et al., 1998).  As interest in GPR35 
developed, publications began to speculate on roles for GPR35 and investigators further 
quantified expression, mainly using quantitative PCR, in human, rat and mouse derived 
tissues.  Studies have confirmed high expression levels of GPR35 in gastrointestinal 
tissue (Taniguchi et al., 2006). Moreover, further studies have also reported significant 
expression levels in the spleen, kidneys, and also in specialised immune cell populations 
such as peripheral leukocytes, monocytes and neutrophils in both humans and rodents 
(Wang et al., 2006a, Barth et al., 2009, Lattin et al., 2008). Also, IgE antibody-challenged 
human mast cells displayed enhanced GPR35 expression levels (Yang et al., 2010).  
Moreover, both a and b GPR35 isoforms are readily detected in the central and peripheral 
nervous system, specifically in the whole human brain and rodent dorsal root ganglia, 
respectively (Taniguchi et al., 2006, Cosi et al., 2011, Guo et al., 2008).  Most recently, 
GPR35 demonstrated robustly high expression in isolated mouse neonatal 
cardiomyocytes following exposure to hypoxic conditions via the activation of hypoxia 
inducible factor-1 (HIF-1) (Ronkainen et al., 2014). Importantly, this finding was evident in 
ischemic primary neonate cells and whole cardiac tissue isolated from a mouse model of 
acute ischemia induced via a transverse aortic constriction procedure (Ronkainen et al., 
2014). This is in agreement with an earlier study which reported increased expression of 
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GPR35 in ischemic myocardial tissue obtained from a small subset of heart failure 
patients (Min et al., 2010). 
The majority of these latter studies employed quantitative, reverse transcription-
polymerase chain reaction (qRT-PCR) analysis to assess GPR35 expression levels.  By 
quantifying DNA corresponding to a gene of interest at an early, exponential phase of the 
PCR cycle, qRT-PCR provides a precise measurement whilst requiring comparatively less 
cDNA than other techniques (Bustin et al., 2005).  It is, therefore, widely considered to be 
both more sensitive and more accurate than northern blot analysis, suggesting that the 
initial expression analysis employed by O’Dowd and colleagues may have lacked 
sufficient sensitivity, accuracy and molecular material to produce conclusive results.  
Given that GPCRs are often expressed at modest levels (Regard et al., 2008), specificity 
and sensitivity are imperative for effective expression analysis.  
Despite the initial contrasting reports, tissue-wide GPR35 distribution has been robustly 
validated in subsequent investigations and, aside from preferential gastrointestinal 
expression, there are also consistent reports of significant expression in spleen and 
immune cells (Wang et al., 2006a, Lattin et al., 2008). Furthermore, owing to the diverse 
range of tissues which have demonstrated GPR35 expression, future expression analysis 
and investigation of GPR35 function in relevant models of health and disease is clearly 
required to comprehensively elucidate its role.  
 
1.3.2 GPR35 polymorphic variation/SNPs  
In addition to the elusive N-terminally extended form of human GPR35, numerous 
polymorphic isoforms of human GPR35 have been identified and may have consequential 
implications within various disease states (Mackenzie et al., 2011).   
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1.3.2.1 Type-2 diabetes 
In some cases, reports have highlighted a link between the increased expression of a 
single nucleotide polymorphism (SNP) in GPR35 and the incidence of diabetes.  For 
example, an identified SNP in GPR35 demonstrated increased expression in a Mexican-
American population with type-2 diabetes (Horikawa et al., 2000).  However, this report 
also established an association with the incidence of type-2 diabetes and a range of 
alternative genes also expressed in the ‘NIDDM1’ loci of chromosome 2 and, therefore, 
the specificity of the association between expression of the GPR35 SNP and type-2 
diabetes remains unclear (Horikawa et al., 2000). A further population study found GPR35 
to be highly polymorphic within an Italian subset of diabetic patients.  However, these 
authors described a non-significant association between GPR35 variation and type-2 
diabetes (Vander Molen et al., 2005). Evidently, more population research is required in 
order to decipher a link between polymorphic variations of GPR35 and the incidence of 
diabetes. 
1.3.2.2 Coronary artery disease 
The first indication that GPR35 could be involved in the progression of coronary artery 
disease (CAD) originated from a genetic study in patients which aimed to identify potential 
gene-markers relating to hypertension and subsequent end-organ damage (Sun et al., 
2008).  These investigators also assessed the progression of coronary artery calcification 
(CAC) burden, via computed tomography scanning whilst accounting for multiple risk 
factors including plasma glucose, cholesterol, and fibrinogen levels (Sun et al., 2008).  
Employing an elegant study design, two initial data sets of 360 hypertensive sib-ships 
were screened for 471 SNPs from candidate biological pathways, or positional candidate 
genes which might influence CAC. Using Random Forest prediction for various risk factor 
importance and RuleFit analysis to prioritise variable-variable interactions, a SNP in 
GPR35 was recognised to have significant association with increased CAC burden (Sun 
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et al., 2008). This SNP, within GPR35, was non-synonymous and resulted in an amino 
acid variation between serine and arginine at position 294 (Sun et al., 2008).  Upon closer 
examination, it was discovered that the Ser294Arg polymorphism is located at one of the 
four conserved c-terminus potential phosphorylation domains on GPR35 and the authors 
of this publication hypothesised that this may have implications for G-protein coupling, but 
failed to specify a pathway which might facilitate its role in calcification or atherosclerotic 
burden (Sun et al., 2008).  
1.3.2.3 Gastrointestinal disease  
Given the robust expression of GPR35 within gastrointestinal tissue, the identification of 
polymorphisms implicating GPR35 in gastrointestinal diseases may be expected.  A SNP 
in GPR35 has been implicated in the early on-set of inflammatory bowel disease (IBD) 
(Imielinski et al., 2009).  In this study, a SNP was highly expressed in a subset of patients 
with ulcerative colitis however, the authors did not comment on the structural location of 
the SNP or hypothesise a functional role for GPR35 in IBD (Imielinski et al., 2009). 
However, taking this evidence together with a recent report which demonstrates a strong 
association between the expression of a SNP located within the TMDIII at position 3.44 of 
GPR35 [a TMD potentially involved in signalling (Jenkins et al., 2011)] and the incidence 
of primary sclerosing cholangitis (PSC) with concurrent ulcerative colitis (UC) (Ellinghaus 
et al., 2013), future investigation relating to the role of various GPR35 polymorphisms in 
gastrointestinal disease is warranted. 
 
1.3.3 Putative functions of GPR35 
Information relating to species and tissue selective expression is valuable in early receptor 
characterisation and can often be indicative of physiological function (Kenakin, 2004). As 
a result of widely reported GPR35 expression, a few publications have begun to examine 
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putative functions for GPR35 in vitro and even at an in vivo level, in the treatment of 
inflammation, pain, hypertension, and cardiac hypertrophy in heart failure (Barth et al., 
2009, Zhao et al., 2010, Cosi et al., 2011, Min et al., 2010, Ronkainen et al., 2014).  
1.3.3.1 Inflammation 
Given the evidence of high expression levels of GPR35 within immune cell populations 
(Wang et al., 2006a), Barth and colleagues examined the role of GPR35 in the early 
stages of inflammation within the vasculature (Barth et al., 2009). Hypothesising that 
GPR35 might act in a similar fashion to a chemoattractant-like receptor, these authors 
quantified the attachment of leukocytes to a human umbilical vein endothelial cell 
(HUVEC) monolayer following exposure to shear stress conditions (Barth et al., 2009).  
Importantly, the shear stress conditions were equivalent to those routinely demonstrated 
in the vasculature within a temperature controlled, fibronectin coated flow-chamber (Barth 
et al., 2009). In doing this, Barth and colleagues demonstrated that GPR35 activation 
contributed to β1 integrin-mediated leukocyte adhesion to an endothelial cell monolayer, 
increasing monocyte adhesion levels by 13-fold, following 300nM KYNU stimulation (Barth 
et al., 2009).  Importantly, these effects were attenuated by the knockdown of GPR35 via 
short-hairpin RNA (shRNA) and in the presence of an α4-integrin blocking-antibody, which 
specifically interferes with β1-mediated cell arrest (Barth et al., 2009). These findings led 
authors to speculate that GPR35 activation may be implicated in the setting of early phase 
inflammation.  However, it was ultimately concluded that further investigation was 
warranted in alternative settings, using a diverse range of ligands with high specificity for 
GPR35 (Barth et al., 2009).   Thus far, there are no additional publications which address 
the role of GPR35 in the setting of acute inflammation. 
1.3.3.2 Pain 
Alternatively, authors have explored a functional role for GPR35 within the central nervous 
system (CNS), specifically in the setting of pain.  In the first instance, GPR35 
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demonstrated high expression in dorsal root ganglion (DRG) neurons of the rat (Guo et 
al., 2008) and following this, demonstrated negative regulation of cAMP via activation of 
Gαi/o and subsequently appeared to co-localise with transient receptor vanilloid receptor  
(TRPV1) channels (Ohshiro et al., 2008).  Notably, TRPV1 is a cation channel involved in 
hyperalgesia (Lawson, 2002) and researchers hypothesised that the evidence of potential 
interactions between TRVP1 and GPR35 may be suggestive of a role for GPR35 in the 
setting of pain. Following this evidence, Zhao et al. investigated the effect of administering 
increasing doses of the GPR35 ligand pamoic acid in a mouse model undergoing an 
acetic acid-induced abdominal constriction test, considered the gold standard model of 
nociception  (Zhao et al., 2010). Interestingly, the administration of increasing dosages of 
pamoic acid (25-100mg/kg/animal) and the number of writhes exhibited by the animal 
negatively correlated (Zhao et al., 2010), leading authors to conclude that GPR35 
activation may contribute to anti-nociception in vivo (Zhao et al., 2010). However, although 
these findings correlate with the hypothesis put forward by Oshiro and colleagues 
(Ohshiro et al., 2008), they conflict with reports from Jenkins et al., who demonstrated that 
whilst pamoic acid is an extremely potent agonist at human GPR35, it displays negligible 
potency at mouse GPR35 (discussed later) (Jenkins et al., 2012). Therefore, without 
successful employment of a second agonist or an antagonist to block GPR35 activation, 
we cannot be sure that the anti-nociceptive effect following pamoic acid administration is 
not an off-target effect (Zhao et al., 2010).   
Subsequently, another report examining nociceptive properties of GPR35 shortly followed 
(Cosi et al., 2011). Here, it was demonstrated that zaprinast and KYNA significantly 
attenuated, but did not completely abolish, forskolin-induced increases in cAMP via the 
Gαi/o signalling path in primary mouse glial cells (Cosi et al., 2011); providing a potential 
explanation for anti-nociception in spinal cord tissue following GPR35 activation. Further 
to this, authors examined this hypothesis in vivo, demonstrating that systemic 
administration of 100-300mg/kg of L-kynurenine (a precursor of KYNA, see Figure 1-4, for 
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a schematic diagram of the kynurenine pathway) or 20mg/kg of zaprinast, decreased the 
number of writhes exhibited by mice undergoing an abdominal constriction test by up to 
42%, inferring a level of anti-nociception following GPR35 ligand administration (Cosi et 
al., 2011). Remarkably, systemic administration of L-kynurenine together with probenecid, 
a molecule which blocks excretion and disposal of KYNA (Santamaria et al., 1996) 
increased spinal cord and plasma KYNA levels by up to 8000% compared to saline 
infused controls (Cosi et al., 2011). Whilst it is highly probable that these levels of KYNA 
may produce off-target effects via antagonism of the NMDA receptor in vivo (Chen et al., 
2009), the anti-nociceptive effects demonstrated here are in agreement with those 
previously reported by Zhao et al. (Cosi et al., 2011, Zhao et al., 2010). 
1.3.3.3 Hypertension 
GPR35 has also been implicated in the regulation of blood pressure in vivo (Min et al., 
2010).  Min and colleagues (2010) examined the haemodynamic parameters of a 
commercially obtained transgenic GPR35 knockout mouse strain (Deltagen, San Mateo, 
CA) alongside other in-house generated strains which included global knockout models of 
orphan GPCR, GPR37like-1 (GPR37L1) and myosin light chain kinase-3 (MLYK3) (Min et 
al., 2010). Importantly, GPR35 and GPR37L1 were chosen for further analysis following 
their high expression profile in myocardial tissue derived from heart failure patients and 
their orphan status (Min et al., 2010). Following PCR genotyping to ensure that 
appropriate gene deletions were evident, systolic and diastolic ventricular pressure were 
measured via Millar catheterisation of the right carotid artery in anesthetised mice (Min et 
al., 2010).  Most notably, GPR35 knockout mice demonstrated a significant, 37.5 mmHg, 
increase in systolic ventricular pressure compared to wild-type littermates (C57 BL/6) (Min 
et al., 2010).  There were no measurable differences in the heart weight/ body weight 
(HW/ BW) ratio between strains.  However, the authors fail to report the age of the mice at 
the onset of hypertension and, therefore, the development of cardiac hypertrophy is 
unaccounted for (Min et al., 2010). Moreover, the data presented in this study were low in 
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power (n≤9).  However, there are to date few studies that have begun to explore the role 
of GPR35 at an in vivo level and given that this study was the first to highlight a potential 
role of GPR35 in the regulation of blood pressure, further exploration is warranted (Min et 
al., 2010). 
1.3.3.4 Heart Failure 
Within the same publication, Min and colleagues (2010) also proposed an association 
between GPR35 and development of heart failure (HF).  In a screen of twelve failing and 
two healthy human myocardial tissue samples, a selection of up-regulated genes was 
chosen for further analysis via a global expression microarray and these included GPR35 
and GPR37L1 (Min et al., 2010). Other chosen genes, which included MLYK3, 
peroxiredoxin 4 (PRDX4) and SPARC related modular calcium binding 2 (SMOC2), also 
demonstrated increased expression.  However, these also demonstrated a positive 
correlation with traditional heart failure biomarkers such as plasma brain natriuretic 
peptide (BNP), ejection fraction (EF) and pulmonary arterial pressure (PAP), facilitating a 
degree of adjustment for disease severity (Min et al., 2010). Authors examined 
physiological parameters in global knockout in vivo models (discussed above), as well as 
changes to the morphology of cardiomyocytes in response to the over-expression of a 
selection of twelve up-regulated genes (Min et al., 2010). Most interestingly, adenovirus 
mediated over-expression of GPR35 promoted a hypertrophic phenotype in primary 
neonatal cardiomyocytes and this was quantified via [3H] phenylalanine incorporation (Min 
et al., 2010).  Interestingly, only over-expression of GPR35 led to a hypertrophic 
morphology amongst the chosen candidates, including genes which displayed high 
expression within the myocardium such as GPR37L1 and those which positively 
correlated with traditional heart failure biomarkers such as MLYK3 expression (Min et al., 
2010).   
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Additionally, a very recent publication demonstrated that the expression of GPR35 is 
significantly increased in ischemic myocardial tissue derived from mice and in primary 
mouse neonatal cardiomyocytes exposed to hypoxia in vitro, and that this response is 
mediated via the activation of hypoxia inducible factor-1 (HIF-1) (Ronkainen et al., 2013).  
Using an experimental system which employed a hypoxic chamber to induce ischemia in 
cultured primary neonatal cardiomyocytes, these authors were able to elegantly 
demonstrate the up regulation of GPR35 mRNA from the onset of hypoxic exposure and, 
furthermore, that this was increased with time together with an alternative hypoxic marker; 
EGL nine homolog 3 (PHD3) (Ronkainen et al., 2014). Importantly, increased expression 
of GPR35 could be induced independently of hypoxia, given that HIF-1α was activated 
and this was demonstrated via the expression of a constitutively active form of HIF-1α in 
primary neonatal cardiomyocytes in normoxia (Ronkainen et al., 2014).  Consequently, 
these authors were able to identify a putative binding site for HIF-1α, located on the 
promoter region of mouse GPR35, via chromatin immunoprecipitation, and the interaction 
between GPR35 and HIF-1α was evident following the use of a luciferase assay 
(Ronkainen et al., 2014). Moreover, these authors also demonstrated that GPR35 
expression and HIF-activation are concomitantly up-regulated in ischemic ventricular 
tissue derived from experimental mice which have undergone ligation of the left anterior 
descending (LAD) coronary artery (an acute model of myocardial infarction and 
pathological hypertrophy) or transversal aortic constriction (TAC) which represents acute 
ischemic injury (Ronkainen et al., 2014).  Results from these procedures indicated that 
GPR35 is up regulated in ventricular tissue in the compensatory and de-compensatory 
stages of heart failure represented by LAD and TAC procedures, respectively (Ronkainen 
et al., 2014).  Finally, this publication also demonstrated zaprinast-induced GPR35 
internalisation and the alteration of actin stress fibre formation in mouse cardiomyocytes, 
this is consistent with literature relating to GPR35-Gα13 coupling (Jenkins et al., 2011, 
Jenkins et al., 2012, Mackenzie et al., 2014) and subsequent activation of the Rho A/ 
ROCK1/2 axis (Ronkainen et al., 2013). 
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1.3.4 G protein coupling profile of GPR35; Gαi/o and Gα12/13  
Alongside the initial discovery of the activity of zaprinast at GPR35 (discussed in section 
1.4.2), Taniguchi and colleagues employed an aequorin assay, utilising chimeric 
constructs of Gαq and reported that both rat and human orthologues of GPR35 coupled to 
the Gαi/o family of G-proteins (Taniguchi et al., 2006).  Further evidence suggesting PTX 
sensitive interactions between GPR35 and Gαi/o have been highlighted by studies on 
monocytes (Barth et al., 2009) and mouse glial cells activated by KYNA (Guo et al., 2008, 
Ohshiro et al., 2008) and human iNKT cells endogenously expressing GPR35 (Fallarini et 
al., 2010).  However, evidence also demonstrates that GPR35 is able to couple effectively 
to the Gα12/13 G-protein family, indeed selectively to Gα13 in assays ranging from chimeric 
aequorin assays, through GTP-Gα13 immunoprecipitation experiments, to IP1 
accumulation assays (Jenkins et al., 2011, Jenkins et al., 2012, Mackenzie et al., 2014).  
As a result of varying reports, it has been suggested that cell/ ligand bias may exist 
following GPR35 activation and, whilst this has not shown to be the case for any 
previously identified GPR35 ligands (Jenkins et al., 2012, Deng et al., 2012a), gathering 
evidence relating to KYNA activation and subsequent activation of the Gαi/o family of 
proteins may require further investigation.  
1.3.4.1 The role of Gα13 in Cardiovascular Disease  
Evidence that GPR35 selectively couples to Gα13 (Jenkins et al., 2011, Mackenzie et al., 
2014) is a prominent finding in relation to GPR35 and its potential role in cardiovascular 
disease (CVD). However, Gα13, along with the related Gα12 is, as noted earlier, by far the 
least studied mammalian G-protein. This is largely due to the reality that activation of Gα13 
does not directly regulate easy-to-measure secondary messengers and is unaffected by 
bacterial toxins, such as cholera toxin and pertussis toxin, which are well established tools 
that modify other G-protein families (Wettschureck and Offermanns, 2005).  
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In a range of studies, it has been demonstrated that Gα13 plays significant regulatory roles 
in embryonic development, cell migration, proliferation and contraction (Suzuki et al., 
2009). Most recently, Gα13 has been implicated in the regulation of angiogenesis via the 
promotion of expression of the vascular endothelial growth factor (VEGF) receptor via 
activation of transcription factor NFКB (Sivaraj et al., 2013); thus establishing Gα13 as an 
important mediator linked to signalling pathways relating to the pathology of CVD.  
Interestingly, Ruppel and colleagues generated a vascular endothelial cell-specific 
knockout mouse model for Gα13 via the CreLoxP recombination system and demonstrated 
a loss of appropriate vascular development which proved to be fatal in embryos at mid-
gestation (Ruppel et al., 2005).  The CreLoxP viral recombination system is an effective 
tool utilised to selectively abolish gene expression in specific cell types and is established 
by breeding two transgenic model lines; the first of which expresses a ‘floxed’ gene of 
interest (flanked by LoxP recombination sites) and a second that expresses a cell/ tissue 
specific Cre recombinase enzyme which has been virally introduced, encoding a promoter 
region. By crossing these strains, the cells which express Cre recombinase undergo 
recombination and the floxed allele is excised and, thus, selective gene deletion has been 
engineered to establish a new transgenic strain.  Importantly, Ruppel et al. (2005) 
demonstrated that neonatal fatality and abnormal vascular development did not occur in 
transgenic models which only expressed a Gα13 ‘floxed’ allele, suggesting that targeting of 
vascular endothelial cells using the CreLoxP system is not harmful in itself and, therefore, 
the abnormal vascular development could be attributable entirely to the elimination of Gα13 
in endothelial cells (Ruppel et al., 2005). This report was consistent with previous studies 
which had also demonstrated vascular defects and embryonic lethality in response to Gα13 
deficiency (Offermanns et al., 1997) and others which implicated Gα13 in the regulation of 
morphogenesis and capillary assembly in angiogenesis via Rho GTPase activation 
(Connolly et al., 2002). Convincingly, introducing Gα12/13 knockout specifically to 
cardiomyocytes in adult mice is not detrimental to life.  However, it does lead to protection 
from pressure overload heart failure (Takefuji et al., 2012).  This suggests that, while the 
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Gα12/13 pathway is essential for growth and angiogenesis in the early stages of 
development, its activation may contribute to cardiac pathophysiology and heart failure in 
later life (Takefuji et al., 2012). 
The activation of the Rho A pathway following Gα13 activation has been extensively 
reported.  An early publication by Hart and colleagues in 1998 was the first to identify a 
specific RhoGEF, p115 RhoGEF, which was sensitive to Gα13 activation (Hart et al., 
1998).  This was also reported elsewhere within the same year (Kozasa et al., 1998).  
Hart and colleagues reported substantial quantification of p115RhoGEF bound to Gα13 
following stimulation via autocrine motility factor (AMF) in co-immunoprecipitation assays 
and radioisotope based GDP-dissociation assays. Moreover, this study also reported that 
p115RhoGEF contains an RGS binding domain and, therefore, could be an effector GEF 
in the stimulation of Rho A activation, but also a decelerator of Gα13 activation via GAP 
activity (Hart et al., 1998).  A more recent study also focusing on p115RhoGEF 
quantification to assess ligand-receptor-Gα13 interactions, employed receptor mediated 
visualisation of fluorescent p115RhoGEF translocation from the cytosol to the plasma 
membrane following transfection of constitutively active isoforms of both Gα12/13 (Meyer et 
al., 2008).  Coupling this technique with cell fractionation and subsequent immunoblotting; 
compartmentalisation of active G-protein and Rho A was elegantly visualised and 
quantified at the cell membrane (Meyer et al., 2008).   
Rho A is understood to mediate a range of cellular responses which include smooth 
muscle cell contraction, polarity and migration and is, therefore, implicated in the 
pathology of hypertension and vessel remodelling (Wirth, 2010, Cotton and Claing, 2009). 
A number of studies also demonstrate that the expression and activation of Rho A is 
increased in hypoxic conditions in a wide range of cell types which include porcine and 
human pulmonary artery ECs (PAECs) (Wojciak-Stothard et al., 2005, Wojciak-Stothard et 
al., 2012) and human mesenchymal stem cells (MSC) (Vertelov et al., 2013). These 
cellular responses are largely produced via activation of the Rho A effectors, Rho 
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associated kinases (ROCK1/2).  However, Rho A has also been shown to cross-talk with 
c-Jun NH2-terminal kinase (JNK) in the setting of angiogenesis and cardiac hypertrophy 
(Maruyama et al., 2002) (Figure 1.3).  ROCK1/2 is understood to exert its contractile 
action by phosphorylating myosin light chain (MLC) and inhibiting myosin light chain 
phosphatase (MLCP) (Barandier et al., 2003).  Furthermore, ROCK1/2 up-regulates a 
selection of myofilament proteins, including Lim kinases 1 and 2, adducin and profilin, to 
regulate assembly of the actin cytoskeleton via the serum response factor (SRF) (Wirth, 
2010). Inhibition of ROCK using the small molecule Y-27632 has been shown to prevent 
vascular endothelial growth factor (VEGF)-induced behaviours in endothelial cells such as 
increased migration and permeability (Bryan et al., 2010) and to lower blood pressure in 
spontaneously hypertensive rats (SHR) (Moriki et al., 2004).  
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Figure 1-3. Gα13-mediated signalling via Rho A upon ligand binding to a GPCR. 
Following the activation of Gα13, p115RhoGEF can translocate from the plasma 
membrane to the cytosol where it facilitates Rho A activation via the exchange of GDP for 
GTP.  Active GTP-Rho A then binds to the RBD domain of ROCK1/2 to allow the 
previously closed, auto-inhibitory loop to unfold and become active. ROCK1/2 inhibits 
myosin light chain phosphatase (MLCP), directly phosphorylates myosin light chain (MLC) 
at serine 19 and activates serum response factor (SRF) for transcriptional regulation of 
cytoskeletal genes.  
 
1.4 Small molecule screening of orphan GPCRs 
It has been recently estimated that 27% of medications available on the market target 
various classes of GPCRs, with the majority targeting members of the ‘rhodopsin/ class A’ 
family (Garland, 2013). As research within this field continues to progress, the 
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requirement for novel, potent and highly specific ligands has become of utmost 
importance in modern drug development.  It has become common practise to employ 
high-throughput in vitro screening technologies in the initial search for novel and 
efficacious ligands.  To promote this, extensive and well-defined chemical libraries are 
now broadly available and are frequently utilised to screen small-molecule compounds 
against both well-characterised and therapeutically validated GPCRs as well as lesser 
studied and even ‘orphan’ GPCRs, often within an academic setting.  The following 
sections will discuss various screening techniques which have been used to identify both 
potential endogenous and surrogate synthetic ligands with affinity at GPR35. For ‘orphan’ 
GPCRs, where the endogenous ligand remains unidentified or disputed, screening studies 
can provide surrogate tool molecules to study the function of otherwise poorly defined 
GPCRs.  According to the International Union of Clinical and Basic Pharmacology 
(IUPHAR) database, there are currently 57 GPCRs within the ‘rhodopsin/ class A’ family 
which remain ‘orphan’ (Davenport and Harmar, 2013).  However, it has been estimated 
that up to 6 GPCRs become ‘de-orphaned’ per year (Foord et al., 2005).  To explore the 
mechanisms by which GPR35 mediates signalling endogenously, natural ligand 
identification has fundamental importance.   
 
1.4.1 Endogenous ligand identification for GPR35 
1.4.1.1 Kynurenic acid  
The kynurenine metabolite, kynurenic acid (KYNA) was the first endogenously produced 
ligand reported to activate GPR35 (Wang et al., 2006a).  In addition to the tryptophan 
pathway, which facilitates the conversion of L-tryptophan (an essential amino acid) to 5-
hydroxytryptamine ((5-HT, serotonin), an essential aminergic neurotransmitter); the 
kynurenine pathway is also a major facilitator of L-tryptophan degradation and conversion 
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(Ruddick et al., 2006). In the kynurenine pathway, the degradation of L-tryptophan 
commences via stimulation of indoleamine-2,3-dioxygenase, an enzyme which is up 
regulated following the release of interferon-γ (INF-γ) in inflammation (Chen and 
Guillemin, 2009); please refer to Figure 1-4 for a schematic representation of the 
kynurenine pathway.  Following this initial conversion, various intermediates are 
generated and subsequently implicated in a variety of signalling pathways and diseases 
including cancer, cerebral-inflammation and schizophrenia (Stone et al., 2013b). To this 
end, metabolites of the kynurenine pathway are attractive therapeutic targets (Schwarcz, 
2004). As an example, the metabolite 3-hydroxyanthranilic acid is understood to exert 
neuroprotective effects in glial cells via transcriptional suppression of the pro-inflammatory 
molecule tumour necrosis factor (TNF)-α and this could be targeted via alteration of the 
kynurenine pathway (Krause et al., 2011).   KYNA is a direct metabolite of kynurenine and 
was initially shown to act as a non-competitive antagonist of the N-methyl-D-aspartate 
(NMDA) receptors, which are predominantly expressed in neuronal synapses (Stone, 
1993, Perkins and Stone, 1982).  However, it was later discovered that KYNA is also a 
potent antagonist at the α7-nicotinic cholinoceptors (α7NR) (Hilmas et al., 2001).  
Interestingly, the dysregulation of KYNA levels in disease, and subsequently decreased 
antagonism at this level, has been linked to various neurological and psychiatric 
conditions, including Huntington’s disease and schizophrenia (Albuquerque and 
Schwarcz, 2013). 
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Figure 1-4. The kynurenine pathway.  
A schematic representation of the kynurenine pathway and the enzymes which are 
involved in the degradation of L-tryptophan and conversion of metabolites to produce 
kynurenic acid (KYNA), a proposed endogenous activator of GPR35. 
 
Acknowledging that numerous pathway metabolites have been discovered to activate and 
thus de-orphan various GPCRs (Civelli et al., 2006), Wang and colleagues (2006) 
screened a chemical library comprising 300 metabolic intermediates for activity at GPR35 
(Wang et al., 2006a).  The ability of KYNA to activate and internalise each of the human, 
rat and mouse orthologues of GPR35 with micromolar (µM) potency was reported. This 
was the only metabolite within the screen to elicit a response at GPR35 (Wang et al., 
2006a).  Upon reflection, it has been suggested that the acidic moiety of KYNA may 
facilitate its interaction with GPR35, given that this is the most prominent differential 
feature between KYNA and alternative tryptophan metabolites (Zhao et al., 2014).  In 
utilising an experimental system which incorporates Gq-protein chimeras and employs an 
aequorin assay to measure signals via a Ca2+ sensitive dye upon agonist stimulation, it 
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was reported that GPR35 coupled to Gi/o following KYNA stimulation (Wang et al., 2006a). 
Most interestingly, however, comparative Ca2+ transients revealed that there were 
significant potency differences between the species orthologues - ranging from those of 
rat GPR35 (EC50 7.4µM), followed by mouse GPR35 (EC50 10.3µM) and to human GPR35 
(EC50 39.2µM) (Wang et al., 2006a).  Importantly, these results established two central 
issues that have hampered subsequent GPR35 research; the variation in ligand potency 
between species and the fact that, for a ‘natural’ ligand, KYNA displays only modest 
potency at GPR35 (Wang et al., 2006a). 
Despite consistent observations that plasma KYNA is present at nanomolar levels in 
normal physiological conditions (Amirkhani et al., 2002, Turski et al., 2013), it has been 
argued these can reach micromolar levels in inflammatory states and this could, therefore, 
prove sufficient for GPR35 activation (Wang et al., 2006a).  It has indeed been reported 
that circulating KYNA levels are elevated in patients with IBD and this may be linked to the 
disease association of GPR35 and IBD (see section 2-3-2 on GPR35 polymorphic 
variations).  However, there is limited other evidence for this association (Forrest et al., 
2002).  Analysis of pancreatic, bile and intestinal secretions also demonstrated higher 
concentrations of KYNA, but these remain within nanomolar concentration ranges 
(Paluszkiewicz et al., 2009).  By contrast, a study conducted in 2008 assessed 
endogenous KYNA in various rodent tissues and reported concentrations of up to 16µM in 
the small intestine of the rat (Kuc et al., 2008).  These levels are the highest reported and 
together with the clear evidence of robust GPR35 expression within gastrointestinal 
tissue, the hypothesis that KYNA is an endogenous ligand remains strong in relation to rat 
GPR35 (Milligan, 2011).  
In the human context, evidence of GPR35 activation via KYNA remains ambiguous. For 
example, Oka and colleagues were unable to generate a response at human GPR35 to 
KYNA when measuring changes in intracellular Ca2+ levels, nor were they able to 
demonstrate receptor internalisation following transfection of a fluorescently tagged form 
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of human GPR35 (Oka et al., 2010).  However, in a study which assessed the adhesion 
properties of mononuclear cells under flow conditions, a 2-fold increase in leukocyte arrest 
in endothelial cells stimulated with KYNA was observed and, interestingly, this difference 
was abolished following knockdown of human GPR35 via short-hairpin RNA (shRNA) 
transfection (Barth et al., 2009).  Furthermore, the authors reported functionally significant 
effects following treatment with 300nM KYNA (Barth et al., 2009), a comparatively low 
concentration compared to those required to elicit GPR35 activation in various transfected 
cell studies (Wang et al., 2006a, Jenkins et al., 2010). Subsequently, Jenkins and 
colleagues were only able to report a minor response at human GPR35 after assessing a 
KYNA dose-stimulation for β-arrestin recruitment in transiently transfected cells via 
bioluminenscence resonance energy transfer (BRET) analysis (Jenkins et al., 2010).  This 
remains one of the few studies to directly compare ligand potency of KYNA at various 
GPR35 species orthologues and reproduced the previously demonstrated effects (Wang 
et al. 2006); although the latter study showed that activation of human GPR35 by KYNA 
was 100-fold less potent than for rat GPR35 (Jenkins et al., 2010).  Similar results were 
also published by Zhao and colleagues, who reported 217µM (EC50) KYNA potency at 
hGPR35 (Zhao et al., 2010). Finally, a recent short publication outlining results from a 
screen of ligands against various orphan GPCRs reported no effect at human GPR35 
following KYNA addition (Southern et al., 2013).   
Notably, screening technologies based upon β-arrestin recruitment were used routinely in 
these latter publications and, whilst it is possible that the differences observed may be 
attributable to the use of varied techniques across data sets, it is also possible that a 
degree of functional selectivity or ligand bias may exist following GPR35 activation via 
KYNA.  Failing to account for functional selectivity can be a limiting factor in the initial 
stages of ligand screening and may result in an inaccurate reflection of ligand potency or 
even future therapeutic value (Reiter et al., 2012). It has been suggested that the 
identification of endogenous ligands for GPR35 may have been hampered by the use of 
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second messenger assays which are solely dependent upon Gα signalling (Southern et 
al., 2013).  Therefore, future experimental strategies which account for both β-arrestin 
recruitment and secondary signalling events may help to disentangle some of the 
conflicting evidence which exists in relation to GPR35 activation. 
To employ a β-arrestin based strategy, Jenkins and colleagues modified human and rat 
GPR35 by introducing both an N-terminal epitope tag and C-terminal in-frame fusion of 
enhanced yellow fluorescent protein (eYFP) and co-transfected these into HEK293 cells 
along with Renilla luciferase-tagged β-arrestin-2 (Jenkins et al., 2010). (See Figure 1.5). 
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Figure 1-5. Bioluminescence Resonance Energy Transfer (BRET) assay. 
 1. HEK 293T cells are co-transfected with FLAG-hGPR35-eYFP and β-arrestin-2-Renilla 
luciferase-6 (βarr2-Rluc).  2. Following the addition of the Renilla luciferase substrate, 
coelentrazine-h, cells are incubated in the dark at 37oC. 3. Upon the addition of agonists, 
cells are incubated for a further 5 minutes.  4. BRET ratio is calculated from the emission 
at 530 nm/485 nm minus the BRET ratio of cells expressing only the Renilla luciferase 
construct within the same experiment.  
 
1.4.1.2 Lysophosphatidic acid  
Whilst Oka and colleagues were unable to generate a GPR35 response upon KYNA 
addition, they did report a second potential endogenous ligand for human GPR35, 2-acyl 
lysosphophatidic acid (2-acyl LPA) (Oka et al., 2010).  The LPA family is a group of 
bioactive phospholipids which are present in serum, often in excess of micromolar levels 
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(Mills and Moolenaar, 2003).  Various isoforms of LPA are able to activate the LPA(1-5) 
receptors and these promote coupling to several G-proteins including Gi/o, Gq/11 and G12/13, 
and they have been implicated in cardiovascular disease, cancer and inflammation (Lin et 
al., 2010). Classical LPA(1-3) receptors are not closely related to GPR35.  However, novel 
LPA receptors including GPR55, GPR23 (LPA4) and GPR92 (LPA5) share significant 
homology with GPR35, (Lin et al., 2010, Zhao and Abood, 2013, Milligan, 2011).  On this 
basis, Oka and colleagues screened various lysophospholipids which are structurally 
similar to lysophosphatidylinositol (LPI), the natural ligand at GPR55, with which GPR35 
shares 27% identity (Sawzdargo et al., 1999).   
Various forms of LPA were found to activate human GPR35 to a minor degree, though, 
further analysis proved 2-acyl LPA to be most efficacious ( EC50 30-50nM) (Oka et al., 
2010).  Following stimulation with 1-10µM 2-acyl LPA, HEK293 cells transiently 
expressing human GPR35 exhibited greater intracellular Ca2+ mobilisation, ERK 1/2 
phosphorylation (pERK), active GTP-bound Rho A protein and receptor internalisation 
than vector-only transfected controls. Conversely, stimulation with 1-100µM of KYNA 
failed to produce any response at human GPR35 (Oka et al., 2010) which is largely in 
agreement with Jenkins and colleagues (Jenkins et al., 2010).  Despite the strength of 
these findings, the identification of 2-acyl LPA as an endogenous activator of GPR35 has 
had limited impact on subsequent GPR35 research. Whilst investigators have since 
employed various screening strategies in a bid to identify additional GPR35 ligands these 
findings have yet to be confirmed (Southern et al., 2013, Deng et al., 2012a).  A 
reluctance to investigate further may reflect the potential difficulties which are involved in 
disentangling signalling pathways mediated exclusively via GPR35 activation following 
LPA stimulation, given the ability of forms of LPA to mediate signalling via multiple 
alternative LPA receptors that are widely expressed (Lin et al., 2010). Despite these 
issues, the homology which exists between the newly identified LPA receptors and 
GPR35, and the robust experimental protocol employed by Oka et al. provide strong 
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evidence that LPA may be an endogenous activator of GPR35 (Oka et al., 2010).  What is 
more, the recent identification of antagonists which block activation of human GPR35 
(Jenkins et al., 2012) may prove useful in confirming the activity of 2-acyl LPA specifically 
via GPR35 in future studies. 
1.4.2 Synthetic ligand identification for GPR35 
Although natural ligands can be advantageous tools in the process of receptor 
characterisation, the ability of synthetic ligands to modulate GPCR signalling should not 
be discounted as an effective means to elucidate receptor function. Whilst GPR35 
remains a poorly characterised receptor in relation to its physiological function, the 
identification and exploration of various structurally distinct agonist sets is extensive and 
complex. 
1.4.2.1 Zaprinast 
The first synthetic surrogate ligand identified to activate GPR35 was zaprinast (Taniguchi 
et al., 2006).  Like many other agonists at GPR35, zaprinast also has other physiological 
targets and is better known as a selective inhibitor of cyclic guanosine monophosphate-
phosphodiesterases (cGMP-PDEs), specifically PDEs 5 and 6 (Gibson, 2001).  Since the 
actions of zaprinast may produce increases in cGMP and other off-target effects, its use to 
explore the role of GPR35 in functional experimental systems is significantly limited.  
Alternatively, zaprinast has proven an excellent gold-standard reference compound in an 
array of GPR35 screens, demonstrating robust activation in multiple assay systems, in an 
unbiased manner, and with moderate potency (Jenkins et al., 2010, Zhao et al., 2010, 
Deng and Fang, 2012b, Mackenzie et al., 2014, Southern et al., 2013).  However, as with 
previously identified GPR35 ligands such as KYNA, zaprinast displays selective potency 
amongst species and is 50-fold more potent at rat than human GPR35 (Taniguchi et al., 
2006, Jenkins et al., 2010). 
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1.4.2.2 Identifying GPR35 ligands within the Prestwick Chemical library  
Three independent publications simultaneously performed a screen of the Prestwick 
Chemical Library® (Yang et al., 2010, Zhao et al., 2010, Jenkins et al., 2010).  This 
commercially available small scale chemical library is composed of 1120 small molecule 
drugs which are clinically marketed and pre-approved by the Food and Drug 
Administration (FDA) (Wermuth, 2004).  These are principally advantageous in relation to 
potential in vivo investigation and human trials as substantial information is available on 
ligand toxicity and both pharmacodynamics and pharmacokinetics.  Most crucially, the 
aforementioned publications all independently identified and verified a substantial number 
of hits in their primary screens and re-confirmation assays.  These included pamoic acid 
(Zhao et al., 2010), an ‘inactive’ salt component of many clinically marketed drugs, and 
the anti-asthma medication, cromolyn disodium (Yang et al., 2010).   
1.4.2.3 Pamoic acid 
Until recently, pamoic acid was the most potent agonist reported at GPR35, displaying 
nanomolar potency (Zhao et al., 2010, Jenkins et al., 2011).  Upon first identifying pamoic 
acid as a potent activator via a range of assays which included receptor internalisation, 
ERK1/2 phosphorylation and β-arrestin translocation, Zhao and colleagues did not report 
any discrepancy in potency between species; demonstrating that pamoic acid effectively 
induced receptor internalisation of both human and mouse GPR35 (Zhao et al., 2010).  
They also reported a dose-dependent increase in nociception following pamoic acid 
infusion in a mouse model undergoing an abdominal constriction test (Zhao et al., 2010).  
However, these findings were contradicted in subsequent publications from Jenkins and 
colleagues who consistently report that pamoic acid is virtually inactive at both rat and 
mouse orthologues of GPR35; measured via β-arrestin interaction, receptor internalisation 
and IP1 accumulation assays in vitro (Jenkins et al., 2010, Jenkins et al., 2012). 
Furthermore, Jenkins and colleagues reported pamoic acid to be a partial agonist (~50% 
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efficacy compared to zaprinast) at human GPR35 and investigated this further via 
competition assays using increasing concentrations of zaprinast.  Results revealed that 
high concentrations of pamoic acid reduced the effectiveness of zaprinast, consistent with 
this notion (Jenkins et al., 2011).  Of course, without testing a potent, endogenous agonist 
at human GPR35, it is impossible to fully investigate the implications of using pamoic acid 
as a surrogate ligand at GPR35 and, therefore, a comparative study to assess the mode 
of binding for both ligands may be useful. 
Most intriguingly, prior to its identification as a GPR35 agonist pamoic acid was 
considered by drug manufacturers as an inactive ‘salt’, often utilised to increase the 
longevity of commercially marketed drug formulations, including a range of antihistamine 
and antipsychotic medications (Neubig, 2010).  Considering its recently identified potential 
to evoke signalling via GPR35, the continued use of pamoic acid in such formulations may 
have to be carefully considered.   
1.4.2.4 Flavonoids, phenolic acids and aspirin metabolites 
Other agonists of micromolar potency identified via the Prestwick Chemical Library screen 
included the anti-inflammatory bio-flavonoids luteolin and quercetin, which displayed 
substantial selectivity for rat GPR35, but had little efficacy at human GPR35 (Jenkins et 
al., 2010).  By contrast, niflumic acid, a potassium and chloride ion channel blocker, 
displayed significant selectivity for human GPR35 (Jenkins et al., 2010).  To account for 
possible ligand bias towards β-arrestin recruitment, the ligand hits which were identified 
via β-arrestin translocation assays were further verified using a Gα13 [35S]GTP[S] binding 
assay, for human GPR35.   Importantly, there were no discrepancies between assays - 
indicating an absence of ligand bias (Jenkins et al., 2010). 
Finally, the most recent screen of the Prestwick Chemical Library® produced results in 
agreement with the earlier publications, confirming luteolin, quercetin and niflumic acid as 
GPR35 agonists via a multi-assay protocol (Deng et al., 2012a). However, these authors 
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also identified an additional agonist at human GPR35; ellagic acid. Ellagic acid is a natural 
phenol and displayed potency comparable to, or slightly lower than, zaprinast, and 
furthermore acted as a partial agonist (Deng et al., 2012a).  Ellagic acid is present in high 
concentrations in fruit and vegetables, particularly in berries, and is known to exert 
powerful anti-oxidant effects in cardiovascular disease and cancer (Lesca, 1983).  
Following these findings, the authors postulated that additional phenolic acids may also be 
ligands for GPR35 and subsequently demonstrated that this is true for gallic acid, an anti-
inflammatory and anti-allergenic natural phenol, which also displayed micromolar potency 
at human GPR35 (Deng and Fang, 2012a).   
Despite the extensive evidence for multiple GPR35 ligands with known bioavailability and 
powerful anti-oxidative effects, there have been no functional studies to examine a 
potential role for GPR35 in the modulation of redox status. However, in hypothesising a 
role for GPR35 in the treatment of inflammation, these authors further highlighted the fact 
that oxygenated products of aspirin are structurally related to phenolic acids (Deng and 
Fang, 2012b). Moreover, these authors identified a further set of human GPR35 ligands in 
aspirin metabolites.  Two of those identified; 2,3,4 THB and 2,3,5 THB, demonstrated 
moderate potencies ranging between 8-11µM (EC50). However, it is notable that these 
were not equivalent between assay systems, underlining a potential degree of ligand bias 
(Deng and Fang, 2012b).  The molecular mode of action of aspirin is well-understood and 
involves the acetylation and suppression of cyclooxygenase (COX) 1/2 enzyme 
expression, and subsequent down regulation of the production of prostaglandins, to exert 
its effect (Vane et al., 1998).  The studies of Deng and Fang. (2012b) demonstrated that 
aspirin does not activate GPR35 directly but instead they hypothesised a supporting role 
for GPR35 activation in the anti-nociceptive and anti-inflammatory effects which ensue 
following aspirin administration and subsequent oxidation of the ligand 
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1.4.2.5 Cromolyn disodium and other mast cell stabilisers 
Yang and colleagues first identified cromolyn disodium as an agonist at GPR35 and 
reported selective potency for rodent GPR35 at micromolar levels using an aequorin and 
an IP-1 accumulation assay in their screen of the Prestwick Chemical Library (Yang et al., 
2010).  Although, Jenkins and colleagues reported similar potency values in their screen, 
they demonstrated equipotent activation between rat and human orthologues using the 
BRET assay system (Jenkins et al., 2010).  Cromolyn disodium is a well-known anti-
asthma medicine which exerts its action via inhibition of the degranulation of mast cells, 
thus preventing the release of histamine and other mediators of type I hypersensitivity 
reactions.  However, the fundamental molecular mechanism of action (MMA) of this 
inhibition is unknown (Howell and Altounyan, 1967).  Yang and colleagues included an 
additional mast cell stabilising compound within their screen, and consequently 
demonstrated that nedocromil sodium also activated GPR35 at equivalent potency to 
cromolyn disodium, despite their chemical formulations being distinct (Yang et al., 2010). 
Given the significant lack of information regarding the MMA of these drugs, these authors 
hypothesised a role for GPR35 (Yang et al., 2010). 
These initial findings prompted further investigation of mast cell stabilising compounds as 
GPR35 agonists, resulting in the identification of brufolin and lodoxamide; two anti-allergic 
medications which activate both human and rat GPR35 with low nanomolar potency and 
are, therefore, the most potent activators identified to date (Mackenzie et al., 2014). In 
examining the pharmacological and structural similarities of GPR35 activating-mast cell 
stabilising compounds, this publication highlighted an obvious commonality in that the two 
most potent ligands shared a symmetric, di-acid structure. It was evident therefore that it 
was not merely the presence of carboxylic acid containing structures within chemicals 
which were GPR35 agonists, but that it may further relate to mirror-image structures. 
Although this may not provide a functional explanation of their possible role in the 
stabilisation of mast cells, it is an intriguing finding (Mackenzie et al., 2014).  
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Further screening also identified amlexanox, doxantrazole and permirolast as nanomolar 
potency agonists at GPR35 (Mackenzie et al., 2014).  Although not symmetrical di-acids, 
each of these ligands displays anti-allergenic pharmacology and have similar chemical 
properties to previously identified ligands at GPR35 in that they also possess a fixed 
negative charge (Mackenzie et al., 2014). Ultimately, these studies have begun to define 
common structural components for synthetic GPR35 agonists and this information will be 
useful in future screening studies. 
1.4.2.6 Tyrophostin analogues  
Although displaying limited potency at human GPR35, the identification of tyrophostin 
analogues was the first of many efforts to identify GPR35 agonists by researchers at 
Corning, NY (Deng et al., 2011a).  Notably, the human colon cancer cell line HT-29, that 
endogenously express GPR35, was utilised in their initial screening process.  By 
measuring changes in dynamic mass redistribution (DMR), a label-free cell biosensor 
assay (Schroder et al., 2010),  tyrophostin analogues were identified and flagged hits 
were then subject to further analysis, including receptor internalisation, ERK 
phosphorylation and use of a commercially available β-arrestin recruitment assay, 
Tango® (Deng et al., 2011a).  Fourteen tyrophostin analogue hits were identified.  The 
most potent of these were Tyrophostin-51, which displayed potencies similar to zaprinast 
across all assays, and also entacapone, a tyrophostin analogue used in the treatment of 
Parkinson’s disease (Rascol et al., 2000). Tyrophostins are inhibitors of receptor tyrosine 
kinases, the molecules responsible for regulating cellular functions via transmembrane 
induced protein tyrosine phosphorylation (Levitzki and Gazit, 1995).  The authors 
postulated that the moderate potency of entacapone at GPR35 may be indicative of 
clinical relevance, despite the primary clinical action of entacapone being well understood 
(Deng et al., 2011a) 
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Following this, an additional compound screen was performed using the same range of 
experimental assays (Deng et al., 2011b).  Unusually, these compounds were synthesised 
in-house, and with unknown pharmacology and/ or containing malononitrile groups, which 
are structurally similar to the previously identified tyrophostins (Deng et al., 2011a, Deng 
et al., 2011b).  Here activity of two high potency ligands at human GPR35 was 
demonstrated, the first being 2-(4-methylfuran-2(5H)-ylidene) malonitrile (EC50 32nM) and 
the second being thieno[3,2-b]thiophene-2-carboxylic acid (EC50 63nM) .  These 
researchers were able to compare the chemical and structural properties with the 
exhibited pharmacology to deduce that the presence of the carboxylic acid and malonitrile 
group was important for potent GPR35 activation (Deng et al., 2011b).  This is in 
agreement with previous observations, relating to the presence of one or more carboxylic 
acid groups in GPR35 activating compounds (Jenkins et al., 2010, Milligan, 2011, 
Mackenzie et al., 2014, Funke et al., 2013). 
1.4.2.7 Catecholics 
Another recently identified group of GPR35 ligands is a family of catechol-containing 
compounds. Catecholics are known free-radical scavengers which protect against lipid 
peroxidation and are utilised in an array of FDA approved drugs (Deng and Fang, 2013).  
Deng and colleagues initially identified 10 catecholic compounds which activated GPR35.  
However, only pyrogallol, propyl gallate and benserazide displayed moderate to low 
potency, ranging between EC50 1-11µM (Deng and Fang, 2013).  It was noted that this 
group of GPR35 active compounds was lacking a carboxylate function and, therefore, this 
may indicate a distinct mode of binding in comparison to previously identified GPR35 
agonists that contain a formal negative charge. 
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1.4.3 Receptor mutagenesis studies 
Despite the evident structural diversity which exists between GPR35 agonists, only a 
handful of studies has addressed the basis of ligand binding, either in relation to the 
importance of the acidic moieties or the wide ranging species selectivity. 
The first insights into amino acids critical for ligand-binding or activation of GPR35 
resulted from a mutagenesis study carried out by Jenkins and colleagues (Jenkins et al., 
2011).  An earlier publication highlighted that an arginine in TMDIII, located at position 
3.36 [according to the Ballesteros and Weinstein (1995) numbering system], was of critical 
importance for the binding of small ligands containing a carboxylate moiety, including 
lactate, to GPR81 (Liu et al., 2009). Given that residues crucial for ligand binding are often 
conserved amongst closely related ‘rhodopsin-like’ GPCRs and that GPR35 ligands are 
generally negatively charged and contain a carboxylate moiety or a related bioisoteric 
group; Jenkins and colleagues (2011) carried out a similar mutagenesis study (Jenkins et 
al., 2011). The substitution of arginine - a positively charged basic residue, for an alanine 
– a non-polar residue, at position 3.36 in both rat and human GPR35, eliminated efficacy 
and potency of zaprinast, KYNA and a newly identified ligand, compound 10, at GPR35 in 
both species whilst membrane expression of these mutants remained unaffected. 
Moreover, a second mutant, this time substituting tyrosine for leucine (a non-polar 
residue) at position 3.32 had a similar effect in that both human and rat GPR35 essentially 
lost responsiveness to both zaprinast and KYNA (Jenkins et al., 2011). A series of 
competition assays was then performed to assess allosteric binding potential and results 
suggested that increasing concentrations of either ligand had no effect on the ability of the 
other to reach a maximal response at GPR35.  These findings, and those relating to 
mutagenesis, are consistent with zaprinast and KYNA sharing an overlapping, orthosteric 
binding site to which the positively charged arginine located within TMDIII at position 3.36 
contributes (Jenkins et al., 2011).  
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Alongside the identification of the high potency GPR35 agonists lodoxamide and brufolin, 
MacKenzie et al. (2014) also explored the importance of site specific residues within the 
GPR35 ligand binding pocket (Mackenzie et al., 2014).  Computational modelling and 
ligand docking studies helped to generate a series of GPR35 mutants designed to define 
additional crucial arginine residues within the boundaries of TMDIII and VII, a suggested 
area of ionic interaction.  Mutation of two arginines at positions 6.58 and 7.32 significantly 
reduced the potency of lodoxamide, whilst having little effect upon zaprinast, suggesting 
that the binding sites of these ligands are distinct (Mackenzie et al., 2014). This may not 
be surprising, given that lodoxamide and brufolin possess a di-acid structure. However, in 
contrast to many high potency GPR35 ligands containing a carboxylate moiety, which 
often exhibit rodent GPR35 selectivity, these compounds show equivalent potency 
between rodent and human orthologues.  This led MacKenzie et al. (2014) to generate 
and examine a series of cross-species amino acid substitutions.  Interestingly, the results 
suggested that whilst the majority of these ligands share a central, arginine-based binding 
domain, those ligands possessing additional carboxylate groups require a further binding 
site and this may facilitate high potency interactions with GPR35.  Furthermore, these 
additional binding sites are often poorly conserved between species and may explain the 
frequency of species selective ligands, with the exception of lodoxamide and brufolin 
(Mackenzie et al., 2014). 
These findings are largely in agreement with a study recently published by Zhao and 
colleagues (2014).  These authors also performed computational modelling and more 
restricted site-directed mutagenesis to identify crucial amino acid residues essential for 
the binding of zaprinast and pamoic acid to human GPR35 (Zhao et al., 2014).  Their 
findings suggest, like MacKenzie et al. (2014) that key positively charged arginine 
residues residing within TMD 3, 4, 5 and 6 are most prominently involved in ligand 
recognition (Zhao et al., 2014). Furthermore, this study also assessed the importance of 
arginines located within the second extracellular loop (ECL) of GPR35 and discovered 
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that, whilst several of these are common recognition sites for zaprinast and pamoic acid, 
the mutation of one arginine, R(167) selectively reduced pamoic acid potency by 4-fold 
(Zhao et al., 2014).  Despite the highly conserved nature of ‘rhodopsin-like’ GPCRs, the 
second ECL is understood to be most variable in relation to both receptor type and 
species (Katritch et al., 2013) and, therefore, this publication is the first to demonstrate 
that differential binding sites exist within the second ECL for GPR35 ligands and this also 
may contribute to human orthologue selectivity displayed by pamoic acid (Zhao et al., 
2014). 
1.4.4 Identification of GPR35 Antagonists 
Two antagonists of GPR35 have been described; CID-2745687 (methyl-5 
[(tertbutylcarbamothioylhydrazinylidene) methyl]-1-(2, 4-difluorophenyl) pyrazole-4-
carboxylate) (Zhao et al., 2010) and ML-145 (2-hydroxy-4-[4-[(5Z)-5-[(E)-2-methyl-3-
phenylprop-2-enylidene]-4-oxo-2- sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino] 
benzoic acid) (Heynen-Genel et al., 2010).  Both demonstrate nanomolar potency at 
GPR35, and are highly selective for the human orthologue and elicit little or no effect at 
rodent orthologues (Zhao et al., 2010, Heynen-Genel et al., 2010, Jenkins et al., 2012). 
First identified by Zhao and colleagues (2010), CID-2745687 demonstrated an ability to 
block agonist induced β-arrestin translocation and ERK1/2 phosphorylation with high 
affinity with a reported Ki  of 12.8nM and 18nM, respectively (Zhao et al., 2010).  
Furthermore, these authors noted that this compound only elicited an antagonistic 
response at human GPR35, with no effect upon the mouse orthologue.  This is in 
agreement with findings published by Jenkins and colleagues, who have consistently 
demonstrated nanomolar potency of CID-2745687 at the human orthologue, with 
negligible effects at rodent forms of GPR35 (Jenkins et al., 2012). A short time later a 
second high affinity GPR35 antagonist, ML-145, was identified (Heynen-Genel et al., 
2010). This compound was highlighted via a probe report from the NIH Molecular Libraries 
Program and resulted from a screen for antagonists against both GPR35 and GPR55.  
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Importantly, ML-145 demonstrated >1000-fold affinity for GPR35 over GPR55 (Heynen-
Genel et al., 2010). Following this, Jenkins and colleagues examined the molecular 
pharmacology of ML-145 more closely using multiple assay systems, which included β-
arrestin translocation, receptor internalisation and IP-1 accumulation (Jenkins et al., 
2012).  Notably, ML-145 was also a human GPR35-selective antagonist and, like CID-
2745687, a competitive inhibitor of zaprinast and cromolyn disodium but a non-
competitive antagonist of pamoic acid (Jenkins et al., 2012) at this receptor. The 
molecular basis for the species selectivity of these compounds has not yet been reported. 
1.5 Cardiovascular Disease 
Recent epidemiological evidence highlights that cardiovascular disease (CVD) is the 
predominant cause of mortality within western civilisation and it is estimated that one 
person will die every 37 seconds of a cardiovascular related disease in the USA alone 
(Lloyd-Jones et al., 2010).  CVD is a multifaceted condition and incorporates various 
diseases including hypertension, atherosclerosis and resulting end-organ damage of the 
kidneys, brain and heart (Wald et al., 2009).  Hypertension and subsequent 
atherosclerosis are thought to be significant hallmarks of CVD and up to 11% of all deaths 
in developed countries are attributed to the hypertensive state (Lloyd-Jones et al., 2010). 
In order to target multiple disease pathologies treatment often constitutes a combination of 
medications including β-blockers, Ca2+ channel inhibitors, angiotensin converting enzyme 
(ACE) inhibitors and diuretics (Wald et al., 2009).  
As research within this field progresses and diagnostic biomarkers become increasingly 
more accurate (Wang et al., 2006b, Vasan, 2006), it is expected that the prevalence of 
conditions stemming from CVD will continue to rise.  It is unsurprising, therefore, that 
translational medicine remains at the forefront of research directed toward the 
development of new therapies to treat CVD and its related conditions.  
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1.5.1 A role for GPR35 in the pathology of CVD 
As discussed in section 1-3-3 (Putative functions of GPR35), GPR35 has been implicated 
in numerous disease pathologies since its discovery almost 15 years ago (O'Dowd et al., 
1998).  However, despite various investigations, such links remain uncertain.  Collectively, 
evidence, although in many cases circumstantial, strongly suggests that GPR35 may play 
a part in the pathology of CVD, particularly in hypertension and heart failure (Barth et al., 
2009, Min et al., 2010, Ronkainen et al., 2014). Moreover, data from genome wide 
association studies (GWAS) have further implicated GPR35 in multiple disease states 
which include the identification of a polymorphic isoform which strongly and positively 
correlates with the incidence of CAD in man (Sun et al., 2008). The following section aims 
to discuss the pathologies of the various diseases which affect the cardiovascular system, 
the treatment options which currently exist and evidence of a requirement for the 
development of novel interventions and therapeutics.  
1.5.1.1 Hypertension, its treatment and limitations 
The World Health Organisation (WHO) defines the diagnosis criteria for human essential 
hypertension as a reading of systolic blood pressure (SBP) ≥140mmHg and/ or diastolic 
blood pressure (DBP) ≥90 (Whitworth, 2003).  Most recent guidelines categorise this in to 
three fields of severity; ‘pre-hypertension’ (SBP 120-139mmHg, DBP 80-89mmHg), ‘stage 
I hypertension’ (SBP 140-159mmHg, DBP 90-99mmHg) and the most severe, ‘stage II 
hypertension’ (SBP≥160mmHg, DBP≥100mmHg) (Weber et al., 2014).  Before a 
diagnosis is confirmed, it is common for patients to receive two consecutive readings on 
separate occasions, 1-4 weeks apart, or in some cases, 24-hour ambulatory monitoring is 
required (Weber et al., 2014).  
The etiology of human essential hypertension is complex and its development is often 
idiopathic in nature.  However, factors such as age, gender, environment and genetics 
highly influence its prevalence (Whitworth, 2003, Egan et al., 2010).  For example, it has 
78 
 
been estimated that genetic factors may account for up to 15-40% of hypertensive 
pathophysiology (Staessen et al., 2003).  To this end, genetic disorders which relate to 
ethnicity, geographical location and gender are well documented (Carretero and Oparil, 
2000).  However, the contribution of specific genetic interactions in human essential 
hypertension remains largely unknown (Delles et al., 2010).  Ultimately, if uncontrolled, 
hypertension can lead to an increased pulse pressure and arterial stiffness translating to 
end-organ damage of the heart, kidney, vasculature and brain (Safar et al., 2012). 
Consequently, undiagnosed hypertension can significantly increase cardiovascular risk 
and is thought of as a silent killer (Korhonen et al., 2013). 
As previously noted, the conventional mode of treatment for patients with essential 
hypertension is often a combination of two or more medications (Staessen et al., 2003, 
Gradman et al., 2010).  Practically, combination treatment is designed to address several 
fundamental mechanisms that regulate BP; total blood volume, vascular tone and cardiac 
function (Lifton et al., 2001).  Therefore, a representative treatment regimen may 
constitute a diuretic to increase sodium excretion; an angiotensin converting enzyme 
(ACE) inhibitor to prevent the conversion of angiotensin-I (Ang I) to angiotensin-II (Ang II), 
(a potent vasoconstrictor) and, finally, β-blockers are also prescribed to reduce total 
cardiac output via the dual antagonism of the β1AR in heart tissue and kidneys, reducing 
heart rate and the release of renin, respectively (Gradman et al., 2010). Information 
gained from randomised clinical trials indicate that the development of combination 
treatment has significantly improved the number of patients with ‘controlled hypertension’ 
by up to 25% in the recent decade (Egan et al., 2010, Turnbull, 2003). Despite these 
outstanding achievements, on a population scale it is estimated that between 30-55% of 
hypertensive patients remain resistant to existing therapies or have poor adherence levels 
as a result of unwanted side-effects to medication and are therefore classed as having 
‘resistant’ or ‘uncontrolled’ hypertension, respectively (Calhoun et al., 2008a, Egan et al., 
2010).  Unfortunately, poor control of BP, for whichever reason, significantly increases 
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mortality risk and therefore, the treatment of hypertension is an area of unmet clinical 
need and further investigative research is warranted towards the discovery and 
development of new therapies (Persell, 2011). 
1.5.1.2 Atherosclerosis and CAD, interventions and treatment  
Together with hypertension, the presence of atherosclerosis is a significant hallmark of the 
cardiovascular disease state (Lloyd-Jones et al., 2010). The pathophysiology of 
atherosclerosis involves a progressive inflammatory cascade within the vasculature and 
ultimately results in the formation of a ‘fatty streak’ which can develop into a fibrotic plaque 
or ‘fibroatheroma’ (Weber and Noels, 2011).  This process is initiated following endothelial 
cell damage and activation caused by exposure to increased biomechanical forces within 
the vasculature, often specifically at ‘pro-atherosclerotic’ artery bifurcation points (Moore 
and Tabas, 2011, Sima et al., 2009). Once activated, endothelial cells express vascular 
cell adhesion molecule-1 (VCAM-1) and pro-inflammatory chemokines which attract 
circulating low-density lipids (LDLs); a process which is greatly exacerbated in 
hypercholesterolemia (Khan et al., 1995, Dansky et al., 2001).  The atherosclerotic 
process is advanced following the adhesion of circulating leukocytes, namely monocytes 
and neutrophils, to the endothelium via interactions between α/β-integrins and adhesion 
molecules (Weber and Noels, 2011). Following this, intercellular adhesion molecule-1 
(ICAM-1) and VCAM-1 promote the lateral migration of monocytes into the sub-endothelial 
space (Dansky et al., 2001) where, due to their high level of plasticity, they are able to 
differentiate into macrophages which scavenge oxidised LDL (oxLDL) and other cell 
debris (Woollard and Geissmann, 2010).  These become macrophage ‘foam cells’ and 
form the initial lipid laden ‘fatty streak’ evident in early atherosclerosis.  However, as 
atherosclerosis advances macrophages become apoptotic, giving rise to the development 
of a necrotic core (Moore and Tabas, 2011). Advanced atherosclerosis involves plaque 
stabilisation via the deposition of extracellular matrix (ECM) proteins and migration of 
smooth muscle cells (SMCs) into the sub-endothelial space (Moore and Tabas, 2011). 
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However, over time, destabilisation and rupture may occur following plaque exposure to 
shear stress, macrophage-specific protease enzymes which can degrade the fibrotic cap 
[matrix metalloproteinase (MMP)] and further vascular cell apoptosis, enlarging the 
necrotic core (Moore and Tabas, 2011). Critically, mobilisation of a plaque or subsequent 
thrombus formation may cause cerebral stroke or myocardial infarction (MI), depending on 
the origin of the lesion (Virmani et al., 2005).  
Atherosclerotic lesion formation and calcification burden can be quantified in patients 
using non-invasive imaging techniques such as intravascular ultrasound (IVUS) (Taylor et 
al., 2003) and hypercholesterolemia can be identified via assessment of total cholesterol 
and HDL:LDL ratio (Stone et al., 2013a).  Primary prevention strategies encompass the 
control of hypertension, a modified lifestyle regimen and the use of statin therapy to inhibit 
cholesterol synthesis and reduce inflammation of the endothelium (Weber and Noels, 
2011, Charo and Taub, 2011).  Unfortunately, following a major adverse cardiovascular 
event (MACE) such as MI, primary prevention strategies are not singly appropriate and 
must be applied alongside secondary prevention revascularisation procedures such as the 
deployment of percutaneous transluminal coronary angioplasty (PTCA) and drug eluting 
stents or coronary artery bypass grafting (CABG), depending on the site and severity of 
vessel occlusion (Thygesen et al., 2012).  
Patients receive PTCA treatment following the narrowing of one or more vessels and the 
procedure involves the advancement of a balloon tipped catheter via the groin and into the 
heart where it is inflated at the location of vessel occlusion in order to the ‘clear’ the 
obstructive plaque.  Following this, a metal framed cylinder (stent) is deployed to stabilise 
the vessel and the catheter is removed.  Although 5 year survival rates are high; 89.5-
95%, associated with the number of vessels affected, a major contributor to failure rates is 
restenosis of the vessel and this occurs following 30-40% of stent deployments (Smith et 
al., 2001).  Restenosis occurs following loss and dysfunction of the vascular endothelium 
and subsequent injury to the internal elastic lamina following balloon inflation and stent 
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deployment can damage the medial layer of the vessel wall, collectively promoting the 
stimulation of vascular SMC proliferation, migration and inflammatory reactions (Otsuka et 
al., 2012).  To prolong longevity, researchers have developed drug-eluting stents (DES) 
as opposed to bare metal stents (BMS), which utilise coated polymers including, for 
example, sirolimus and paclitaxel to prevent the induction of proliferative and migratory 
SMCs (Van der Heiden et al., 2013, Otsuka et al., 2012).  However, it became evident that 
DES were subject to severe late restenosis and this was related to a 50% reduction in re-
endothelialisation up to 5-40 months following the deployment of drug eluting stents in 
comparison to BMS, highlighting the importance of endothelial cell viability in the 
prevention of restenosis (Joner et al., 2006).  
CABG is the most widely elected procedure following MI which involves multi-vessel 
occlusion.  According to recent statistics, it has been estimated that >400,000 CABG 
procedures are performed in a single year in the USA alone (Rosamond et al., 2008).  
Despite the investment of time and resources to treat this disease, and the use of 
alternative vessel sources such as radial and mammary arteries in the bypass procedure, 
autologous saphenous vein is still widely utilised, especially when multi-bypass 
procedures are required. The effective patency rates of vein grafts are severely reduced 
over time and, currently, failure rates are as high as 50%, 10 years post CABG (Rienstra 
et al., 2008) and previous evidence has shown that 5 years post CABG, >25% of vein 
grafts will fail (Eagle et al., 1999).  In order to effectively prevent vein graft failure, it is 
important to understand its causal mechanisms.  Intimal hyperplasia plays an important 
role in vein graft occlusion, with neointima formation resulting from vascular smooth 
muscle cell (VSMC) proliferation and migration to the sub-endothelial intima alongside the 
deposition of circulating monocytes and neutrophils.  The most common source for 
coronary artery bypass vessels is the human saphenous vein (HSV) due to its ready 
availability, autologous nature and the frequent requirement for bypassing multiple vessel 
occlusion in many patients.  However, shear stress presented by the coronary circulation 
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can cause damage to, and potential loss of, endothelial cells (ECs) or induce EC 
activation, resulting in the secretion of inflammatory cytokines and growth factors that 
promote VSMC proliferation and migration (Rienstra et al., 2008).  Furthermore, ischemia 
and subsequent reperfusion result in reactive oxygen species (ROS) production 
contributing to EC and VSMC death and inflammation via activation of the NFkB pathway 
(Eltzschig and Eckle, 2011).  NFkB is also integral to VSMC migration and proliferation via 
modulating matrix metalloproteinases (MMPs) and their endogenous inhibitors, the tissue 
inhibitors of metalloproteinases (TIMPs) (Wan et al., 2012b).  Given that the nature of the 
bypass procedure presents a short therapeutic window for ex vivo vessel treatment, 
investigators have begun to assess the potential of adenoviral mediated gene delivery 
alongside drug exposure in this setting (Wan et al., 2012a). Despite this progress, limited 
novel therapies have successfully reached the clinic and there remains a requirement for 
new interventions in the setting of vein graft failure. 
1.5.1.3 Heart failure and treatment  
Of the many pathologies which lead to heart failure, a 5 year prognosis following 
myocardial infarction indicates it is fatal for 65% of patients (Passier et al., 2008). 
Ischemic heart disease results from a single coronary artery occlusion or multi-vessel 
disease which prevents adequate blood perfusion to the surrounding myocardium, further 
resulting in cardiomyocyte death and the formation of scar tissue via fibrosis (Maillet et al., 
2013). Cardiac hypertrophy and remodelling is an adaptive response which enables 
cardiac output to be maintained and stabilises the heart, reducing its acute vulnerability to 
rupture. However, following prolonged cardiac remodelling and fibrosis, progressive scar 
formation and lack of functional cardiomyocytes detracts from the overall pump function of 
the heart, resulting in severely diminished contractile function (left ventricular ejection 
fraction <35%) (Keteyian, 2013). This leads to detrimental effects upon vital organs to 
which a limited oxygen supply is being delivered, ultimately resulting in end-organ 
damage. Moreover, when large areas of the myocardium become ischemic, cell-cell 
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interactions may become disrupted resulting in an uncoupling of electrical activity, 
potentially giving rise to ventricular-arrhythmias and sudden cardiac death (Cascio et al., 
2005). 
Thus far, treatment options for heart failure are challenging and pharmacological 
interventions are designed to reduce pre- and after-loads which are exacerbated by 
hypertension, as well as total cardiac output (McMurray et al., 2012).   This can be 
managed via therapies such as diuretics, ACE inhibitors and β-blockers.  However, due to 
the non-regenerative nature of the human heart, progressive heart failure ultimately 
requires heart transplant and thus, patient mortality rates are high (Passier et al., 2008).  
Therefore, the importance of developing novel pharmaceuticals which have improved 
specificity in relation to patient and disease whilst presenting minimal risk of cardiac-
toxicity, is becoming increasingly evident (Matthews and Frid, 2010).  
 
1.6 Hypothesis and aims 
Taking together the evidence which suggests a role for GPR35 in disease, a robust 
cardiovascular element exists within the current literature.  Whilst evidence from genome-
wide association and gene expression studies has linked GPR35 to both CAD (Sun et al., 
2008) and heart failure (Min et al., 2010), respectively, subsequent investigation of the 
phenotypic profile of mice lacking the GPR35 gene has highlighted that systolic blood 
pressure is significantly increased in these models, suggesting that GPR35 expression 
and thus, activation, may be essential for the maintenance of blood pressure. Moreover, a 
recent study, investigating the expression of GPR35 in vitro and in vivo following exposure 
to acute and chronic ischemia within cardiomyocytes and tissue, reported GPR35 as a 
prominent and novel biomarker in the development of acute heart failure, directly 
promoted by the binding of hypoxic marker, HIF-1 (Ronkainen et al., 2013).   Therefore, to 
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investigate the potential role GPR35 may play in the development of cardiovascular 
diseases, a series of aims were devised: 
• To pharmacologically characterise and identify potent agonists and antagonists of 
GPR35 which activate multiple species orthologues, providing the opportunity to 
realistically target GPR35 in both an in vitro and in vivo setting, for the first time.  
• To investigate the role GPR35 might play in human saphenous vein smooth 
muscle and endothelial cell migration, proliferation and morphology, which 
demonstrate high expression levels of GPR35. 
• Further to this, an additional aim will be to dissect the role of GPR35 and Gα12/13 
mediated signalling in vascular cell culture models, using a multiple assay system 
approach.  
• Finally, we hope to elucidate a role for GPR35 in the setting of hypertension and 
related end-organ damage by measuring the effects of GPR35 activation on 
haemodynamic and cardiac properties in the spontaneously hypertensive stroke 
prone rat (SHRSP). 
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2 Materials and Methods 
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2.1 Pharmacological reagents 
Zaprinast (2-(2-Propyloxyphenyl)-8-azapurin-6-one), CID-2745687 (1-(2,4-
Difluorophenyl)-5-[[2-[[(1,1-
dimethylehyl)amino]thioxomethyl]hydrazinylidene]methyl]-1H-pyrazole-4-carboxylic 
acid methyl ester), and ML-145 (-Hydroxy-4-[4-(5Z)-5-[(E)-2-methyl-3-phenylprop-2-
enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid): 
Tocris Bioscience, Bristol, UK. 
Pamoic acid (1, 1′-Methylene-bis(2-hydroxy-3-naphthoic acid)), cromolyn disodium 
(disodium;5-[3-(2-carboxylato-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-
oxochromene-2-carboxylate) and amlexanox (2-Amino-7-(1-methylethyl)-5-oxo-5H-
[1]Benzopyrano[2,3-b]pyridine-3-carboxylic acid): 
Sigma-Aldrich Company, Dorset, UK 
Y-27632 (R)-(+)-trans-4-(1-Aminoethyl)-N-(4-Pyridyl)cyclohexanecarboxamide 
dihydrochloride: 
Calbiochem, UK 
Y-16 (4-{3-[(3-methylbenzyl)oxy]benzylidene}-1-phenyl-3,5-pyrazolidinedione): 
ChemBridge, CA, US 
 
2.2 Chemical reagents 
Coelentrazine-h: 
Promega, Southampton, UK 
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Hygromycin-B and Zeocin: 
Roche, West Sussex, UK 
Blasticidin: 
Life Technologies, Thermo Fischer Scientific, Renfrew, Scotland, UK 
Polyethylenimine (PEI): 
Polysciences, Warrington, PA, USA 
Tetramethylrhodamine (TRITC) actin phalloidin stain and dimethyl sulfoxide 
(DMSO): 
Sigma-Aldrich Company, Dorset, UK 
ProLong® Gold Antifade Mountant with DAPI and Immumount: 
Life Technologies, Thermo Fischer Scientific, Renfrew, Scotland, UK 
 
2.3 Buffers and solutions 
Hank’s Balanced Salt Solution (HBSS) and Phosphate Buffered Saline (PBS): 
GIBCO® Life Technologies, Thermo Fischer Scientific, Renfrew, Scotland, UK 
0.25% Trypsin-ethylenediaminetetraacetic acid (EDTA) and poly-D-lysine: 
Sigma-Aldrich Company, Dorset, UK 
Tris-EDTA (TE) buffer: 
5mM Tris-base, 5mM EDTA in 5 Litres in H2O (pH 7.4) 
DNA loading dye (5X): 
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QIAGEN, West Sussex, UK 
Laemmli Buffer (5X): 
0.4M DTT, 0.17M sodium dodecyl sulphate (SDS), 50mM Tris-base, 5M urea and 0.01% 
bromophenol blue. Stored at 4°C. 
 
Tris-Buffered Saline with Tween 20 (TBST) Buffer: 
50mM Tris, 150mM sodium chloride (NaCl), 0.05% Tween 20 in 500mL of H2O. 
 
Competent bacteria: 
Buffer 1: 1M potassium acetate, 1M rubidium chloride (RbCl2), 1M calcium chloride 
(CaCl2), 1M manganese chloride (MnCl2), 80% (w/v) glycerol = 100mL de-ionised water 
(pH 5.8). Stored at 4°C. 
Buffer 2: 100mM 3-(N-morpholino)propanesulfonic acid (MOPS) (pH 6.5), 1M CaCl2, 1M 
RbCl2, 80% (w/v) glycerol = 40mL de-ionised water (pH 6.5).  Stored at 4°C. 
 
Radioimmunoprecipitation assay (RIPA) buffer (1X): 50mM Hepes, 150mM NaCl, 1% 
(v/v) Triton-X-100, 0.5% (w/v) NaDeoxycolate, 0.1% (w/v) SDS, 10mM sodium fluoride 
(NaF), 5mM EDTA, 10mM monosodium phosphate (NaH2PO4), 5% (v/v) ethylenglycol (pH 
7.3) + protease inhibitor cocktail. Stored at -20°C. 
 
Paraformaldehyde (4%): 40g polyoxymethylene, 800ml PBS at 60°C (pH 6.9). Stored at 
-20°C. 
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Luria-Broth (LB): 1% Tryptone, 0.5% yeast extract and 10g NaCl = 1L H2O (pH 7.0) 
Autoclaved at 126°C and used within 24 hours. 
 
Luria-agar (LA): 1% (w/v) Tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl and 1.5% 
(w/v) Bacto-agar = 1L H2O (pH 7.0) and autoclaved at 126°C. Once cooled, 50mg/mL 
ampicillin was added and the agar broth was poured into 10cm3 dishes and solidified 
before storage at 4oC. 
 
Krebs solution: 0.25M NaCl, 0.001M KCL, 2mM magnesium sulphate (MgSO4), 50mM 
sodium bicarbonate (NaHCO3), 2mM potassium dihydrogen orthophosphate (KH2PO4), 
2mM CaCl2 (pH 7.4). Oxygenated with 95% O2 and 5% CO2. 
 
2.4 Molecular biology and cloning techniques 
2.4.1 Preparation of competent bacteria 
XL1 Blue competent cells were streaked out on an agar plate without antibiotics and 
grown overnight at 37oC. A single colony was grown in 5mL of L-broth overnight at 37oC 
within a shaking incubator and this was sub-cultured into 100mL of L-broth and grown 
until optical density at 550nM was 0.48 using a spectrophotometer. After chilling on ice for 
5 minutes, the cells were subjected to centrifugation at 1000 g for 10 minutes at 4oC.  
Each pellet was re-suspended in 20mL of ‘buffer 1’ (see 2-3 Buffers and Solutions), then 
chilled on ice for 5 minutes and the centrifugation step repeated. Each pellet was then re-
suspended in 2mL of ‘buffer 2’ (see 2-3 Buffers and Solutions) by gentle pipetting and 
chilled on ice for a further 15 minutes. Cells were then aliquotted into 220µL volumes and 
were stored at -80°C. Once thawed, these were not re-used. 
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2.4.2 DNA Transformation 
50ng of plasmid DNA was incubated with 50µL of competent cells on ice for 15 minutes. 
The cells were heat treated for 90 seconds at 42°C in a water bath (to make them porous) 
and were returned to ice for 2 minutes prior to addition of 450µL sterile L-broth. Cells were 
then recovered at 37°C for 45-60 minutes within a shaking incubator. Next, 50-200µL was 
then added to an agar plate containing 50mg/mL Ampicillin. The plates were incubated 
overnight at 37°C and transformed colonies were selected and cultured overnight in 5mL 
of L-broth containing 50mg/mL Ampicillin. The resulting cultures were either DNA mini-
prepped or sub-cultured within 100mL of L-broth containing 50mg/mL Ampicillin to 
produce larger amounts of plasmid DNA. 
 
2.4.3 DNA mini prep 
Small cultures of plasmid DNA were purified using the Wizard® Plus SV Minipreps DNA 
Purification System (Promega, Southampton, UK) as per manufacturer’s instructions. 
Briefly, plasmid culture was subjected to centrifugation at maximum speed for 5 minutes 
at room temperature (RT) and the remaining pellet was gently re-suspended in 250μL of 
re-suspension buffer [50 mM Tris-hydrogen chloride (HCl), 10 mM EDTA, 100 μg/mL 
RNase A (pH 7.5)]. Cells were then lysed following the addition of 250μL of lysis buffer 
(0.2M sodium hydroxide (NaOH), 1% SDS). After 5 minutes, the lysis buffer was 
neutralised by the addition of 350μL of neutralisation buffer [4.09M guanidine 
hydrochloride, 0.76M potassium acetate, 2.12M glacial acetic acid (pH 4.2)]. 850µL of 
cultured plasmid DNA was then transferred to a spin column and subjected to 
centrifugation at maximum speed for 1 minute at RT. The flow-through was discarded and 
750μL of wash solution [162.8mM potassium acetate, 22.6mM Tris-HCl (pH 7.5), 
0.109mM EDTA (pH 8.0) (diluted with 95% ethanol)] was added to the spin column and it 
was again subjected to centrifugation at maximum speed for 1 minute at RT. This step 
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was then repeated using 250μL of wash solution and centrifugation was at maximum 
speed for 2 minutes at RT using a new collection tube. The column was transferred into a 
new, sterile 1.5mL Eppendorf tube and plasmid DNA was eluted by adding 50-100μL of 
nuclease-free water and subjecting to centrifugation at maximum speed for 1 minute at 
room temperature. Plasmid DNA was quantified by measuring the absorbance of a 1:00 
dilution in H2O at 260nm and 280nm using a spectrophotometer.  Ratios of A260/A280 
between 1.7 and 2.0 were considered pure and plasmids were then stored at –20°C or 
below for future use. 
 
2.4.4 DNA maxi prep 
Larger volumes of plasmid cultures were purified using a QIAGEN plasmid maxiprep kit 
(QIAGEN, West Sussex, UK) according to the manufacturer’s instructions. Briefly, 50mL 
aliquots of cultured plasmid were harvested via centrifugation at 6000 x g for 15 min at 
4°C and the remaining pellet was then vigorously re-suspended within suspension ‘buffer 
P1’ [50mM Tris·Cl, 10mM EDTA and 100μg/ml RNase A (pH 8.0)] and then lysed by 
adding 10mL of lysis buffer P2 [200 mM NaOH, 1% SDS (w/v)], gently inverting (so as not 
to shear genomic DNA) the tube to mix and it was then incubated for 5 minutes. The lysis 
reaction was stopped by addition of 10mL neutralisation ‘buffer P3’ [3.0M potassium 
acetate (pH 5.5)] and the solution was chilled on ice for 15 minutes. Next, samples were 
added to QIAfilter Maxi Cartridges which enable filtration and lysate was cleared.  Using a 
QIAGEN-tip 100 which had been ‘primed’ with 10mL of equilibration ‘buffer QBT’ [750mM 
NaCl, 50mM MOPS, 15% isopropanol (v/v), 0.15% Triton X-100 (v/v) (pH 7.0)], the 
remaining supernatant was added and passed through the membrane via gravity flow. 
The QIAGEN-tip was then washed twice with 10mL of ‘buffer QC’ [1.0M NaCl, 50mM 
MOPS, 15% isopropanol (v/v), (pH 7.0)] to remove all contaminants. Finally, the DNA was 
eluted with 5mL of ‘buffer QF’ [1.25M NaCl, 50mM Tris-Cl and 15% isopropanol (v/v) (pH 
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8.5)] and was precipitated by adding 3.5mL of isopropanol and subjected to centrifugation 
at ≥15,000 x g for 30 minutes at 4°C. Once the supernatant was removed, the remaining 
pellet was washed with 2mL ethanol (70%) to remove precipitated salt and centrifugation 
performed at  ≥15,000 x g for 10 minutes. Again, removing the supernatant, the pellet was 
air dried and re-dissolved in 1mL of nuclease-free water. Plasmid DNA was quantified by 
measuring the absorbance of 1:00 dilution at 260nm and 280nm using a 
spectrophotometer.  Ratios of A260/A280 between 1.7 and 2.0 were considered pure and 
plasmid preps were then stored at –20°C or below for future use 
 
2.4.5 Polymerase Chain Reaction (PCR) 
To amplify specific sections of DNA or to introduce terminal sequences, PCR was 
routinely performed within PCR Eppendorfs in a total reaction volume of 50µl; 
• 20ng of DNA template (e.g. genomic DNA) 
• 0.8mM dNTPs (0.2 mM each deoxyadenosine triphosphate (dATP), deoxycytidine 
triphosphate (dCTP), deoxyguanosine triphosphate (dGTP) and deoxythymidine 
triphosphate (dTTP)) 
• 25pmole/µL of forward oligonucleotide primers 
• 25pmole/µL of reverse oligonucleotide primers 
• 1x PFU buffer (20mM Tris-HCl, pH 8.2, 10mM potassium chloride (KCl), 6mM 
ammonium sulfate ((NH4)2SO4), 2mM MgCl2, 0.1 % Triton X-100, 10mg/mL BSA) 
• 2.5U PFU enzyme  
Reaction mixtures underwent specific thermic cycle reactions designed to break down 
hydrogen bonds to create single-stranded DNA by heating, then allowing the primers to 
anneal at a cooler temperature.  The reaction was re-heated to promote elongation of the 
DNA strands. This reaction underwent many repetitions to create an abundance of DNA 
copies. Finally, these were cooled to allow for the hydrogen bonds to reform, once again 
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creating stable, double-stranded DNA.  The following protocol was carried out on an 
Eppendorf Gradient Thermocycler PCR machine: 
1. Preheating 95°C - 5 minutes  
2. Denaturation 95°C - 1 minute 
3. Annealing 50-60°C [depending on primer melting temperature (Tm)] - 1 minute 
4. Extension 72°C - 3 minutes 
5. Repeat step 2-4 (X 29) 
6. Final extension 72°C - 10 minutes 
7. Hold at 4°C 
 
2.4.6 Protein purification 
Following PCR reactions, samples were then purified using a QiaQuick PCR purification 
kit (QIAGEN, West Sussex, UK) according to the manufacturer’s instructions. DNA was 
eluted from the purification column using 30-50μL of sterile H2O. 
2.4.7 Agarose gel electrophoresis 
To isolate specifically amplified PCR products from DNA templates, gel electrophoresis 
was used. The samples were diluted in a DNA loading buffer (x5) and were loaded onto a 
1% (w/v) agarose gel with 1X TAE buffer and 1% (w/v) SYBR Safe gel stain (Life 
Scientific). Once gels were set within moulds, they were immersed in 1X TAE buffer and 
the samples were subjected to electrophoresis at a 75 milliamp voltage alongside a 
molecular weight marker (Rainbow™, Sigma-Aldrich). The appropriately sized fragments 
were then visualised using ultraviolet light and excised for purification. DNA fragments 
were then purified using QiaQuick gel extraction kit (QIAGEN, West Sussex, UK), 
according to the manufacturer’s instructions and were eluted into 30µL sterile H20. 
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2.4.8 DNA restriction endonuclease digest 
To clone newly generated DNA fragments into existing vectors, restriction endonuclease 
digestion was performed to create ‘sticky’ ends for ligation into pcDNA3.1. Samples were 
prepared in 50µL volumes using 16-40U of the appropriate enzyme, 5µL buffer for each 
restriction site, 5µg of DNA or vector and sterile H2O to 50µL. 
Rat and Mouse FLAG-GPR35eYFP: 
pcDNA3.1 - BamHI – FLAG-GPR35 – NotI – eYFP – XhoI– pcDNA3.1 
Human GPR35 FLAG-GPR35eYFP: 
pcDNA3.1 – HinDI – FLAG-GPR35 – NotI – eYFP – XhoI– pcDNA3.1 
 
2.4.9 DNA ligation 
Following digestion of DNA fragments and vectors, ligation reactions were performed 
using T4 DNA ligase. A ratio of 1:4 and 1:6 (vector: DNA) was incubated with 1U T4 ligase 
and 1μL ligase buffer (X10) to make a final volume of 10μL in H2O and these were 
incubated at 4 °C for 16 hours.  
 
2.4.10  DNA sequencing 
DNA sequencing was performed by DNA Sequencing & Services (MRCPPU, College of 
Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using Applied 
Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 automated 
capillary DNA sequencer. The resulting sequences were aligned with published DNA 
nucleotide sequences using online Multiple Sequence Alignment software ‘ClustalW2’. 
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2.5 Generation of the mouse FLAG-GPR35-eYFP construct 
To compare the pharmacology of ligands at mouse orthologues of GPR35 using 
bioluminescence resonance energy transfer (BRET) analysis, a mouse FLAG-GPR35-
eYFP construct was generated. PCR primers were designed to incorporate an N-terminal 
epitope FLAG tag and a stop codon was removed at the C-terminal tail to allow for eYFP 
expression within the vector. 
FLAG-Mouse forward primer with BamHI: 
5’TTTTGGATCCGCCACCATGGATTACAAGGATGACGACGATAAGATGAATAGTACAA
CCTGTAACAGCACC-3’ 
FLAG-Mouse reverse primer with NotI: 
5’ TTTTGCGGCCGCGGTGAGGCTCAGGATCTGG-3’ 
These were applied using a standard PCR protocol (described in section 2.5.5) using a 
mouse genomic DNA template. Following purification, PCR products were ligated into a 
pcDNA3.1 expression vector containing eYFP with BamHI and NotI restriction 
endonuclease sites which are underlined in the primer sequences.  These products were 
sequenced to identify the correct mouse FLAG-GPR35eYFP construct sequence. 
 
2.6 Site-directed mutagenesis: 
To identify the crucial residues involved in receptor interaction with ligands, site-directed 
mutagenesis was performed, whereby one nucleotide within either the fourth or seventh 
transmembrane domain (TMD) regions was swapped for an alternative nucleotide in the 
human and rat FLAG-GPR35eYFP constructs.  To introduce these single-point mutations, 
the Quickchange™ Method (Strategene) was used and primers were designed according 
to the manufacturer’s instructions: 
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Human GPR35 R4.60A Forward: 
5’ – GGCTCCCTGGTGGCTGCCTGGCTCCTGGGGATTC – 3’ 
Human GPR35 R4.60A Reverse: 
5’ – GAATCCCCAGGAGCCAGGCAGCCACCAGGGAGCC – 3’ 
Human GPR35 R4.60M Forward: 
5’ – GGCTCCCTGGTGGCTATGTGGCTCCTGGGGATTC – 3’ 
Human GPR35 R4.60M Reverse: 
5’ – GAATCCCCAGGAGCCACATAGCCACCAGGGAGCC – 3’ 
Human GPR35 R6.58Q Forward: 
5’ – GTGGGGCTGACAGTGCAACTCGCAGTGGGCTGG – 3’ 
Human GPR35 R6.58Q Reverse: 
5’ – CCAGCCCACTGCGAGTTGCACTGTCAGCCCCAC – 3’ 
Human GPR35 R6.58A Forward: 
5’ – GTGGGGCTGACAGTGGCCCTCGCAGTGGGCTGG – 3’ 
Human GPR35 R6.58A Reverse: 
5’ – CCAGCCCACTGCGAGGGCCACTGTCAGCCCCAC – 3’ 
Rat GPR35 R4.60A Forward: 
5’ – CACCTCCCTGGTACTGGCCTGGCGCCTGGGGATAC – 3’ 
Rat GPR35 R4.60A Reverse: 
5’ – GTATCCCCAGGCGCCAGGCCAGTACCAGGGAGGTG – 3’ 
Rat GPR35 R4.60M Forward: 
5’ – CACCTCCCTGGTACTGATCTGGCGCCTGGGGATAC – 3’ 
Rat GPR35 R4.60M Reverse: 
5’ – GTATCCCCAGGCGCCACATCAGTACCAGGGAGGTG – 3’ 
Rat GPR35 Q6.58R Forward: 
5’ – GATCCTGACAGTGAGGGTCTCCCTGAACC- 3’ 
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Rat GPR35 Q6.58R Reverse: 
5’ – GGTTCAGGGAGACCCTCACTGTCAGGATC – 3’ 
 
To introduce site-specific mutagenesis, PCR was performed within PCR Eppendorfs in a 
total reaction volume of 50µL using the primers outlined above: 
• 5μL of 10× reaction buffer 
• 5–50ng of dsDNA template 
• 125ng of oligonucleotide forward primer  
• 125ng of oligonucleotide reverse primer  
• 0.2mM of each dNTP  
• 1μL of PfuTurbo DNA polymerase (2.5 U/μL) 
The following protocol was then carried out on an Eppendorf Gradient Thermocycler PCR 
machine: 
1. 95°C for 30 secs (repeat step 1-2 X30) 
2. 50°C for 1 min 
3. 68°C for 7 min  
To digest the parental methylated dsDNA, the PCR reaction was then incubated with 1μL 
of DpnI restriction enzyme for 60 minutes at 37°C. PCR products were then transformed, 
3 colonies were cultured, DNA extracted and then sequenced to identify the appropriate 
receptor mutations underlined above. 
2.7 Generation of Flp-In™ T-REx™ HEK293 inducible mouse 
FLAG-GPR35-eYFP cell line 
Flp-In™ T-REx™ HEK293 cells were co-transfected with 0.8μg of the mouse FLAG-
GPR35eYFP construct within a pcDNA5/FRT/TO vector and 7.2μg pOG44 vector using 
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Lipofectamine (see section 2.9.3). After 48 hours, Opti-mem™ medium (GIBCO® Fisher 
Scientific) was changed to Flp-In™ T-REx™ HEK293 media with 200μg/mL hygromycin-B 
to select cells harbouring the construct. Cells which had not incorporated the receptor did 
not have resistance to hygromycin-B and died.  To prevent cell-death related cytotoxicity, 
the medium was changed regularly. After 2-weeks, established colonies were evident and 
these were gently passaged using Trypsin-EDTA and sub-cultured to new T25cm2 culture 
flasks to grow in replenished medium without hygromycin-B. When the cell line was 
established and growing optimally, a titration of doxycycline was performed to determine 
the optimal concentration of doxycycline required to initiate uniform receptor expression 
by examining eYFP expression across cells (Figure 2-1.) 
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Figure 2-1. Doxycycline titration of the mouse FLAG-GPR35-eYFP cell line. 
Flp-In™ T-REx™ HEK293 cells were plated on clear, 6-well plates and grown until 80% 
confluent. To stably express mouse FLAG-GPR35eYFP, increasing concentrations of 
doxycycline (0-100ng/mL) were added to fresh media and 24 hours later, these were 
imaged for eYFP expression using an epifluorescence microscope. Magnification = X10, 
scale bar = 100µm. 
 
2.8 Culture of cell lines 
All cell lines were cultured within sterile, laminar flow hoods and were grown in a 
humidified incubator (5 % CO2/ 95% air at 37°C). 
 
2.8.1 Maintenance of HEK293t cells 
Human embryonic kidney-293 cells expressing the large T-antigen of SV40 (simian virus 
40) (HEK293T cells) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(GIBCO® Life Technologies) supplemented with 0.292 g/L L-glutamine and 10% (v/v) 
foetal calf serum (FCS).  Cells were passaged every 2-3 days using 0.25 % Trypsin-EDTA 
when they reached 80% confluence. 
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2.8.2 Maintenance of Flp-In™ T-REx™ HEK293 cells 
Flp-In TREx HEK293 cells were maintained in DMEM without sodium pyruvate (GIBCO® 
Life Technologies), supplemented with 10% (v/v) FCS, 1IU penicillin, 100μg/mL 
streptomycin, and 10µg/mL blasticidin. Cells were passaged every 2-3 days using 0.25 % 
Trypsin-EDTA when they reached 80% confluence. 
2.8.3 Maintenance of H9c2 cardiomyocytes 
H9c2 cardiomyocytes were maintained in DMEM (GIBCO® Life Technologies) 
supplemented with 10% (v/v) FCS, 2mM L-glutamine and 1IU penicillin, 100μg/mL 
streptomycin (Life Technologies, Paisley, UK). H9c2 Cells were passaged every 1-2 days 
using 0.25 % Trypsin-EDTA when they reached 50% confluence. 
 
2.9 Cell transfection 
2.9.1 Polyethylenimine (PEI) 
For BRET analysis, HEK293T cells were transfected with the Renilla-luciferase (Rluc) 
tagged β-arrestin-2 and either human, rat or mouse GPR35eYFP-tagged constructs in 
10cm2 dishes. The DNA ratio of Rluc:eYFP was 1:8.  5µg of DNA was used in a total 
transfection and following the addition of 30µg of PEI (ratio 1:6), these were incubated for 
10 minutes at RT. The mixture was then added drop-wise to the dishes containing 10mL 
of fresh medium and incubated for 16 hours before being used for experiments. 
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2.9.2 Lipofectamine  
For the transfection of constructs for microscopy or the generation of Flp-In™ T-REx™ 
HEK293 cells, Lipofectamine and Opti-mem™ medium were used. Once cells had 
reached 60-70 % confluence, 5μg of DNA was diluted in Opti-mem™ to a final volume of 
600μL and 20μL of Lipofectamine diluted in 580μL Opti-mem™ was added drop-wise (this 
could be scaled up or down for the appropriate culture plate or flask). Following a 30 
minute incubation at RT, these were added to a 10cm2 dish with 5mL of fresh Opti-mem™ 
and these were incubated at 37°C. After 4-8 hours, the transfection mixture was removed 
and replaced with the appropriate growth media and the cells were used for experiments 
within 24-48 hours. 
2.9.3 X-fect™ 
To transfect H9c2 cardiomyocytes with rat GPR35eYFP, we used the X-fect™ 
transfection protocol. The cells were seeded on sterile poly-D-lysine coated 6mm glass 
coverslips within 6-well clear plates at a density of 3x104 cells/well. 0.3μL of X-fect 
polymer was used per 1μg of plasmid DNA and for 6-well plates, 4µg of DNA was added 
to each well plus 1.2µL of X-fect polymer and the total volume was made up to 100µL with 
X-fect reaction buffer. Following a 10-minute incubation at RT, this mixture was gently 
added drop-wise to the cells.  Cells were incubated for 4-6 hours at 37°C, after which time 
the media was replenished and the experiment was carried out 12-24 hours later. 
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2.10   The chemical structures and properties of key GPR35 
ligands 
The species-selective properties displayed by various GPR35 ligands has provided 
challenges for pharmacological assessment and despite reports of endogenous activation 
via KYNA and LPA (Wang et al., 2006a, Oka et al., 2010), literature suggests that it is still 
considered an orphan GPCR, at least in human (Milligan, 2011).  The chemical 
composition of key reference GPR35 ligands used in this chapter are structurally defined 
in Figure 2-1.  These are the agonists zaprinast, cromolyn disodium and pamoic acid, and 
the antagonists CID-2745687 and ML-145.  Importantly, these are representative of 
several chemical characteristics often typical of GPR35 ligands highlighted across the 
literature.  For instance, cromolyn disodium and pamoic acid hold a formal negative 
charge via their carboxylic moiety and zaprinast possesses an acid bioisostere, in line with 
the majority of identified GPR35 ligands (Jenkins et al., 2010, Mackenzie et al., 2011, 
Mackenzie et al., 2014). Another feature of high potency ligands at human GPR35 is the 
characteristic di-acid, mirror image structure common to both cromolyn disodium and 
pamoic acid (inverted mirror image, in the case of pamoic acid) (Mackenzie et al., 2014). 
Furthermore, aside from cromolyn, which displays species neutrality - zaprinast and 
pamoic acid display differential species-selective properties.  For zaprinast, a >50-fold 
difference in potency favours rat GPR35 over human; and pamoic acid is an example of 
extreme ligand selectivity in that it displays virtually no activity at rat, whilst reported 
potencies for human GPR35 are within the nanomolar range (Jenkins et al., 2010).  In this 
respect, these are exemplar GPR35 ligands. Interestingly, the GPR35 antagonists CID-
2745687 and ML-145 also display extreme human-GPR35 selectivity and research 
suggests these share overlapping binding positions with zaprinast and cromolyn disodium 
(Jenkins et al., 2012). 
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Figure 2-2.  The chemical structures of key GPR35 ligands. 
The structural properties of GPR35 agonists; zaprinast, cromolyn disodium and pamoic 
acid and human selective GPR35 antagonists CID-2745687 and ML-145 (adapted from 
Jenkins et al., 2012). 
 
2.11  Bioluminescence Resonance Energy Transfer (BRET) 
HEK293T cells were transfected with human, rat or mouse FLAG-GPR35-eYFP and β-
arrestin-2-Renilla luciferase (ratio 4:1), using the PEI transfection method (described in 
section 1.9.1). After 24 hours, the cells were plated in triplicate onto a poly-D-lysine-
coated white 96-well plates at a density of 1x106cells/well and were further incubated for 
up to 16 hours at 37°C. One triplicate condition of ‘mock’ pcDNA3.1 + β-arrestin-2-Renilla 
luciferase was used as a control.  One hour before BRET analysis, the cells were washed 
twice with HBSS (37°C) and incubated in the remaining volume of 70-80µL per well.  
While the cells recovered, serial drug dilutions were made in HBSS at 10X concentrations 
and each was equalised for DMSO content. Prior to the beginning of the experiment, 
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eYFP expression was measured across all wells using a PHERAstar FS reader (BMG-
Labtech, Offenburg, Germany).  First, 10µL of coelentrazine-h (Promega), the substrate 
for Renilla-luciferase, was added to each well to give a final concentration of 5μM and 
cells were incubated in darkness for 10 minutes at 37°C prior to the addition of an agonist. 
Alternatively, if antagonists were being examined, these were added 10 minutes prior to 
the addition of coelentrazine-h. Cells were incubated for a further 5 minutes at 37°C 
before BRET measurements were performed using a PHERAstar FS reader (BMG-
Labtech, Offenburg, Germany). The BRET ratio was calculated as wavelength emission at 
530/485 nm for eYFP and Rluc expression, respectively, and the values were normalised 
to Rluc only control.  These ‘BRET units’ were then expressed as a percentage of the 
maximal signal of zaprinast. 
 
2.12  Quantitative receptor internalisation  
To quantify receptor internalisation following agonist and antagonist exposure, we 
employed an ‘ArrayScan’ High Content Analysis method. Flp-In T-Rex 293 cells 
containing either human FLAG-GPR35-eYFP or mouse FLAG-GPR35-eYFP were seeded 
into poly-D-lysine-coated, clear-bottomed 96-well plates at a density of 6x104 cells per 
well. 24 hours later, these were treated with 100 ng/mL doxycycline to induce receptor 
expression. Up to 24 hours later, the cells were washed twice in HBSS, leaving a 
remaining 50µL of HBSS per well and were incubated with 50µL of 2X concentrated 
ligands for 1 hour at 37°C. Cells were then incubated for another 30 minutes with ligands 
and 10µg/mL Hoechst nuclear stain at 37°C. Images were acquired immediately by using 
a Cellomics ArrayScan II high content imager (Thermo Fisher Scientific, Waltham, MA), 
and internalised receptors were quantified by using a proprietary algorithm designed to 
identify the number of endosomal recycling compartments per cell. Internalisation was 
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normalised to the number of nuclei present and these were expressed as a percentage of 
unstimulated, basal receptor internalisation.  
 
2.13  Inositol Phosphate-1 (IP1) accumulation 
To examine the coupling profile of human GPR35 following pamoic acid stimulation,  
HEK293T cells were transiently co-transfected with the human FLAG-GPR35-eYFP and 
chimeric G proteins Gαq/12, Gαq/13, Gαq/i or full Gαq in 10cm2 dishes using PEI (see section 
2.9.1) and IP1 accumulation was quantified using a HTRF IP-One Tb kit (Cisbio 
Bioassays, MA, USA). Following a 16-hour incubation at 37°C after transient transfection, 
the cells were removed from the dishes using trypsin-EDTA in cell dissociation buffer 
subjected to centrifugation at 5000 g for 5 minutes,  were re-suspended in IP-One 
stimulation buffer (10 mM HEPES, 1mM CaCl2, 0.5mM MgCl2, 4.2mM KCl, 146mM NaCl, 
5.5mM glucose, and 50mM lithium chloride (LiCl), pH 7.4). Samples were added to white, 
round-well, 384-well plates at a density of 1x104 cells/well within 7µL of stimulation buffer. 
Serial dilutions of pamoic acid were made at X2 concentration in stimulation buffer 
according to the manufacturer’s instructions. The cells were then exposed to 7µL of 
pamoic acid (10nM-100µM, final concentration) for 2 h at 37°C. Following this, d2-
conjugated inositol monophosphate (IP1) was exogenously added alongside an anti-IP1 
Lumi4-Tb cryptate, diluted in lysis buffer. The high-throughput format of the IP1 
accumulation assay employs the use of a Lumi-4® IP1 antibody and this competitively 
binds to increasing concentrations of endogenously produced IP1 rather than dye d2-
tagged IP1, which has been added exogenously. Following ligand administration, GPCR 
activation and subsequent IP1 accumulation produces an inverse signal. Following a 
further incubation for 1 hour at RT, homogeneous time-resolved fluorescence was 
measured using a PHERAstar FS plate reader at wavelengths of 665nm and 620nm to 
create a ratio which was multiplied by 1000 to produce IP1 signal units. 
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2.14  Quantification of Rho A activation in HSV SMCs 
2.14.1 GTP-Rho A pull down-assay 
To investigate if pamoic acid stimulation of endogenously GPR35 expressing HSV SMCs 
resulted in the activation of Rho A following coupling to Gα13, we employed a RhoA 
Activation Assay Kit (CellBiolabs, inc) according to the manufacturer’s instructions. To 
minimalize basal Rho A activation, HSV SMCs were plated at a low density of 5x104 
cells/well within 6-well, clear plates. Prior to the experiment, cells were quiesced for 48-
hours and serial dilutions of pamoic acid in serum free media were incubated with the 
cells at 37°C for 5 minutes. Positive and negative controls for Rho A activation were 5% 
serum and 0% serum, respectively. Following stimulation, the cells were placed on ice to 
inhibit physiological processes and were washed twice with ice-cold PBS. 500µL of ice-
cold 1XRIPA buffer was used to lyse the cells and these were placed in a rocking 
incubator at 4°C for 15-minutes. The cells were then collected using a cell scraper and the 
cell lysates were subjected to centrifugation at 14,000 x g at 4°C. The supernatant was 
removed and adjusted to 1mL with 1XRIPA buffer. Before addition of the agarose beads, 
200µL of sample was snap frozen and stored at -70°C for later analysis of total Rho A 
protein. Next, 30μL of Rhotekin RBD Agarose bead slurry was then added to each sample 
and these were incubated at 4°C for 1 hour on a rotating wheel. The beads were pelleted 
by centrifugation at 14,000 x g for 10 seconds and then were washed three times in 500µL 
of 1XRIPA buffer. The beads were then re-suspended in 2X Laemmli buffer (containing 
5% β-mercaptoethanol) and boiled for 5 minutes using a temperature controlled heating 
block. Finally, the beads were pelleted by centrifugation at 14,000 x g for 10 seconds and 
the supernatant was transferred into fresh Eppendorf tubes for electrophoresis. 
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2.14.2  Electrophoresis and protein transfer 
Samples were loaded onto a precast 12-well NuPage Novex Bis-Tris gel (12 % 
acrylamide) and were electrophoresed alongside a molecular weight marker (Rainbow™) 
within a XCell Surelock mini-cell gel tank at 160-200V in NuPage MOPS 20X running 
buffer (diluted to 1 X with H2O). Once samples reached approximately 90% of the gel 
length, the transfer was stopped and gels were placed in a transfer cassette with 
nitrocellulose membranes, sandwiched between layers of sponge and Whatman paper. 
Protein was transferred for 1 hour at 35V, submerged in 1 X transfer buffer (14.4g glycine, 
3g Tris, 800mL H2O and 200mL methanol (MeOH)). 
 
2.14.3  Immunoblotting 
To visualise active and total Rho A protein, nitrocellulose membranes were washed with 
1X TBST (see section 2.3) and then incubated in blocking buffer (5% milk in TBST) for 1 
hour at RT with gentle agitation. The primary Rho A antibody was diluted 1:500 in 3% 
blocking buffer and incubated for 16-hours at 4°C with gentle agitation. The membranes 
were then washed three times with TBST for 5 minutes and a secondary α-rabbit-
hydrogen peroxide (HRP) conjugated antibody was diluted 1:1000 in 5% blocking buffer 
and applied for 1 hour at RT with constant agitation. The membranes were again washed 
three times in TBST and chemiluminescence reagents SuperSignal West Pico (Pierce 
Biotechnology) were applied at a ratio of 1:1 for 5 minutes for detection of protein and 
these were exposed and developed on Kodak film over a time-course of 5-15 minutes. 
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2.15  Qualitative cell trafficking  
2.15.1 Receptor internalisation 
Flp-In™ T-REx™ 293 cells harbouring human and rat FLAG-GPR35eYFP were grown on 
cover slips in 6-well plates coated with poly-D-lysine until they were 70-80% confluent and 
were induced to stably express human FLAG-GPR35-eYFP by treatment with 25-
100ng/mL of doxycycline for 24 hours.  For live cell imaging, coverslips were placed in a 
temperature controlled (37°C) chamber within HBSS. Next, 100µM concentrations of 
GPR35 agonists zaprinast, pamoic acid and cromolyn disodium diluted in HBSS were 
gently added to the chamber to give a final concentration of 10µM for each ligand. eYFP 
was imaged at emission wavelengths of 495nm. Images were acquired at 5 minutes 
intervals over a 45-minute time-course using a spinning disk structured illumination Viva 
Tome device (Zeiss, Germany) to observe receptor internalisation in the presence of 
GPR35 ligands. 
 
2.15.2  p115-RhoGEF trafficking 
To visualise the trafficking of p115-RhoGEF from the cytosol to the plasma membrane 
upon Gα12 or Gα13 activation, HEK293T cells were grown on glass coverslips in 6-well 
plates until they were approximately 70-80% confluent. These were transiently transfected 
with constitutively active (CAM) or wild-type (WT) versions of Gα12 or Gα13 alongside a 
GFP tagged p115-RhoGEF construct using Lipofectamine (described in section 1.9.3). 
After 16-24 hours, the cells were washed with PBS and fixed for 5 minutes using 4% 
paraformaldehyde (PFA) in the presence of 0.001% (v/v) CellMask® Orange plasma 
membrane stain (Invitrogen, Life Technologies). Cells were then washed five times using 
PBS and mounted onto glass slides with Immumount™ (Invitrogen, Life Technologies). 
GFP and CellMask® Orange were captured at emission wavelengths of 495nm and 
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567nm, respectively, using a spinning disk structured illumination Viva Tome device 
(Zeiss, Germany). 
 
2.16  Phalloidin staining 
To visualise cytoskeletal architecture of cells, a phalloidin stain which binds to F-actin on 
the actin filament within cells was used.  HSV EC, SMC and H9c2 cardiomyocytes were 
seeded on 30mm coverslips and quiesced for 24 hours (EC) and 48 hours (SMC and 
H9c2). Following exposure to GPR35 ligands at 37oC, cells were fixed using 4% (w/v) 
PFA for one hour at RT and for optimal staining, the cells were then permeabilized using 
PBS with 0.1% Triton X-100 for 20 minutes at RT. Cells were then washed with PBS and 
stained with TRITC F-actin phalloidin stain at 5µg/mL for 1 hour at RT (Sigma-Aldrich, 
UK). The unbound F-actin stain was then removed with two PBS washes and the 
coverslips were mounted onto glass coverslips with Prolong® Gold Antifade reagent with 
4',6-diamidino-2-phenylindole (DAPI) (Invitrogen). Cells were then imaged at emission 
wavelengths of 610nm and 461nm for TRITC and DAPI, respectively, using a spinning 
disk structured illumination Viva Tome device. 
 
2.17  Hypertrophy assay 
H9c2 cardiomyocytes were seeded on sterile, poly-D-lysine coated glass coverslips within 
6-well plates at a density of 3x104
 
cells/ well. Once attached, the cells were quiesced for 
48-hours in serum free media. After this, cells were transfected with rat FLAG-
GPR35eYFP using X-fect (as described in section 1.9.3) and were stimulated with 200nM 
of GPR35 ligands zaprinast or amlexanox for 48-hours in triplicate. H9c2 cells were also 
stimulated with 200nM of AngII or maintained in serum free media to provide a positive 
and negative control for hypertrophy, respectively. H9c2 cardiomyocytes were then fixed, 
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stained and imaged for F-actin using the protocol described in section 1.15.  Cell size was 
quantified by measuring the length of at least 100 cells per condition using Image J 
software. 
 
2.18  Isolation and maintenance of primary vascular cells 
Following application for patient consent and ethical approval, we received excess tissue 
from patients undergoing a coronary artery bypass grafting (CABG) using human 
saphenous vein (HSV), at the Golden Jubilee Hospital in Clydebank, Scotland. Once the 
vein tissue was received, a note of the patient number, date and how the vein was used 
was noted in a log book. Immediately following this, primary endothelial and smooth 
muscle cells were then isolated from the vein tissue within sterile conditions. 
2.18.1  Human saphenous vein endothelial cells (HSV EC) isolation 
Firstly, the endothelial cell layer was isolated via collagenase digestion whereby the 
vessel was bathed in wash media (DMEM, 100 IU/mL penicillin, 100μg/mL streptomycin 
and 2mM L-glutamine) and then the lumen bathed with 2µg/mL of collagenase solution 
diluted in wash media. This was incubated within the vessel at 37°C for 15-20 minutes 
and a fresh collagenase dilution was then subsequently used for another 10 minutes. 
Following this, the endothelial cells were collected by pelleting the remaining solution by 
gentle centrifuging at 2000 x g for 15 minutes. The cells were then re-suspended in Large 
Vessel Endothelial Basal Cell Medium (TCS Cellworks Ltd, Bucks, UK) which was 
supplemented with 20% (v/v) FCS, 100 IU/mL penicillin, 100μg/mL streptomycin and 2mM 
L-glutamine and were seeded in T25 culture flasks within a humidified incubator (37°C, 
5% CO2) before the application of fresh medium and future passaging. 
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2.18.2  Human saphenous vein smooth muscle cells (HSV SMC) 
To isolate SMC from the remaining medial layer following collagenase digestion, the vein 
was cut longitudinally and small sections were pinned out with the lumen-side exposed. 
Any remaining HSV ECs were removed by gently buffing the vessel with a rubber 
policeman. Latitudinal scores were then made across the vessel using a scalpel blade and 
strips of smooth muscle cells were peeled from the adventitia using forceps. These were 
placed in wash buffer (as above) and then together, all of the isolated strips were cut into 
small sections using a McIlwain tissue chopper. After washing with wash medium twice, 
the cells were transferred into Smooth Muscle Cell Growth Medium 2 containing 0.5 
ng/mL epidermal growth factor, 2ng/mL basic fibroblast growth factor and 5μg/mL insulin 
(PromoCell, Heidelberg, Germany) and supplemented with 15% FCS, 100 IU/mL penicillin 
and 100μg/mL streptomycin. These were transferred into a T25cm2 cell culture flask to 
grow and the media was replaced the following day. When HSV SMC became fully 
confluent, they were passaged 1:5 using trypsin. 
 
2.19  Migration assay 
HSV EC and SMCs were seeded in 6-well plates, grown to confluence and then quiesced 
for 24 or 48 hours for SMC and EC, respectively. Three horizontal scratches were created 
in each well using a 200µL pipette tip and the cells were gently washed twice with warm 
PBS to remove cell debris. A straight line was drawn on the bottom of each well on the 
outside of the plate to act as an area marker whilst imaging migrating cells. Cells were 
then stimulated with pamoic acid (Sigma-Aldrich) at concentrations of 10nM, 100nM and 
300nM or zaprinast at 100nM, 500nM and 1µM in serum free DMEM or were co-
administrated with 100nM of either GPR35 antagonist CID-2745687 or ML-145. To assess 
the involvement of the Rho A signalling axis in pamoic acid induced migration, cells were 
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also incubated with 10µM Rho A pathway inhibitor Y-16, or ROCK inhibitor Y-27632, 
alongside 100nM pamoic acid in serum free conditions. All conditions were performed in 
triplicate and on at least three occasions. Images of the cells were acquired at time zero, 
followed by incubation at 37ºC and imaged at 12-hour time points for the following 36-
hours.  Importantly, images were taken at the same area following alignment with the 
guideline on the plate and therefore, migration was directly comparable across images. 
Migration was then quantified by measuring the distance (µm) between cells migrating into 
the wound area at approximately 10 areas within each field of view, using Image J 
software. These were then averaged and expressed as percentage migration, compared 
to migration at time point 0. 
 
2.20   Assessment of cell proliferation 
HSV EC and SMC were seeded in clear 96-well plates at a density of 5x103 cells/well and 
quiesced in serum free media for 24 and 48 hours, respectively. To optimise the 
concentration of serum required for a positive proliferative response, each cell type was 
first exposed to 0-20% serum conditions, and it was found that 5% serum was sufficient to 
induce maximal cell proliferation for both HSV EC and SMCs.  Cells were then stimulated 
with a range of concentrations of GPR35 ligands +/- 5% serum, over a period of 24 hours 
(EC) and 48 hours (SMC). Cell proliferation was assessed using either Cell Titer 96 
Aqueous NonRadioactive Cell Proliferation Assay (MTS) (Promega, WI, USA) or the 5-
bromo-2’-deoxyuridine Cell Proliferation Assay Kit (BrdU), (Cell Signalling Technology, 
UK), according to manufacturer’s instructions. Colorimetric output was measured on a 
Wallac VICTOR2 plate reader at absorbance values of 490nm or 450nm for MTS and 
BrdU assays, respectively. 
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2.21  Gene expression analysis 
2.21.1  RNA extraction of cells and tissues 
To isolate ribonucleic acid (RNA) cells were harvested from 6-well plates which were 
washed using PBS and then removed using 700µL of cell lysis reagent, QIAzol® 
(QIAGEN).  The cells were homogenised via pipetting and the lysates were stored in 
RNase free tubes at -80°C until extraction. To isolate RNA from tissues, samples were 
immediately snap frozen in liquid nitrogen upon harvest and were homogenised in 700µL 
of QIAzol® and with the addition of one stainless steel bead (5mm) (QIAGEN), these were 
processed via vigorous mechanical shaking in a TissueLyser System (QIAGEN) at 25Hz. 
RNA from both cells and tissue were then extracted using an RNeasy mini kit (QIAGEN) 
according to the manufacturer’s instructions. Briefly, 700µL of 70% (v/v) ethanol was 
added to each sample and these were applied to an RNeasy spin column which binds the 
cell lysate, these were cleared via centrifugation at 8,000 g.  The samples were washed 
with 350µL RW1 buffer and to eliminate genomic DNA contamination, were treated with 
70µL of DNaseI, diluted in buffer RDD. After a 30 minute incubation period at RT, the 
samples were washed again with 350µL RW1 buffer and twice with 500µL of RLT buffer 
before being eluted into a fresh RNase free tube with 30µL of RNase free H2O. RNA was 
immediately quantified as outlined in section 2.20.2 and then stored at -80°C for future 
analysis. 
 
2.21.2  Nucleic acid quantification  
To quantify RNA, a NanoDrop 1000 Spectrophotometer (Thermo Scientific) was used. 
This equipment is able to quantify RNA via measuring its absorbance at 260nm and 
provides a reading of RNA in ng/µL.  Furthermore, a ratio of absorbance at 260/280nm 
indicated the quality of RNA and this was considered ‘pure’ if the reading was close to 2.0. 
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2.21.3  Reverse Transcription (RT) 
To reverse transcribe the RNA into complementary DNA (cDNA), a Taqman® Reverse 
Transcription Kit (Applied Biosystems) was used according to the manufacturer’s 
instructions.  Briefly, 750ng of RNA was added to a reaction mixture containing 1X reverse 
transcriptase buffer, 5.5mM MgCl2, 0.5mM each of dATP, dCTP, dGTP and dTTP, 2.5μM 
random hexamers, 0.4 U/μL RNase inhibitor, 1.25 U/μL Multiscribe™ and RNase free H2O 
was added to each sample mixture for a final volume of 50µL. These were then added to 
PCR reaction plates and thin, thermogenic film (Thermo Scientific) sealed the plate. The 
following protocol was then performed to transcribe cDNA from RNA: 
• 25ºC for 10 minutes (primer annealment) 
• 48ºC for 30 minutes (reverse transcription)  
• 95ºC for 5 minutes (inactivation of transcriptase) 
• Hold at 4ºC 
The samples were then stored at 4ºC for use within 24-hours or at -20ºC for longer-term 
storage. 
 
2.21.4 Quantitative real-time polymerase chain reaction (qRT-PCR) 
mRNA expression of GPR35, Gα13, collagen I and III in cells and tissues, was quantified 
via real-time PCR using TaqMan chemistries (Applied Biosystems, Warrington, UK). Each 
of the selected TaqMan assays have a fluorescent reporter dye incorporated within the 5’ 
to 3’ primer and this ‘quenched’ by an incorporated inhibitor within the 3’ to 5’ primer.  In 
the presence of the Taq™ polymerase enzyme, the inhibitor is cleaved following primer 
annealling and a fluorescent signal is produced. Importantly, this fluorescence signal is 
measured during the exponential phase of each PCR cycle and upon the application of a 
set cycle threshold (CT), mRNA expression level is quantified. All gene expression 
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analysis was subject to the quantification of a ubiquitously and endogenously expressed 
‘housekeeping’ gene, such as ribosomal 18s or β-actin.  The CT value for each gene was 
normalised for the appropriate housekeeper and the data were expressed as ΔCT values, 
or as fold-expression relative to a control condition (ΔΔCT).  For a 10µL total reaction 
volume, a master mix containing 0.5µL of Taqman probe and H2O was added to 3µL of 
cDNA for GPCR expression or 0.5µL of cDNA for either housekeeping gene. All 
conditions were carried out in biological triplicates with technical replicates. These were 
then analysed on an Applied Biosystems ABI Prism 7000 sequence detection system 
operated according to manufacturer’s instructions: 
• 95ºC for 10 min X40 cycles (to denature) 
• 95ºC for 15 sec (primer annealing) 
• 60ºC for 1 minute (primer extension) 
 
2.22  In vivo techniques and tissue analysis 
2.22.1   Experimental plan for in vivo assessment of GPR35 activation in the 
SHRSP 
10 Male SHRSPs were chosen as a model for a 6-week amlexanox dosing study. At 5-6 
weeks of age, age-matched animals were randomly assigned; vehicle control (n=5) or 
2.5mg/kg/day amlexanox (n=5).  To measure blood pressure in young SHRSPs they 
underwent tail cuff plethysmography at age 5-6 weeks until 8-9 weeks of age, three times 
per week.  Daily dosage of either amlexanox or vehicle control began at 6 weeks of age 
for the duration of the study. To prevent stress induced increases in blood pressure 
associated with oral gavage techniques, amlexanox was administered to rats in 1 mL of 
sweetened, blended food.  At age 8 weeks, SHRSPs underwent wireless radiotelemetry 
probe implantation, for which the gel-tipped probe was inserted into the abdominal aorta 
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and sewn into the abdominal muscle wall to prevent movement. Haemodynamic 
parameters encompassing systolic, diastolic and mean arterial pressure were captured at 
5 minutes intervals for the duration of the study. Radiotelemetry also measured 
locomotion activity and heart rate.  At age 12-13 weeks, all animals were sacrificed and 
tissues were harvested for the analysis of fat deposition, vascular reactivity in isolated 
vessels, cardiac hypertrophy, renal fibrosis and gene expression. NB: one probe became 
dislodged 2-weeks following implantation and although this was not fatal for the animal, 
subsequent analysis of haemodynamic parameters was limited to n=4 animals per group. 
Please refer to Figure 2-3 below, for a schematic overview of the experimental plan. 
 
Figure 2-3. Schematic time-line, outlining the experimental plan for in vivo 
assessment of GPR35 activation in the SHRSP.  
 
2.22.2  Experimental animals 
10 male, 6-week old stroke-prone spontaneously hypertensive rats (SHRSP) were used to 
examine the effect of pharmacological agonism of GPR35 in this study. All of the 
experimental analysis of animals was subject to the Animal Scientific Procedure Act 
(1986) and was carried out under the project licence of Dr. Delyth Graham (60/4286). The 
animals were housed within the animal unit which had controlled lighting (12h-light/ 12-
dark, 7am-7pm/ 7pm-7am) and temperature (21.5°C). One animal per cage was required 
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in this study due to the nature of drug administration. Rats were fed a standard chow diet 
and were able to eat and drink ad-libitum. 
 
2.22.3 Drug administration 
2.5mg/kg of amlexanox powder was mixed into 1mL of banana custard flavoured baby 
food (HEINZ). This was prepared once per week, based on animal weight and was stored 
at -20°C in small petri dishes before being administered daily for the trial duration. There 
were 5 animals per group and the group which were not administered the amlexanox were 
given 1mL of banana custard flavoured baby food (HEINZ) as a ‘vehicle control’. 
 
2.22.4  Tail-cuff plethysmography 
To measure systolic blood pressure (SBP) in young SHRSPs (6-8 weeks), tail-cuff 
plethysmography was carried out every 2-3-days for the first twenty-days of the study. The 
animals were warmed-up in an insulated environment to improve blood-flow to the tail, 
they were then placed on heated mat (30°C) and gently wrapped in a towel to prevent 
movement or distress. Once the animal was composed, an inflatable cuff with a built in 
piezoceramic transducer (Hartmann &Braun) was placed on the base of the tail and to 
obtain a stable reading of SBP, the tail-cuff was inflated approximately 10 times per 
session and the pressure measurement was taken on deflation of the cuff.  Following this, 
outlying readings were rejected and an average of the remaining readings created a 
single measurement of blood pressure.  
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2.22.5  Radiotelemetry 
The SHRSPs underwent surgery to implant a wireless telemetry probe within the 
abdominal aorta at age 8-9 weeks under surgically sterile conditions.  Following the 
removal of abdominal fur, the surgery was carried out under anaesthetic (2.5% Isoflurane 
and 1.5L/min O2) and it was ensured that the animals were unconscious via the tail pinch 
method. Upon abdominal incision, the large intestinal organs were gently positioned out 
with the body and were kept moist using sterile, PBS soaked gauze. Using the pressure of 
surgical thread to prevent blood flow, a small hole was made above the lower abdominal 
aortic branch using a needle and the telemetry probe was gently advanced into the aorta 
(towards the heart). This probe was previously calibrated, re-furbished and re-gelled and 
was held in place using a small patch of sterile gauze and surgical glue.  The probe 
transmitter (radio frequency transducer model TA11PA) was sutured into the abdominal 
muscle wall to prevent any movement. Immediately following the surgery, an analgesic 
(Carprofen 5mg/kg) was administered and the animals recovered in a sterile, warm 
environment under supervision.  Following a 7-day recovery period, SBP, diastolic blood 
pressure (DBP), mean arterial blood pressure (MAP), heart rate (HF) and locomotion was 
received on a consolidation matrix 4650 receiver panel using the Dataquest IV Telemetry 
System (Data Sciences International). These measurements were recorded and stored 
every 5 minutes for the duration of the study and the results were averaged for 12-hour 
light and dark cycles using a previously devised macro spreadsheet (Microsoft Excel). 
 
2.22.6 Tissue harvesting 
The animals were sacrificed at age 12-13 weeks under anaesthetic (4.0% Isoflurane and 
1.5L/min O2).  To sacrifice, the heart was punctured and approximately 2mL of blood was 
collected using a 5mL syringe. Following sacrifice, the heart and kidneys were 
immediately weighed and the heart was dissected to weigh the left ventricle plus septal 
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tissue (LV+S). Tissue from the heart, kidney and spleen were either snap frozen in liquid 
nitrogen for future gene expression analysis or fixed in 10% (v/v) neutral buffered formalin 
for paraffin embedding. The epidydymal and retroperitoneal fat pads were also excised 
and weighed. The thoracic aorta and large intestine (containing the mesenteric arteries) 
were placed in Krebs solution for large and small vessel myography. 
 
2.22.7 Tissue mass index 
Using a double-pointed drawing compass, the tibia length was measured from the knee to 
the ankle joint, which was exposed following scalpel incision to each area. This was then 
measured in millimetres using a standard 30cm ruler. This provided the opportunity to 
create an additional organ mass index whereby whole heart, LV+S and kidney mass were 
normalised tibia length or body weight. 
 
2.22.8  Resin embedding and sectioning 
Heart and kidney tissue previously fixed in formalin were placed in 0.5mL embedding 
cassettes and were processed in a Citadel 1000 (Thermo Scientific, UK) whereby they 
were exposed to a gradual water-histoclear gradient to dehydrate the tissue. These were 
then embedded in paraffin wax and left to solidify on a cooling block before storage at -
20°C prior to sectioning. 5µm sections of LV and kidney tissue were then cut using a 
microtome (Leica RM2125, Leica Microsystems, UK). 
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2.22.9  Histology 
Prior to tissue staining, the heart and kidney sections were mounted onto glass slides and 
were baked overnight at 40°C for 12-16 hours. To remove paraffin, the slides were 
immersed twice in histoclear for 7 minutes.  The tissue sections were then re-hydrated 
using a gradual ethanol gradient [100, 95 and 75% (v/v)] for 7 minutes each and then 
were finally immersed in distilled H2O for 7 minutes. 
 
2.22.9.1 Collagen staining 
To identify the presence of fibrosis within cross-sectional kidney tissue sections, 
picrosirius red staining, specific to collagen I and III, was used. The slides were immersed 
in 0.1% (v/v) picrosirius red solution (300mg sirius red F3B, 300mL saturated picric acid) 
in darkness for 90 minutes at RT. To wash, these slides were then twice immersed in 
0.01M HCl for 5 minutes and twice in dH2O for 5 minutes. The sections were then 
dehydrated using a reverse ethanol gradient (75-100%) and protective glass coverslips 
were mounted using DPX non-aqueous mounting medium (Merck Millipore, Germany). 
Collagen (red-staining) was blindly quantified by measuring pixel density in 4 areas of 
interest per slide (three slides per animal tissue) using ImageProPlus software. 
 
2.22.9.2 Wheat-germ agglutinin (WGA) 
Cardiomyocytes situated within the LV wall were stained using WGA-TRITC conjugate 
which binds N-acetylglucosamine and sialic acid residues to identify cell membranes.  The 
tissue sections were permeablized using HBSS with 0.1% Triton X-100 for 20 minutes at 
RT and then were immersed in HBSS buffer + 5µg/mL WGA-TRITC for 10 minutes at RT. 
These were then washed twice with HBSS. The sections were then dehydrated using a 
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reverse ethanol gradient (75-100%) and protective glass coverslips were mounted using 
Prolong® Gold Antifade reagent with DAPI (Invitrogen). These were imaged at an 
emission wavelength 610nm and cardiomyocyte size was then quantified by measuring 
cell length in 4 areas per slide (three slides per animal) using Image J software. 
 
2.22.10  Wire myography 
Third order mesenteric arteries and thoracic aortas were harvested upon animal sacrifice 
to examine vasoreactivity in small and large vessels, respectively, using a wire myograph. 
Following isolation, these were gently cleaned and excess connective tissue and fat was 
removed.  These were then stored in Krebs solution (see section 2.3) overnight at 4°C 
before the experiment was conducted. Sections of mesenteric artery approximately 1.8-
2.0mm in length (n=2 per animal) were mounted onto the structure using two steel wires 
and were placed into a four channel small vessel myograph (Danish Myotechnology, 
Denmark). Following a 30 minute equilibration period, the tension on each vessel was 
normalised for its internal diameter using Laplace’s equation, where the tension is directly 
proportional to vessel diameter and force applied. Changes in vessel tension were 
measured via the myograph transducer and recorded using Data Acquisition Software 
(Powerlab Systems).  To stimulate contraction and ‘wake-up’ the vessel, the vessels were 
pre-treated with 10mM of KCl in Krebs solution twice, and from the second treatment, the 
maximum vessel contraction for potassium was obtained. The vessels were then washed 
four times in Krebs solution and were left to normalise and return to basal tension for 45-
60 minutes. To examine the vasoreactive pharmacology of the vessels, they were 
exposed to increasing concentrations of noradrenaline (100nM-1mM) and following the 
application of the maximal concentration, the vessels were then exposed to increasing 
concentrations of carbachol (10-30µM) to assess endothelium-dependent vasorelaxation. 
Vessels were washed again four times using Krebs solution and left to normalise to basal 
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tension. The vessels were again exposed to increasing concentrations of noradrenaline 
(100nM-1mM), however, this time smooth muscle cell-dependent vasorelaxation was 
assessed by adding increasing concentrations of sodium nitroprusside (SNP) (100nM-
1mM).  For large vessel myography, aortic rings (3-5mm) were mounted onto two fixed 
steel wires within a large vessel myograph (Danish Myotechnology, Denmark) and these 
were left to equilibrate for 30 minutes following the application of 1.5–3.0grams of tension. 
Vessels were treated with the same stimulation and relaxation protocols used for 
mesenteric arteries, however, instead of using noradrenaline to stimulate vessel 
contraction, phenylephrine was used (10nM-1mM). The resulting contractile responses 
were plotted as a percentage of the maximal KCl response obtained at the beginning of 
the experimental protocol. 
 
2.23  Statistical analysis 
All data are displayed as mean +/- SEM and were analysed using GraphPad Prism® 
software. Student’s t-test for paired data and one-way ANOVA was applied, with Dunnett’s 
test for multiple comparisons when comparing to a control, or, with Bonferroni’s correction 
to compare all of the conditions. Statistical significance was considered if p<0.05.  
Experiments were performed in triplicate and on at least three independent occasions. To 
confirm that the data were normally distributed, the Kolmogorov-Smirnov test was utilised 
(given its ability to account for the distribution within data of an n=5). Although, for higher 
sample numbers (n≥7), the D'Agostino-Pearson test would be preferable in the 
assessment of normality in the distribution of data. For WGA and collagen staining 
quantification, the sample conditions were blinded by a colleague during the quantification 
process.  
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3 Translating the pharmacology of GPR35 in multiple 
species orthologues 
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3.1 Introduction 
The pharmacological characterisation of ligands which act at GPR35 has proved an 
intriguing and challenging process thus far.  As previously described, the majority of 
molecules which act at GPR35 demonstrate considerable species-selectivity and the 
possibility of ligand bias following activation has also been discussed (Milligan, 2011).  
Though research has begun to elucidate a role for GPR35 using functional systems in 
both an in vitro and in vivo context, many questions relating to the species-selective 
properties of ligands remain un-resolved and therefore, targeting GPR35 within an 
endogenous setting has been problematic.  For example, following reports that GPR35 
might have therapeutic implications within the central nervous system (Ohshiro et al., 
2008), investigators assessed the nociceptive response of mice undergoing an acetic 
acid-induced abdominal constriction test in the presence of increasing doses of pamoic 
acid; at that time, a novel GPR35 agonist (Zhao et al., 2010).  A reduction in writhing 
behaviour correlated with increased pamoic acid dosage and led the authors to conclude 
that GPR35 activation may alter pain tolerance (Zhao et al., 2010).  However, these 
conclusions contrast reports demonstrating that pamoic acid is highly selective for human 
GPR35, displaying virtual inactivity at the rat orthologue via β-arrestin-2-receptor 
interaction (Jenkins et al., 2010). Upon consideration of these conflicting indications, it 
remained unclear if the reported nociceptive response following pamoic acid 
administration in a mouse model was attributable to GPR35 activation (Zhao et al., 2010).   
Furthermore, in an attempt to reverse pamoic acid induced nociception, investigators co-
administered a newly identified GPR35 antagonist; CID-2745687.  However, its previous 
in vitro antagonistic action was not replicated in the animal model (Zhao et al., 2010). Prior 
to evidence published by Jenkins and colleagues (2012), which involves work presented 
in this chapter, it was uncertain if, like human-selective agonists, the novel antagonists 
CID-2745684 and ML-145 also exhibit species-selective properties.  Thus far, GPR35 
antagonists have demonstrated limited use in functional systems. 
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To understand the mode of ligand binding to a receptor, investigators often employ site-
directed mutagenesis and thus, by introducing single-point mutations to areas of potential 
ionic interaction, it is possible to identify critical residues for receptor activation.  To this 
end, several key binding residues crucial for ligand interaction have been successfully 
identified within GPR35 and these include critical residues within the third TMD, for which 
zaprinast and kynurenic acid share overlapping binding positions (Jenkins et al., 2011).  
Most recently, residues within the sixth and seventh TMDs have proved critical for 
interaction with lodoxamide, a novel high-potency GPR35 agonist (Mackenzie et al., 
2014).  Research has only begun to identify crucial domains within human GPR35 that 
mediate interaction with pamoic acid. Latterly, the effect of single residue substitutions 
with differential charges was investigated within TMD regions III – VI of human GPR35 
(Zhao et al., 2014). Without emphasis on implication for species selectivity, the authors 
reported that positively charged residues located within TMD III, IV, V and VI of human 
GPR35 are crucial for interaction with both pamoic acid and zaprinast, suggesting 
overlapping binding positions (Zhao et al., 2014).  Importantly, substitution of positively 
charged residues within the second ECL, specifically of arginine167, reduced the potency 
of pamoic acid by four-fold in a β-arrestin-receptor interaction assay (Zhao et al., 2014).  
Essentially, this mutation is the first to produce differential effects on ligand potency and 
thus, is strongly suggestive of an additional binding site for pamoic acid which may, in 
part, facilitate its selectivity for human GPR35.  Evidently, more research is required to 
identify crucial differential residues which account for the species-selective properties of 
pamoic acid. 
Another aspect to promote discussion within the field of GPR35 research has been its G-
protein coupling profile.  Upon identification of its two most prominent and widely utilised 
ligands; zaprinast (Taniguchi et al., 2006) and kynurenic acid (KYNA) (Wang et al., 
2006a), it was reported that GPR35 coupled to the Gαi/o family of proteins and, in both 
cases, this was demonstrated via Ca2+ mobilisation following the transfection of Gαq/i 
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chimeric constructs (Taniguchi et al., 2006, Wang et al., 2006a).  Additional studies have 
also reported PTX sensitive activation in cells stimulated with KYNA (Barth et al., 2009, 
Ohshiro et al., 2008) and pamoic acid (Zhao et al., 2010).  On the other hand, consistent 
evidence that GPR35 couples to the Gα12/13 family of proteins following activation by a 
range of ligands including zaprinast, pamoic acid and cromolyn disodium, also exists 
(Jenkins et al., 2011, Jenkins et al., 2012, Mackenzie et al., 2014). Moreover, these 
authors report that GPR35 displays selectivity for Gα13 over Gα12 to elicit an intracellular 
Ca2+
 
response in the presence of zaprinast (Jenkins et al., 2011).  Given the wealth of existing 
and somewhat conflicting evidence, it remains unclear if multiple pathways are activated 
following GPR35 activation or if ligand bias promotes differential Gα signalling.  
 
3.1.1 Hypothesis and aims 
Given that studies from our lab have demonstrated that pamoic acid is not effective at rat 
GPR35 (Jenkins et al., 2012), it is hypothesised that this might also extend to alternative 
rodent species, such as mouse.  Previous research also links species specificity of 
GPR35 ligands to differential binding positions within the GPR35 structure (Jenkins et al., 
2010), and therefore, it is expected that the identification and exploration of these might 
help to clarify the governance of ligand specificity amongst species. Likewise, it is also 
hypothesised that ligand-species selectively may affect recently identified GPR35 
antagonists, CID-2745687 and ML-145. Finally, considering that previous research has 
highlighted a selective coupling between GPR35 and Gα13 following activation by 
zaprinast (Jenkins et al., 2010), it is thought that this coupling profile may also exist 
following stimulation with pamoic acid, to promote Rho A activation and downstream 
signalling. Therefore, the aim of this study was to explore the pharmacology of previously 
identified GPR35 ligands at human, rat and for the first time, mouse GPR35. This chapter 
will also endeavour to identify crucial residues responsible for pamoic acid’s selectivity for 
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human GPR35 and clarify the G-protein coupling profile following activation with this 
ligand. Outlined below are a series of aims which have been devised to investigate this 
fully: 
• To identify if pamoic acid, and other human-selective GPR35 ligands are able to 
activate the mouse orthologue of GPR35. 
• To identify key residues within GPR35 which are crucial for activation and account 
for the human-selectivity displayed by pamoic acid. 
• To identify if the newly identified antagonists CID-2745684 and ML-145 display 
GPR35 orthologue selectivity. 
• To confirm that GPR35 couples selectively to Gα13 following pamoic acid induced 
activation to promote activation of the Rho A pathway. 
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3.2 Results 
3.2.1 Evidence of β-arrestin-2 recruitment following GPR35 activation and 
subsequent optimisation of the bioluminescence resonance-energy 
transfer assay  
To begin to explore ligand function at GPR35, a β-arrestin-2-receptor interaction assay 
was employed. This mode of assessment is essentially G-protein independent and 
therefore, provides an objective assessment of immediate ligand pharmacology that 
allows β-arrestin-2 recruitment to the receptor complex. To demonstrate the mobilisation 
of β-arrestin-2 following agonist stimulation, doxycycline (DOX) inducible Flp-In™ T-
REx™ cells stably expressing FLAG-humanGPR35-eYFP were transiently transfected 
with β-arrestin-2-mCherry using Lipofectamine™ and were then imaged in the presence 
and absence of 10µM zaprinast. In Figure 3-1.A, compartmentalisation of FLAG-
humanGPR35-eYFP and β-arrestin-2-mCherry expression is evident in unstimulated cells.  
Following a sustained 45-minute stimulation with 10µM zaprinast, both humanGPR35-
eYFP and β-arrestin-2-mCherry constructs cluster within the cytosol at close proximity to 
the plasma membrane, indicative of β-arrestin-2 recruitment to the receptor complex 
following ligand activation (Figure 3-1.A).  To quantify β-arrestin-2 recruitment to GPR35, 
a bioluminescence resonance-energy transfer (BRET) assay was employed in HEK293T 
cells transiently transfected with β-arrestin-2-Renilla-luciferase (β-arrestin-2-Rluc) and 
FLAG-humanGPR35-eYFP (Figure3-1.B) or FLAG-ratGPR35-eYFP (Figure3-1.C). Given 
that GPCR activation can occur within a short time-frame, these cells were stimulated with 
increasing concentrations of zaprinast at time points ranging from 5 to 20 minutes.  The 
BRET ratio was calculated at emission wavelengths of 530 nm/485 nm using a Pherastar 
FS plate reader and ratios were normalised to β-arrestin-2-Rluc only expressing cells.   
Results indicate that the potency of zaprinast at human and rat GPR35 remains 
unchanged following increased ligand exposure time (hGPR35 EC50= 3.06-4.2µM ± 0.08-
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0.18, rGPR35 EC50=74nM-94nM ± 0.04-0.07) (p>0.05). However, maximal efficacy 
becomes more variable; reduced following increased ligand exposure at human GPR35 
(Emax=107.2-70.59% ± 3.4-4.7%) (Figure3-1.B) and increased at rat GPR35 (Emax=106.6-
151.9% ± 1.9-2.2%), however these effects were non-significant between time points 
(Figure3-1.C).  From these results, it was deduced that the optimal and most comparable 
time point in going forward for ligand exposure in the BRET assay was 5 minutes for both 
species of GPR35. 
 
 
 
 
 
 
 
 
130 
 
 
Figure 3-1. GPR35 co-localisation with β-arrestin-2 and BRET optimisation. 
Doxycycline (DOX) inducible Flp-In™ T-REx™ cells stably expressing FLAG-
humanGPR35-eYFP, transfected with β-arrestin-2-mCherry were fixed, mounted and 
imaged using Vivatome™ spinning disk confocal microscopy. A) FLAG-humanGPR35-
eYFP (green) internalisation and co-localisation with β-arrestin-2-mCherry (red) ± 10µM 
zaprinast for 45 minutes. B & C) A comparison of β-arrestin-2 receptor interaction derived 
concentration-response curves in HEK293T cells transfected with β-arrestin-2-Renilla-
luciferase and B) FLAG-humanGPR35eYFP or C) FLAG-ratGPR35eYFP in the presence 
of increasing concentrations of zaprinast for 5-20 minute incubation periods. All data are 
representative of n=3-4 individual experiments and each condition was performed in 
triplicate.  Scale bar represents 20µm. 
 
Human Rat 
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3.2.2 The assessment of key reference ligands; zaprinast, cromolyn 
disodium and pamoic acid at mouse GPR35 via BRET analysis 
Previous research has established the potency and efficacy of the ligands zaprinast, 
pamoic acid and cromolyn disodium to activate human and rat orthologs of GPR35; 
showing rodent-selectivity in the case of zaprinast, human-selectivity for pamoic acid and 
equivalence for cromolyn disodium (Jenkins et al., 2010). However, it was unclear if 
GPR35 ligands follow a trend in that they are either human or rodent specific, and 
therefore, it was questioned if the potency and efficacy of these ligands would were 
different at mouse GPR35.  To make the necessary comparisons, mouse GPR35 flanked 
by an N-terminal epitope tag (FLAG) and C-terminally fused eYFP was cloned into a 
pcDNA3.1 expression vector and co-transfected into HEK293T cells with β-arrestin-2-
Renilla-luciferase.  Similar to previous research (Jenkins et al., 2011), a BRET assay was 
performed to assess the potency and efficacy of increasing concentrations of key 
reference GPR35 agonists zaprinast, cromolyn disodium and pamoic acid. In Figure 3-2, 
the concentration-response curves indicated robust and comparable BRET signals at all 
GPR35 orthologs and furthermore, demonstrated that rodent orthologues of GPR35 
displayed a similar ligand-activation pattern.  For example, both rodent species exhibited 
higher potency for zaprinast; mouse GPR35 (EC50=950.0 ± 0.082nM), rat GPR35 
(EC50=11.0 ± 0.035nM) compared to human GPR35 (EC50=3.9 ± 0.07µM) (Figure 3-2.).  
Cromolyn disodium displayed micromolar potency for the mouse ortholog (EC50=48.0 ± 
0.19µM) (Figure 3-2.C), but this was also true for human GPR35 (EC50=14.0 ± 0.06µM) 
(Figure 3-2.A) and rat GPR35 (EC50=5.0 ± 0.075µM) (Figure 3-2.B).  Most clearly in line 
with rat GPR35, pamoic acid demonstrated negligible activity at the mouse ortholog, 
contrasting nanomolar potency displayed at human GPR35 (EC50=45.0 ± 0.1nM) (Figure 
3-2.A).  This evidence indicated that zaprinast and pamoic acid ligands were largely 
rodent or human GPR35 selective, respectively.  To investigate this further, the 
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pharmacology of alternative GPR35 ligands with distinct species selective properties was 
next investigated (Table 3-1.).  
 
Figure 3-2.  BRET analysis highlights the species selectivity of key reference 
ligands; zaprinast, pamoic acid and cromolyn disodium.  
Representative concentration-response curves derived from a β-arrestin-2-receptor 
interaction assay in HEK293T cells transfected with β-arrestin-2-Renilla-luciferase and A) 
FLAG-humanGPR35-eYFP, B) FLAG-ratGPR35-eYFP or C) FLAG-mouseGPR35-eYFP 
in the presence of increasing concentrations of zaprinast, cromolyn disodium or pamoic 
acid.  All data are representative of n=3-4 individual experiments, values are displayed as 
a mean % of maximal zaprinast response, +/- SEM and were performed in triplicate.  
Significant difference EC50: *** = p<0.001, compared to pamoic acid or, δ = p<0.001, 
compared to zaprinast. 
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3.2.3 BRET analysis of GPR35 ligand hits from the Prestwick Chemical 
Library® screen and KYNA at mouse GPR35  
Next, the potency of ligands previously identified to act at human and rat GPR35 via 
screening of the Prestwick Chemical Library ® (Deng et al., 2012b, Jenkins et al., 2010, 
Zhao et al., 2010), as well as the rat-selective endogenous agonist, KYNA (Wang et al., 
2006a) were assessed at mouse GPR35 via BRET analysis.  Given that zaprinast 
demonstrates substantial potency for mouse GPR35, it was utilised as a reference agonist 
for the concentration-response curves displayed and therefore, the data are presented as 
percentage of maximal zaprinast response. Table 3-1 displays the comparative potencies 
(log EC50) of a range of ligands at human, rat and mouse GPR35 and the majority of these 
present a similar species-selective trend identified in the analysis of zaprinast, cromolyn 
disodium and pamoic acid. For example, Figure 3-3 demonstrates that niflumic acid (NFA) 
exhibits low potency (Log EC50=4.01 ± 0.54) (Table 3-1) and low efficacy (Emax=11.3% ± 
2.96%) at mouse GPR35 and this is similar to the actions of NFA at rat GPR35.  
Additionally, the data suggest that ellagic acid displays low potency at mouse GPR35 (Log 
EC50=4.36 ± 0.18).  This is slightly lower than values previously recorded for rat GPR35 
(Log EC50=5.37), however, these contrast with negligible potency exhibited by NFA at 
human GPR35 (Table 3-1). Whereas, the bioflavonoid luteolin reaches high efficacy 
(Emax=165.4% ± 8.9%) yet maintains low potency at mouse GPR35 (Log EC50=4.35 ± 
0.08); the potency was similar to values derived from human and rat GPR35 concentration 
responses.  Interestingly, not all ligands follow a rodent-selective trend and this is 
particularly evident in the response to the endogenous tryptophan metabolite, KYNA.  The 
data suggest that KYNA has very low potency and efficacy for mouse GPR35 (Log 
EC50=3.1 ± 0.43, Emax =18.8% ± 6.2%) and uncharacteristically, this is comparable to the 
negligible activity displayed at human GPR35 rather than potency displayed at rat GPR35, 
which was at least ten-fold higher (Log EC50 = 4.2) (Table 3-1).   
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Table 3-1. A comparison of the species selective properties exhibited via GPR35 
agonists.   
A comparison of potency values (logEC50 ±SEM) of various Prestwick Chemical Library® 
GPR35 hits and the endogenous agonist kynurenic acid at human, rat and mouse FLAG-
GPR35-eYFP transiently expressed in HEK293T cells and measured via a β-arrestin-2-
receptor interaction BRET assay. Data are representative of n=3-4 individual experiments, 
values are displayed as mean LogEC50 +/- SEM and were performed in triplicate. 
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Figure 3-3. The activity Prestwick Library® hits at FLAG-mouseGPR35-eYFP. 
Representative β-arrestin-2 receptor interaction concentration-response curves in the 
presence of GPR35 ligands in HEK293T cells transiently transfected with FLAG-
mouseGPR35-eYFP and β-arrestin-2-Renilla-luciferase.  Data are representative of n=3 
individual experiments, values are displayed as mean percentage of maximal zaprinast 
BRET response, +/- SEM and were performed in triplicate. 
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3.2.4 Internalisation of FLAG-humanGPR35-eYFP and FLAG-ratGPR35-eYFP 
demonstrate species selectivity of zaprinast, cromolyn disodium and 
pamoic acid  
An alternative indication of receptor activation is the visualisation of receptor 
internalisation following ligand administration. Here, zaprinast, pamoic acid and cromolyn 
disodium demonstrate the ability to effectively activate and internalise FLAG-
humanGPR35-eYFP in doxycycline inducible Flp-In™ T-REx™ cells stably expressing the 
receptor construct following a 40 minute incubation period with each ligand.  These effects 
are represented by live cell imaging captured via VivaTome™ spinning disk illumination 
microscopy at 0 and 40 minutes (Figure 3-4.A).  These images clearly illustrate the ability 
of zaprinast, pamoic acid and cromolyn disodium to internalise FLAG-humanGPR35-
eYFP (Figure 3-4.A).  In contrast, internalisation of FLAG-ratGPR35-eYFP is only evident 
following exposure to zaprinast and cromolyn disodium (Figure 3-4.B).  This is consistent 
with the human-selective GPR35 activation exhibited by pamoic acid via BRET analysis 
which also highlighted a lack of activity of pamoic acid at rodent orthologs (Figure 3-2.). 
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Figure 3-4. Species orthologue selectivity of GPR35 ligands is evident by 
examining receptor internalisation.   
Live cell images of doxycycline induced Flp-In™ T-REx™ cells stably expressing A) 
FLAG-hGPR35-eYFP or B) FLAG-rGPR35-eYFP stimulated with either 10µM zaprinast, 
10µM pamoic acid or 10µM cromolyn disodium (0 and 40 minutes, at 37°C, 5% CO2). Live 
receptor internalisation was captured via VivaTome™ spinning disk illumination 
microscopy (x 64 objective). Images are representative of n=3 individual experiments, and 
conditions were performed in triplicate. Scale bar represents 20µm. 
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3.2.5 Identifying residues crucial for the binding of the human selective 
GPR35 agonist pamoic acid via site-directed mutagenesis 
To address the fundamental mechanism of human GPR35 selectivity exhibited by pamoic 
acid, it is important to identify differential and crucial binding domains which exist between 
species and further examine their importance in mediating species selective GPR35 
activation via site directed mutagenesis.  Protein sequence alignments of human GPR35a 
(the first identified, short isoform of human GPR35), rat GPR35 and mouse GPR35 are 
detailed in Figure 3-5.  GPR35 is relatively well conserved amongst these species - 
denoted by asterisks underneath the alignment, however, there are areas which differ in 
sequence and these are denoted with a semi-colon (semi-conservative) or a period 
(conservative) in Figure 3-5. Putative transmembrane domain (TMD) regions are also 
highlighted within red-dashed boxes and these are considered crucial areas for small 
molecule interaction with Class A/ Rhodopsin-like GPCRs.  Research in this area has 
previously employed site directed mutagenesis to examine the significance of interactions 
between the positively charged arginine located within TMDIII at position 3.36 (according 
to the Ballesteros and Weinstein numbering system (Ballesteros et al., 1998)) and GPR35 
agonists zaprinast and KYNA (Jenkins et al., 2011), highlighted in green in Figure 3-5.  
Following a collaborative exchange with researchers specialising in computational 
modelling and fit-docking analysis at the University of Barcelona, putative binding sites for 
pamoic acid within human GPR35 were identified as suggested areas of ionic interaction.  
To examine the relevance of these residues for human GPR35 selectivity for pamoic acid, 
a series of cross-species mutations were generated for both human and rat GPR35.  
Computational analysis carried out by collaborators suggested that two arginines (R), 
located at position 4.60 and 6.58, may be crucial for potential interactions between human 
GPR35 and negatively charged carboxylic acid groups belonging to pamoic acid 
(highlighted in purple in Figure 3-5). Notably, the nominated arginines are conserved 
between species at TMD IV but, are not within TMD VIII - resulting in a positively charged 
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arginine at human GPR35a and polar residue, glutamine (Q), at both rodent orthologs of 
GPR35. 
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Figure 3-5.  Comparative protein sequence features of human GPR35a, rat GPR35 
and mouse GPR35.   
A comparison of amino-acid sequences of humanGPR35a, ratGPR35 and mouseGPR35.  
The putative positions of transmembrane domains (TMDs) I-VII are highlighted within red 
dashed boxes. The DRY motif is also highlighted within TMDIII, a highly conserved 
feature amongst Rhodopsin-like/ Class A GPCRs.  Potential ligand binding positions are 
highlighted in green and purple. Arginine (R) 3.36 (green) is a reportedly crucial amino 
acid for zaprinast and KYNA recognition (Jenkins et al., 2010) and further computational 
modelling has identified R4.60 and R6.58 as potential binding positions for pamoic acid in 
human GPR35a (purple). 
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To assess if either of these arginine residues was essential for ionic interaction with 
pamoic acid, a series of mutations were introduced via site directed mutagenesis, 
predominantly replacing positively charged arginines (R) with polar, or negatively charged 
amino acids in FLAG- humanGPR35-eYFP at position 4.60 and 6.58 or FLAG- ratGPR35-
eYFP at position 4.60 (Figure 3-6 & Figure 3-7, respectively). Alternatively, positively 
charged arginine (R), or non-polar residue methionine (M) substituted native glutamine 
(Q) in the FLAG-ratGPR35-eYFP construct at position 6.58 (Figure 3-7).   
Results indicated that replacing arginine (R) with alanine (A) at both 4.60 and 6.58 
eliminated agonist activity of zaprinast and the human selective agonist pamoic acid 
altogether in human GPR35 (Figure 3-7.B&F).  However, replacing arginine (R) at position 
4.60 with glutamine (Q) had no effect on the activity of zaprinast at human GPR35 and 
reduced the potency of pamoic acid by ten-fold and efficacy by 50%, suggesting that its 
presence can partially retain agonist activity of pamoic acid (Figure 3-7.C).  Replacing 
arginine (R) with methionine (M) at position 6.58 abolished activity of zaprinast and 
reduced the potency of pamoic acid by ten-fold and efficacy by 50% (Figure 3-7.D), 
compared with WT human GPR35 (Figure 3-7.A). This suggests that the presence of an 
alternative, non-polar hydrophobic based residue can maintain interaction with pamoic 
acid, to a degree.  To assess variation in cell-surface receptor delivery efficiency following 
the introduction of single-residue mutations, which may be indicative of alterations in 
protein-folding and trafficking, a cell-surface immuno-absorbance ELISA assay was 
performed in HEK293T cells transiently transfected with each mutant construct (Figure 3-
7.E). Compared to WT-humanGPR35a, which was more highly expressed compared to 
vector only (p<0.01), the overall cell-surface expression of the mutant constructs was 
reduced following the introduction of single-point mutations indicating that cell surface 
delivery was very limited. 
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Figure 3-6. Site-directed mutagenesis suggests that positively charged arginines 
located at 4.60 and 6.58 are essential for agonist function at hGPR35.  
β-arrestin-2 interaction assays were performed in HEK293T cells transiently transfected 
with A) Wild-type (WT) humanGPR35-eYFP, B) arginine (R) mutation to alanine (A) at 
4.60 in hGPR35, C) arginine (R) mutation to glutamine at 6.58 (Q) in hGPR35, D)  
arginine (R) mutation to methionine (M) at 4.60 in hGPR35, and F)  arginine (R) mutation 
to alanine (A) at 6.58 in human GPR35, following exposure to increasing concentrations of 
zaprinast or pamoic acid.  E) Cell surface expression of human WT and mutant GPR35 
constructs in comparison to vector only transfection (pcDNA3.1), assessed via ELISA. 
Data are representative of n=4 individual experiments, values are displayed as mean % of 
maximal zaprinast response, +/- SEM and were performed in triplicate. ** = p<0.01, 
compared to vector only. 
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Interestingly, the results demonstrated that replacing arginine (R) with alanine (A) at 
position 4.60 generated a high level of basal activity in rat GPR35 (Figure 3-7.B). This 
indicates a shift in receptor conformation to produce constitutive activity and therefore, the 
presence of a positively charged residue at this position may be vital to sustain basal 
receptor confirmation (Figure 3-7.B). However, substituting methionine (M) at the same 
position – another hydrophobic residue – eliminated activity of both ligands (Figure 3-7.C) 
and a similar effect was observed following the introduction of this mutation at human 
GPR35, which abolished the potency of zaprinast and diminished the effect of pamoic 
acid (Figure 3-6.B).  These results suggest that arginine (R) at 4.60 is also crucial for 
zaprinast interaction at human and rodent orthologues, however, less so for pamoic acid 
activation.  Furthermore, it was hypothesised that by replacing glutamine (Q) at position 
6.58 with arginine (R), it may be possible to gain potency of pamoic acid at rat GPR35, 
however, the activity of zaprinast and pamoic acid remain unchanged (Figure 3-7.D).  This 
was also true of the opposite mutation in human GPR35, which did not fully abolish the 
activity of pamoic acid (Figure 3-6.C). In contrast to human GPR35 mutant constructs, 
which were not consistently well expressed at the cell surface, single-point mutations 
introduced into rat GPR35 remained highly expressed at the cell surface in comparison to 
vector only expression (p<0.001), assessed via ELISA (Figure 3-7.E). 
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Figure 3-7. Site-directed mutagenesis suggests the positively charged arginine 
located at 4.60 is essential for agonist activation and basal state preservation of rat 
GPR35. 
β-arrestin-2 interaction assays were performed in HEK293T cells transiently transfected 
with A) Wild-type (WT) ratGPR35-eYFP, B) arginine (R) mutation to alanine (A) at 4.60 in 
rat GPR35, C) arginine (R) mutation to methionine (M) at 4.60 in rGPR35, and D) 
glutamine (Q) mutation to arginine (R) at 6.58 in rat GPR35, following exposure to 
increasing concentrations of zaprinast or pamoic acid. E) Cell surface expression of WT-
ratGPR35 and mutant-ratGPR35 constructs in comparison to vector only transfection 
(PCDNA3.1) assessed via ELISA. Data representative of n=4 individual experiments, 
values are displayed as mean % of maximal zaprinast response, +/- SEM and were 
performed in triplicate. *** = p<0.001, compared to vector only. 
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3.2.6 Novel GPR35 ligands CID-2745687 and ML-145 are competitive 
antagonists, highly selective for human GPR35 
Initial research to identify the GPR35 antagonists CID-2745687 (Zhao et al., 2010) and 
ML-145 (Heynen-Genel et al., 2010) failed to investigate if these ligands exhibited species 
selectivity, a feature often reported in GPR35 agonists.  For that reason, alterations in 
agonist potency in the presence of increasing concentrations of either of these GPR35 
antagonists across multiple species orthologues was assessed via BRET.  Representative 
experiments shown in Figure 3-8 and Figure 3-9 demonstrate that CID-2745687 and ML-
145 both exhibited a high degree of human-species selectivity. Moreover, Schild analysis 
indicated that CID-2745687 displays competitive and surmountable antagonism at human 
GPR35 (R2 = 0.89-0.95) (Figure 3-8.A).  Moreover, CID-2745687 demonstrates high affinity 
for human GPR35 (Kb = 1.1µM) (Figure 3-8.A).  Conversely, zaprinast concentration 
curves at FLAG-ratGPR35-eYFP (Figure 3-8.B) or FLAG-mouseGPR35-eYFP (Figure 3-
8.C) remained uninhibited following exposure to increasing concentrations of CID-
2745687, indicating that this compound lacks significant affinity for the rodent orthologues.  
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Figure 3-8. GPR35 antagonist CID-2745687 displays human selective, competitive 
activity.  
β-arrestin-2-receptor interaction BRET assays were performed in response to various 
concentrations of zaprinast in the presence of fixed concentrations of CID-2745687 in 
HEK293T cells transfected with A) FLAG-hGPR35-eYFP B) FLAG-rGPR35-eYFP or C) 
Data were constrained to global fit a Schild analysis (H =1).  Data are representative of 
n=3 individual experiments, values are displayed as mean % of maximal zaprinast 
response, +/- SEM and were performed in triplicate. 
 
 
 
 
Human 
Rat Mouse 
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ML-145 also exhibited competitive antagonism of zaprinast (R2 = 0.84-0.92) at 
humanGPR35.  Moreover, ML-145 demonstrated substantially higher affinity at FLAG-
humanGPR35-eYFP (Kb = 1.4nM) (Figure 3-9.A) than did CID-2745687.  However, ML-
145 also displayed negligible inhibition of zaprinast induced effects at FLAG-ratGPR35-
eYFP (Figure 3-9.B) and FLAG-mouseGPR35-eYFP (Figure 3-9.C), indicating human 
GPR35 selectivity. 
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Figure 3-9. The GPR35 antagonist ML-145 also displays human selective, 
competitive behaviour.  
β-arrestin-2-receptor interaction concentration-response curves  constrained to global fit 
Schild analysis (H =1) in HEK293T cells transfected with A) FLAG-hGPR35-eYFP B) 
FLAG-rGPR35-eYFP and C) FLAG-mGPR35-eYFP in the presence of increasing 
concentrations of both agonist zaprinast and the antagonist ML-145. Data are 
representative of n=3 individual experiments, values are displayed as mean % of maximal 
zaprinast response, +/- SEM and were performed in triplicate. 
 
 
 
 
 
Human 
Rat Mouse 
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To further investigate this apparent species selectivity of the antagonist ligand, an in-cell 
‘Arrayscan’ of doxycycline induced Flp-In™ T-REx™ cells stably expressing FLAG-
humanGPR35-eYFP and FLAG-mouseGPR35-eYFP was performed (Figure 3-10). This 
quantitative measurement of receptor internalisation captures live cell internalisation and 
subsequently applies computational algorithms to identify clusters of receptor-eYFP 
expression within each cell, indicative of the formation of endosomal compartments in 
receptor recycling.  These were normalised to the number of nuclei present, identifiable 
via Hoescht stain and were expressed as a percentage of spots per cell (% spots/ cell).   
Results indicated that FLAG-humanGPR35-eYFP internalisation induced by EC80 
concentrations of GPR35 agonists zaprinast, pamoic acid or cromolyn was inhibited in a 
concentration-responsive manner following the addition of increasing concentrations of 
CID-2745687 (Figure 3-10A) and ML-145 (Figure 3-10.B).  Interestingly, results also 
indicated that GPR35 internalisation surpasses baseline measurements at the highest 
concentrations, suggesting that CID-2745687 and ML-145 may also display inverse 
agonism (Figure 3-10.A&B). By contrast, there was no evidence of reduced FLAG-
mouseGPR35-eYFP internalisation following exposure to increasing concentrations of 
CID-2745687 (Figure 3-10.C) and ML-145 (Figure 3-10.D) in the presence of EC80 
concentrations of zaprinast or cromolyn, indicating that CID-2745687 and ML-145 do not 
exert an antagonistic effect at mouse GPR35. 
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Figure 3-10.  Quantitative GPR35 internalisation demonstrates human GPR35 
selective antagonism of CID-2745687 and ML-145.   
In-cell Arrayscan analysis performed on doxycycline induced Flp-In™ T-REx™ cells stably 
expressing FLAG-humanGPR35-eYFP (A&B) or FLAG-mouseGPR35-eYFP (C&D) to 
quantify GPCR internalisation in the presence of increasing concentrations of the 
purported antagonists CID-2745687 (A&C) and ML-145 (B&D) in response to zaprinast, 
cromolyn disodium or pamoic acid ([EC80] defined for the corresponding orthologue).  
Data are representative of n=3 experiments, values are displayed as mean % of maximal 
internalisation, +/- SEM and were performed in triplicate. 
 
 
Human Human 
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3.2.7 Screening potential GPR35 antagonists via BRET analysis 
In a bid to identify antagonists which are equipotent amongst species or rodent selective, 
competitive BRET analysis was performed using a selection of commercially available 
compounds, including dogoxigenin, stropanthidin, hexestrol, dienestrol and bisacodyl; that 
were highlighted as potential antagonists of GPR35 by screening of the Prestwick 
Chemical Library® in antagonist mode by collaborators from the University of Santiago de 
Compostela, Spain.  BRET competition assays demonstrated in Figure 3-11 were 
performed using an EC80 concentration (calculated for each orthologue) of the reference 
agonist zaprinast, in the presence of increasing concentrations of potential antagonists in 
HEK293T cells transiently transfected with FLAG-humanGPR35-eYFP (Figure 3-11.A) or 
FLAG-ratGPR35-eYFP (Figure 3-12.B).  Results from these assays indicated that three 
molecules, bisacodyl, dienestrol and hexestrol, exhibited potential for antagonistic activity 
at both human and rat orthologues of GPR35 and therefore, warranted further 
investigation.  Schild analysis was performed in the presence of increasing concentrations 
of both zaprinast and either dienestrol or bisacodyl at FLAG-humanGPR35-eYFP (Figure 
3-11.C&E) and FLAG-ratGPR35-eYFP (Figure 3-11.D&F). Results demonstrated that 
whilst the concentration-response curves to zaprinast displayed a ‘rightward’ shift to 
higher concentrations, to some degree, in response to bisacodyl, the data points poorly fit 
the global model of constraint within the Schild analysis (Schild slope=1) for each 
orthologue. Therefore, bisacodyl appeared to act as a non-competitive antagonist at 
GPR35, but displayed modest potency at each orthologue (Figure 3-11.C&D).  
Furthermore, dienestrol, a second potential GPR35 antagonist, exhibited negligible 
antagonistic activity in the presence of EC80 concentrations of zaprinast for FLAG-
humanGPR35-eYFP (Figure 3-11.E) and FLAG-ratGPR35-eYFP (Figure 3-11.F). Taking 
this evidence together, it was clear that neither biscodyl nor dienestrol were appropriate 
tools for future exploration of role of GPR35 in human and rodent systems. 
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Figure 3-11. Screening potential novel GPR35 antagonists via BRET .  
β-arrestin-2-receptor interaction was examined in HEK293Tcells  transfected with A) 
FLAG-hGPR35-eYFP or B) FLAG-rGPR35-eYFP in the presence of increasing 
concentrations of potential GPR35 antagonists in the presence of an EC80 concentration 
of zaprinast (defined for each orthologue) and; C, D, E & F) β-arrestin-2-receptor 
interaction was assessed in response to varying concentrations of zaprinast, and data 
constrained to fit Schild slope (= 1), in HEK293T cells transfected with C&E) FLAG-
hGPR35eYFP or D&F) FLAG-rGPR35eYFP in the presence of increasing concentrations 
the potential GPR35 antagonists bisacodyl or dienestrol. Data are representative of n=3 
individual experiments, values are displayed as mean % of maximal zaprinast response, 
+/- SEM and were performed in triplicate. 
Human 
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3.2.8 The G-protein coupling profile of human GPR35
 
and assessment of 
p115RhoGEF trafficking 
By means of chimeric single-cell Ca2+
 
influx assays, Jenkins and colleagues have 
previously demonstrated that GPR35 couples to the Gα12/13 family of G-proteins and 
indeed selectively to Gα13 following zaprinast activation.  However, G-protein selectivity 
has yet to be explored following stimulation with alternative agonists, such as pamoic acid 
(Jenkins et al., 2011, Mackenzie et al., 2014).  Given that pamoic acid has been identified 
as a high-potency agonist at human GPR35, it provides an opportunity to assess a role for 
GPR35 in endogenously expressing cells of human origin and, therefore, it is important to 
understand the signalling pathways it may potentiate within a functional setting.  This was 
next assessed via a homogeneous time resolved fluorescence (HTRF) inositol-phosphate-
1 (IP1) accumulation assay.  Following Gαq activation, the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) at the plasma membrane generates the 
second messenger inositol 1,4,5-trisphosphate (IP3), which rapidly transforms into IP2 and 
in the presence of lithium chloride IP1 formed from this is protected from further 
metabolism.  The high-throughput format of the IP1 accumulation assay employs the use 
of a Lumi-4® IP1 antibody and this competitively binds to increasing concentrations of 
endogenously produced IP1 rather than dye d2-tagged IP1, which has been added 
exogenously.  Therefore, following ligand administration, GPCR activation and 
subsequent IP1 accumulation; an inverse signal is produced.  This assay was employed in 
the presence of increasing concentrations of pamoic acid in HEK293T cells which were 
transfected with FLAG-humanGPR35 alone or co-transfected with the receptor and G-
protein chimeras Gαq/12, Gαq/13, Gαq/i or full length Gαq (Figure 3-12.A).  Interestingly, 
results demonstrated that human GPR35 activation via pamoic acid exhibited a second 
messenger IP1 response via both Gαq/12 and Gαq/13 chimeric constructs, indicating that 
pamoic acid induced activation of human-GPR35 enabled coupling to both members of 
the Gα12/13 family and was not selective for one form (Figure 3-12.A).  Notably, the potency 
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of pamoic acid was 100-fold lower (EC50=3.4µM ± 0.3) in this assay than observed 
previously in the BRET assay (EC50=45nM ± 0.117) (Figure 3-12.A) and this contrasted 
with recently published data which reported that pamoic acid was 10-fold more potent in 
an IP1 accumulation assay compared to BRET analysis (Jenkins et al., 2012). 
Moreover, given that Gα12/13 activation is implicated in downstream signalling involving 
Rho A and ROCK1/2, an attempt to visualise the trafficking of GFP-tagged p115RhoGEF; 
a monomeric GTPase activating protein which is understood to translocate from the 
cytosol to the plasma membrane to activate Rho A following Gα12/13 activation was 
performed (Maruyama et al., 2002) (Figure 3-12.B).  Unfortunately, since eYFP and GFP 
produce overlapping emission wavelengths both humanGPR35-eYFP and induced 
translocation of p115RhoGEF-GFP could not be imaged together effectively.  
Alternatively, HEK293T cells were transiently transfected with p115RhoGEF-GFP alone, 
or co-transfected with Gα13 wild type (WT), Gα13 constitutively active mutant (CAM), Gα12 
wild type (WT) or Gα12 constitutively active mutant (CAM) and 24-hours later were fixed 
using 4% PFA, stained with Cell Mask Orange and Hoechst and imaged using 
VivaTome™ spinning disk illumination microscopy, at x 64 magnification (Figure 3-12.B).  
Representative images in Figure 3-12.B demonstrate that p115RhoGEF-GFP is basally 
located within the cytosol when expressed alone or in the presence of WT Gα13 and WT 
Gα12.  Conversely, co-transfection with either CAM Gα13 or CAM Gα12 promoted the 
translocation of p115RhoGEF-GFP from the cytosol to the plasma membrane where it co-
localised with membrane stain, Cell Mask Orange (Figure 3-12.B).  
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Figure 3-12. Human GPR35 couples to the Gα12/13 family of G-proteins and these 
promote p115-RhoGEF translocation to the plasma membrane.  
A) IP1 accumulation in HEK293Tcells transfected with FLAG-hGPR35-eYFP alone or also 
with chimeric constructs Gαq/13, Gαq/12, Gαq/i, Gαq in the presence of increasing 
concentrations of the GPR35 agonist pamoic acid, assessed via homogeneous time 
resolved fluorescence. B) p115-RhoGEF-GFP translocation in the presence of 
constitutively active Gα12 or Gα13 protein in fixed and stained (Hoescht – nuclei, Cell Mask 
Orange – plasma membrane) HEK293T cells transfected with p115-RhoGEF-GFP alone, 
or p115RhoGEF-GFP with Gα13 wild type (WT), Gα13 constitutively active mutant (CAM), 
Gα12 wild type (WT) or Gα12 constitutively active mutant (CAM).  IP1 accumulation data are 
representative of n=2 individual experiments, values are displayed as mean IP1 ratio, +/- 
SEM and were performed in duplicate.  Images are representative of n=3 experiments 
and were performed in triplicate. Scale bar represents 10µm. 
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3.3 Discussion 
In this chapter, the pharmacology of previously identified ligands across human and 
rodent species of GPR35 was assessed.  Earlier research has established there exists an 
element of species-selectivity amongst ligands which either activate (Jenkins et al., 2010) 
or block GPR35 (Jenkins et al., 2012).  Prior to this latter publication – to which this study 
contributed (Jenkins et al., 2012), it was unclear if this was true for ligand activity at the 
mouse orthologue of GPR35 or, if the recently identified antagonists CID-2745687 and 
ML-145 also displayed species-selective properties. By improving our understanding of 
ligand activity amongst species, it has been possible to gain further insight as to whether 
GPR35 ligand selectivity is evident amongst rodent species and, therefore, their future 
applications in functional systems can be realistically explored. 
The inactivity of the human-selective agonist pamoic acid at rat or mouse GPR35 
highlighted an existing trend towards ligand-selectivity for either human or rodent GPR35.  
Further screening of alternative GPR35 ligands confirmed this.  However, the trend in 
ligand species-selectivity was not entirely exclusive. This was most prominently 
emphasised by KYNA’s limited potency for mouse GPR35.  This finding was unexpected, 
given that KYNA, the first reported endogenous agonist for GPR35 (Wang et al., 2006a), 
demonstrates considerable selectivity for rat GPR35 (Jenkins et al., 2010).  Although an 
unexpected finding, it is important to note that species-selectivity of endogenous ligands 
has also been reported in cannabinoid receptors (CB1 and CB2) (Mukherjee et al., 2004) 
and these are receptors which share close homology with GPR35 (Zhao and Abood, 
2013).  On the other hand, there is research to suggest that some GPCRs do not have an 
endogenous ligand and may be terminally orphaned (Lagerstrom and Schioth, 2008). The 
γ-aminobutyric acid B (GABAB1) receptor is an excellent example, reportedly forming 
heterodimers with GABA to mediate cell surface delivery and function, thus, replacing 
endogenous ligand-receptor activation (Jones et al., 1998). Currently, research which 
addresses the potential of GPR35 to form homo- or heterodimers is lacking.  Approaches 
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to address a mechanism for extreme species-selectivity have previously utilised site-
directed mutagenesis to identify critical residues for KYNA activation.  However, binding 
positions within TMD III at position 3.36 were demonstrated to be common to both rat and 
human GPR35 (Jenkins et al., 2010).  Species sequence alignment confirms this residue 
to be conserved at mouse GPR35 and therefore, it is also unlikely to be responsible for 
the ortholog selectivity described here (Figure 3-5.). Differential KYNA potency between 
rodent orthologues further suggests that additional sites of interaction exist at rat GPR35. 
In going forward, the investigation of residues which are different between human and 
murine GPR35 may prove helpful in future mutagenesis studies designed to elucidate 
KYNA’s selective mode of binding to rat GPR35.   
Of course, the findings reported here also have significant implications towards the 
conclusions drawn from a former publication demonstrating a dose-dependent, 
nociceptive effect of pamoic acid in an experimental mouse model (Zhao et al., 2010).  β-
arrestin-2-receptor interaction demonstrates that pamoic acid is virtually ineffective at both 
the mouse and rat orthologues of GPR35, and this is consistent with previous evidence of 
inactivity at the rat orthologue (Jenkins et al., 2010). The extreme human-GPR35 selective 
agonism of pamoic acid is also demonstrated here via receptor internalisation in cells 
stably expressing human or rat GPR35-eYFP. Taking this evidence together, it is possible 
to suggest that pamoic acid may have effects on nociception, however, it is unlikely that 
these effects are mediated via GPR35 (Zhao et al., 2010).   
It was also confirmed that CID-2745687 and ML-145 are competitive, high affinity 
antagonists which display surmountable activity in the presence of zaprinast, and this is in 
line with published evidence (Jenkins et al., 2012).  Given that neither CID-2745687 nor 
ML-145 are effective antagonists at the rodent orthologues, it is now clear that the 
species-selective properties displayed by the majority of GPR35 ligands also extended to 
antagonists.  This clarification is particularly useful considering that initial reports that 
identified these antagonists failed to investigate this (Zhao et al., 2010, Heynen-Genel et 
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al., 2010) and, therefore, CID-2745687 was employed as an antagonist of GPR35 within a 
mouse model - with no effect (Zhao et al., 2010).  Importantly, results from this chapter 
highlight that neither CID-2745687 nor ML-145 are appropriate tools to decipher a role for 
GPR35 in rodent models. Taking this information together, the differences in species-
selectivity demonstrated here may have particular implications for future studies which 
derive associations between ligand administration, GPR35 activation and subsequent 
alteration of physiological parameters in vivo.    
To further our understanding of the nature of the human-selectively displayed by pamoic 
acid, a series of single-point, cross-species mutations were introduced to human GPR35, 
substituting positively charged arginine (a potential residue which may interact with one of 
the carboxylate moieties in pamoic acid) for polar, neutral residues such as alanine and 
methionine or glutamine, the corresponding residue in both mouse and rat.  Substituting 
arginine for alanine at both 6.58 and 4.60 resulted in a complete loss of potency and 
efficacy for zaprinast and pamoic acid, indicating that these ligands share an overlapping 
binding position which is critical for interaction.  This finding is in agreement with recently 
published data suggesting that arginine residues within TMDs III and V are critical binding 
positions for pamoic acid and zaprinast (Zhao et al., 2014). Most interestingly, replacing 
arginine at 6.58 with glutamine (the corresponding residue in rat) merely reduced the 
potency of both zaprinast and pamoic acid by 10-fold and the efficacy by 25%, suggesting 
that glutamine substitution has only a moderate effect on the interaction with either ligand. 
Notably, however, the cell-surface expression for all human GPR35-mutant constructs 
was minimal and despite demonstrating a sustained trend towards higher expression, this 
was not significantly different to the vector-only control.  In functional systems, single-
residue mutations are understood to present post-translational modifications relating to 
membrane expression via an alteration in protein folding, endosomal sorting and 
subsequent degradation which can often result in disease and signalling modifications via 
GPCRs (Conn et al., 2006).  The repercussions of this are extensive for the gonadotropin 
159 
 
releasing hormone (GnRH) receptor and vasopressin type 2 receptors (V2Rs), for which 
single-point mutations have been implicated in hypogonadotropic hypogonadism and 
nephrogenic diabetes, respectively (Conn et al., 2006, Conn et al., 2007). However, given 
that the BRET assay is essentially G-protein independent in nature and its signal 
remained unaffected by lowered cell-surface expression, its use is advantageous to 
assess the pharmacology of potential ligand-receptor interaction at this level. Notably, 
Zhao and colleagues also employed a β-arrestin-receptor interaction assay in their 
assessment of single-point mutations and reported differences in potency of up to 30-fold 
compared to an ERK1/2 phosphorylation assay, suggesting that secondary-endpoint 
assays may obscure basic pharmacology at the receptor complex (Zhao et al., 2014). 
Though a gain in potency by pamoic acid was not demonstrated by replacing glutamine 
with arginine at position 6.58 in rat, this was expected, given that opposing substitutions 
(arginine6.58glutamine) in the human orthologue did not result in the loss of potency of 
pamoic acid. It is clear that arginine and glutamine are somewhat interchangeable at this 
position and this may be unsurprising, considering they are both polar, hydrophilic 
residues (Betts and Sternberg, 1999).  Furthermore, it is clear that arginine4.60 is a critical 
binding position for zaprinast at the rodent orthologues and more interestingly, when 
substituted for alanine, rat GPR35 becomes constitutively active.  This evidence suggests 
an interruption of ionic constraints which have shifted GPR35 towards an active 
confirmation.  Constitutive activity has not been reported in previously generated GPR35 
mutants.  However, is it understood that single-point mutations within a critical binding site 
can often produce constitutive activity and sustained signalling (Smit et al., 2007).  Given 
that results in secondary end-point signalling may be affected by constitutive activity, its 
potential use is limited in this respect.  However, it could be useful for the identification of 
inverse agonists for GPR35 in the future. It was also important to note that unlike human 
GPR35 mutants, rat GPR35 mutant constructs were very well expressed at the cell 
surface (p<0.001, compared to vector-only control). This may indicate a propensity for 
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single-point mutations to disrupt protein-folding and subsequent trafficking more readily in 
human than rodent GPR35. Further investigation may be required to understand if this 
finding reflects the numerous SNPs reported to have implications for disease in man 
(Mackenzie et al., 2011). 
Despite the steady increase in newly identified synthetic ligands at GPR35 (Mackenzie et 
al., 2014, Deng and Fang, 2013), much of the evidence of a role for GPR35 is conflicting 
and this is largely due to a lack of functional ligand pairs which transcend species-
selectivity (Jenkins et al., 2012).  To this end, this study also endeavoured to identify novel 
GPR35 antagonists which act at both human and rodent species.  Competitive BRET 
analysis indicated that bisacodyl, a commercially available stimulant laxative (Manabe et 
al., 2009) and dienestrol, a synthetic estrogen, may exert antagonistic effects at both 
human and rat GPR35.  However, baseline BRET values were not re-established 
following exposure to high concentrations of bisacodyl in a competitive BRET assay - 
indicating non-surmountable activity.  This was confirmed by application of Schild 
analysis, for which global Schild-slope constraints equal to one were used in the 
assessment of dose-response curves.  Given that neither compound elicited a potent or 
competitive antagonistic action at either orthologue, it would be impractical to utilise these 
ligands within a functional setting for either species.  Conclusively, these results 
emphasise the importance of applying basic pharmacological approaches to the screening 
of GPR35 ligands in order to identify functional ligand pairs within a multi-orthologue 
setting.    
Research here also investigated the coupling profile following GPR35 activation and 
discovered that it couples to both Gα12 and Gα13 isoforms following pamoic acid 
stimulation. This is not in dispute with reports that pamoic acid, amongst others, promotes 
robust coupling to Gα13 via GPR35 activation in IP1 assays (Jenkins et al., 2012, 
Mackenzie et al., 2014). However, it does contrast previous research published by 
Jenkins and colleagues who demonstrate that GPR35 selectively couples to Gα13 via Ca2+ 
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mobilisation following zaprinast activation (Jenkins et al., 2011).  Whilst the data 
presented here are initially suggestive of either assay or ligand bias, it is important to note 
that this study did not employ the use of an additional GPR35 agonist, such as zaprinast.  
Moreover, the potency reported here is 100-fold lower than those reported at BRET and 
IP1 assays for pamoic acid (Jenkins et al., 2012).  Evidently, more work is required to 
confirm these findings, alongside other, well-characterised, GPR35 ligands.    
Lastly, trafficking of p115-RhoGEF GFP from the cytosol to the plasma membrane 
following co-transfection with CAM forms of either Gα12 or Gα13 was also assessed.  
Importantly, the findings are in line with previous reports of RhoGEF cell trafficking to the 
cell membrane in the presence of active Gα12 or Gα13 (Meyer et al., 2008).  Moreover, 
constitutively active Gα13 has been shown to induce p115-RhoGEF translocation to 
promote selective activation of Rho A (Hart et al., 1998) and given that GPR35 has been 
shown to couple to Gα13 here, and in numerous other reports (Jenkins et al., 2011, 
Jenkins et al., 2012, Mackenzie et al., 2014), evidence strongly indicates that GPR35 
activation might lead to Rho A signalling via Gα13. Importantly, this signalling pathway has 
been implicated in hypertension (Wirth, 2010), vessel remodelling and cardiac 
hypertrophy (Maruyama et al., 2002, Cotton and Claing, 2009).  Taking this together with 
research implicating GPR35 in numerous disease pathologies relating to the 
cardiovascular system inclusive of hypertension (Min et al., 2010), heart failure (Min et al., 
2010, Ronkainen et al., 2014) and coronary artery disease (Sun et al., 2008); a potential 
mechanism of action is evident. To successfully identify a functional role for GPR35, this 
signalling axis must be investigated within an appropriate setting, relevant to 
cardiovascular disease.  
3.3.1 Conclusions 
Results from this study represent significant challenges for the elucidation of GPR35 
function within rodent models, given that neither CID-2745687 nor ML-145 demonstrate 
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activity at rat or mouse orthologues of GPR35. Therefore, successful investigation of a 
role for GPR35 in rodent models will require close correlation with existing 
pharmacological insights derived from in vitro studies. Of course, whilst novel drug 
discovery has not always been limited by the requirement of rodent trials, existing clinical 
trials which have foregone this route have ultimately suffered due to a lack of information 
for the efficacy and bio-availability of a compound in an in vivo setting (Bindels et al., 
2013). 
In conclusion, this study has contributed to the knowledge and understanding of species 
orthologue selectivity of GPR35 ligands and highlighted potential key binding positions for 
pamoic acid and zaprinast within TMD IV and VI.  Importantly, information relating to 
species-selectivity of GPR35 agonists and antagonists will provide a secure basis to 
dissect the mechanism by which GPR35 might be mediating its effects, at least, within a 
human setting.  
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4 The role of GPR35 in vascular smooth muscle and 
endothelial cells and cardiomyocytes 
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4.1 Introduction 
Although not widely investigated within the cardiovascular system, literature suggests that 
GPR35 expression and activation may have significant implications for various 
pathologies relating to the progression of vascular disease and cardiac dysfunction. Two 
such studies have highlighted a potential role for GPR35 in the development of early, 
acute phase vascular inflammation and consequential vessel calcification (Sun et al., 
2008, Barth et al., 2009).  First, a genetic study inclined to identify novel gene-biomarkers 
associated with hypertension and end-organ damage highlighted a significant association 
between the expression of a non-synonymous GPR35 SNP and coronary artery 
calcification burden within a hypertensive patient cohort, assessed by computed 
tomography (Sun et al., 2008).  Upon closer inspection, it became clear that this mutation, 
which resulted in a serine-arginine swap at position 294, was located within a highly 
conserved region of the cytoplasmic tail of GPR35 and might have consequential 
implications for G-protein coupling and subsequent signalling (Sun et al., 2008).  
However, the significance of this has yet to be assessed.  An alternative publication found 
circulating inflammatory mediator cells, inclusive of leukocytes and neutrophils, displayed 
robust endogenous GPR35 expression and this led investigators to assess their potential 
role in vascular inflammation (Barth et al., 2009).  In this, it was subsequently 
demonstrated that GPR35 activation, stimulated via KYNA, promoted β1 integrin-mediated 
leukocyte arrest to an endothelial monolayer and this was quantified in a flow-chamber 
under vascular shear stress conditions (Barth et al., 2009).  Conflicting evidence for KYNA 
activation of human GPR35 aside, monocyte tethering, rolling and arrest to the 
endothelium is indicative of acute-phase inflammation within the vasculature and this 
study may have identified a potential role for GPR35 as an early mediator of progressive 
atherosclerosis (Barth et al., 2009).   
A role for GPR35 has also been investigated in the setting of cardiomyocyte hypertrophy 
and progressive cardiac remodelling, with further tentative implications for GPR35 
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expression in the development of hypertension.  In a microarray screen of heart failure 
patients, GPR35 was reported to have increased expression levels in failing myocardial 
tissue (Min et al., 2010).  This study further reported that adenovirus-mediated 
overexpression of GPR35 induced hypertrophy and decreased cell viability in rat neonatal 
cardiomyocytes (Min et al., 2010).  Moreover, GPR35 knock-out mice were reported to 
have significantly increased blood pressure compared to wild-type littermates (Min et al., 
2010).  The association between GPR35 expression and cardiomyocyte hypertrophy was 
more widely investigated in a recent report which recommended GPR35 as a novel gene-
biomarker in the setting of progressive cardiac remodelling (Ronkainen et al., 2014).  
Interestingly, authors demonstrated hypoxia-dependent increases in GPR35 expression 
within hypertrophic cardiomyocytes in an in vitro setting and this finding was further 
replicated in cardiac hypertrophy following induced acute MI in mice (Ronkainen et al., 
2014). Upon closer examination, it was revealed that a transcription factor, hypoxia 
inducible factor-1 (HIF-1), was able to bind to the promoter region of GPR35 and this 
resulted in an increase in GPR35 expression following exposure to hypoxic conditions 
(Ronkainen et al., 2014).  Taking this information together, it is evident that GPR35 
expression and activation might have significant implications for disease pathologies 
relating to both vasculature and cardiac tissue and therefore further investigation is 
warranted. 
The major challenges presented by the species-selective properties of GPR35 ligands 
have promoted continuous characterisation and identification of successful ligand pairs in 
order to elucidate a function for GPR35 (Jenkins et al., 2012). The tryptophan metabolite 
kynurenic acid (KYNA) was the first reported endogenous GPR35 ligand (Wang et al., 
2006a) and whilst micromolar potency has been confirmed at rat GPR35, further analysis 
of β-arrestin recruitment demonstrate that KYNA activation of human GPR35 is almost 
undetectable (Jenkins et al., 2011).  Moreover, results in Chapter 3-2-4 demonstrate that 
KYNA also has limited activity at the mouse ortholog of GPR35. More recently, other 
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natural agonists of GPR35 were identified within the LPA family, specifically 2-acyl LPA 
(Oka et al., 2010), however, there have not been any subsequent reports which explore 
this further. Given reports of extreme-species selectivity for KYNA and the evidence of 
alternative endogenous targets for both ligands (Stone, 1993, Lin et al., 2010), GPR35 is 
still regarded as an orphan GPCR, prompting investigators to identify alternative surrogate 
ligands in order to successfully investigate functional roles for GPR35.  The first identified 
and best utilised of these is zaprinast (Taniguchi et al., 2006), a potent agonist at all 
species of GPR35, however, significantly more so at rodent orthologs and zaprinast is the 
customary ligand of reference in chemical screens targeting GPR35 (Deng and Fang, 
2013, Mackenzie et al., 2014, Jenkins et al., 2011).  Despite this, its use in functional 
assays is limited by its potency as an inhibitor of cGMP phosphodiesterase (PDE), 
specifically PDEs 5 and 6 (Gibson, 2001). Work from Jenkins et al, and others have 
reported detailed pharmacology for alternative novel, synthetic GPR35 ligands and this 
includes the identification of pamoic acid as a highly potent agonist at human GPR35 
(Jenkins et al., 2010, Zhao et al., 2010). This study has also contributed to recently 
reported detailed species pharmacology for novel GPR35 antagonists CID-2745687 and 
ML-145, revealing that they are also highly selective for human GPR35 (Jenkins et al., 
2012).   Given that pamoic acid and both GPR35 antagonists are highly potent for human 
GPR35 and not reported to target other receptors, they provide an excellent set of tools to 
assess GPR35 function in endogenously expressing cells of human origin. 
The use of autologous human saphenous vein (HSV) is the most common surgical 
intervention for bypass of occluded multi-vessel coronary artery disease (CAD), despite 
use of alternative sources of graft such as internal mammary artery and advances in 
interventional revascularisation via coronary intervention (Anderson et al., 2002).  
Although successful in reducing overall rates of mortality and morbidity in CAD patients, 
50% of long term vein grafts become occluded due to intimal hyperplasia (Rienstra et al., 
2008).  The pathophysiology of vein graft disease is defined by a cascade of events 
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leading to neointimal formation and graft occlusion; early graft failure and thrombosis can 
result from endothelial dysfunction and loss, due to injury by shear stress, from the 
coronary circulation (Shukla and Jeremy, 2012).  Furthermore, ischaemia and subsequent 
reperfusion results in reactive oxygen species (ROS) production, contributing to 
endothelial and vascular smooth muscle cell (VSMC) death and inflammation via 
activation of the NFκB pathway.  Importantly, NFκB is also integral to VSMC migration 
and proliferation via the modulation of matrix metalloproteinases (MMPs) and their 
endogenous tissue inhibitors (TIMPs) (Bond et al., 2001, Bond et al., 1999) (reviewed in 
(Wan et al., 2012b). Therefore, the migration, proliferation and integrity of vascular cells, 
together with the deposition and activation of inflammatory mediators, is central for 
neointimal development and if left unchecked, can lead to graft occlusion via atheroma 
(Shukla and Jeremy, 2012). Current therapeutic options are limited and only by repeating 
the intervention is it possible to relieve an occluded graft. Therefore, vascular remodelling 
is an important target for the development of new therapies. 
In agreement with published literature (Jenkins et al., 2010), this study has shown that 
GPR35 couples to Gα12/13, although others have reported Gαi/o coupling leading to ERK1/2 
activation (Zhao et al., 2010).  Following its interactions with Rho A and subsequent 
activation of ROCK1/2 effectors, the coupling and activation of Gα12/13 mediated signalling 
has been widely demonstrated to have significant implications for the progression of 
various pathologies relating to cardiovascular disease including angiogenesis, vascular 
remodelling, neointima formation and cardiac hypertrophy (Wirth, 2010, Moriki et al., 
2004, Takefuji et al., 2012).   
 
4.1.1 Hypothesis and aims 
Given that GPR35 has been reported to selectively couple to the Gα13 signalling pathway 
(Jenkins et al., 2010), a coupling well understood to promote pathways governing 
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vasculature function via Rho A activation (Wirth, 2010), it was hypothesised that GPR35 
activation might play a functional role within the vascular cell population. Therefore, this 
study was designed to investigate a functional role for GPR35 in the setting of acute 
vascular injury using in vitro models in human primary saphenous vein endothelial and 
smooth muscle cells, for the first time. Moreover, given evidence that GPR35 expression 
is implicated in cardiomyocyte hypertrophy and progressive cardiac remodelling, a role for 
GPR35 activation in the setting of cardiomyocyte hypertrophy was also explored using a 
novel, highly potent GPR35 ligand. To investigate these in detail, a series of aims are 
outlined below: 
• To assess the endogenous expression levels of GPR35 in human tissue and 
primary vascular endothelial and smooth muscle cells. 
• To investigate the effects of human-selective GPR35 ligands on actin-cytoskeleton 
organisation in primary human vascular smooth muscle and endothelial cells 
endogenously expressing GPR35. 
• To investigate the effects of human-selective GPR35 agonism and antagonism on 
the migratory and proliferative capacity of primary human vascular endothelial and 
smooth muscle cells. 
• To investigate the effects of GPR35 agonists on actin-cytoskeleton organisation 
and hypertrophy in cardiomyocytes. 
 
 
 
 
 
 
169 
 
 
4.2 Results 
4.2.1 The expression of GPR35 in human tissue and vascular cells  
Expression of GPR35 is widely reported in a variety of tissues.  However, much of the 
research previously conducted focuses upon a limited range of tissue and the methods 
used to detect expression are inconsistent and imprecise (O'Dowd et al., 1998, Wang et 
al., 2006a).  In this study, the expression of human GPR35 mRNA was comparably 
quantified in a wide ranging array of tissue samples and isolated primary vascular cells via 
real-time, quantitative reverse transcription-polymerase chain reaction (qRT-PCR). 
Consistent with previous literature reports (O'Dowd et al., 1998, Taniguchi et al., 2006), 
GPR35 was detected in the small intestine, colon and spleen and these were 347.3-fold, 
122.4-fold and 22.5-fold higher than in heart tissue, respectively. (Figure 4-1.A).  
However, it is notable that GPR35 mRNA expression could also be detected in many 
other tissues of the body including the kidney, cervix, ovaries and prostate, albeit at lower 
levels (6.7-11.4-fold, relative to heart expression) (Figure 4-1.A). Most interestingly, 
primary human saphenous vein endothelial cells (HSV EC) demonstrated significant 
levels of GPR35 expression (92.7-fold, relative to heart expression), and these levels 
were comparable to those found in the colon (Figure 4-1.A). Of course, it was important to 
recognise that GPR35 expression within niche cell populations, such as HSV EC, might 
not be best compared to whole tissue expression which constitutes multiple cell-types.  
Therefore, to investigate if GPR35 was also highly expressed in alternative vascular cells, 
expression levels were examined in primary human saphenous vein endothelial and 
smooth muscle cells (HSV EC/ SMCs), and human umbilical vein endothelial cells 
(HUVECs) (Figure 4-1.B). To provide a positive control for GPR35 expression, a 
doxycycline-inducible cell line stably expressing human GPR35 and human colon 
adenocarcinoma cell line, HT-29, were included. Robust equivalent levels of GPR35 
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expression could be detected across all vascular cell types tested (Figure 4-1.B)., 
Importantly, this evidence provided a strong platform to endogenously target GPR35 in 
vascular cells using previously identified, high-potency, human-selective ligands. 
 
 
Figure 4-1. GPR35 is robustly expressed within human tissue and primary vascular 
cells. 
A. hGPR35 mRNA expression in a commercially available, healthy human tissue panel 
and primary human saphenous vein endothelial cells (HSV EC), expressed as RQ relative 
to hGPR35 expression in the heart and normalised to ribosomal 18s.  B. hGPR35 mRNA 
expression in a range of immortalised and primary cells; stable FLAG-hGPR35-eYFP 
(positive control), HT-29 cells (positive control), human umbilical vein endothelial cells 
(HUVECS), HSV EC and human saphenous vein smooth muscle cells (HSV SMC). 
Values are expressed as cycle threshold (CT), for which an inverse relationship is 
indicative of high expression levels, and normalised to ribosomal 18s.  All data are 
representative of n=3-4 biological replicates and were performed in technical duplicates. 
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4.2.2 The effects of human-selective GPR35 ligands on the cytoskeletal 
arrangement of cells endogenously expressing GPR35. 
It is well understood that Gα12/13 activation leads to downstream signalling via RhoA and 
that subsequent effectors (ROCK1/2) promote the reorganisation of the actin-cytoskeletal 
architecture via an inhibition of MLCP and up-regulation of myofilament proteins adducin 
and prolifin (Wirth, 2010).  In Chapter 3-2-9, it was shown that human GPR35 activation 
promoted Gα12/13 coupling and that tonic Gα12/13 activation results in the translocation of 
p115-RhoGEF from the cytosol to the plasma membrane where it is hypothesised to 
activate RhoA (Hart et al., 1998, Maruyama et al., 2002).  Therefore, the effects of GPR35 
ligand exposure on the cytoskeletal arrangement of engineered and endogenously 
GPR35 expressing cells was tested here.  The effects of human-selective ligands were 
first assessed in HEK293t cells engineered to express GPR35 in a doxycycline-inducible 
manner (Figure 4-2). Importantly, the induction of GPR35 expression did not introduce 
any changes to actin cytoskeleton and the architecture of intracellular actin filaments 
remained consistent across the cross-sectional cell area (Figure 4-2.). On the contrary, 
following exposure of doxycycline-treated cells to 500nM of pamoic acid for 45 minutes, 
close inspection of the cytoskeletal architecture revealed a definite alteration in cell 
morphology whereby the cells became contracted and exhibited distinctly fewer 
intracellular filaments (Figure 4-2).  Importantly, pamoic acid exposure to cells lacking 
GPR35 expression i.e. cultured in the absence of DOX, had no effect on the cytoskeleton 
indicating that its effects were indeed mediated via GPR35. Furthermore, co-
administrating pamoic acid with either of the human-selective antagonists, CID-2745687 
or ML-145, at equal concentrations (100nM) prevented any pamoic acid-induced changes 
in the actin cytoskeleton (Figure 4-2). Given that two distinct human-selective antagonists 
produced identical actions, it was clear that pamoic acid was mediating its effects on the 
actin cytoskeletal architecture via GPR35 activation. 
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To date, there have been no studies on the functional aspects of these ligands in human 
vascular cells. Therefore, the effects of these ligand pairs on HSV SMC morphology and 
cytoskeletal rearrangement were next analysed. Following 45 minutes incubation with 
100nM pamoic acid, a striated, contractile and elongated morphology was evident in HSV 
SMCs (Figure 4-3).  This phenotype was not apparent in HSV SMCs in serum free 
conditions or following the co-administration of pamoic acid with the antagonists CID-
2745687 or ML-145 (Figure 4-3.A.).  By quantifying cell length via ImageJ analysis, it was 
evident that pamoic acid exposure significantly lengthened HSV SMCs by up to 74 
±15.7µm, in comparison to agonist free conditions (p<0.001) (Figure 4-3.B).  Most 
importantly, this effect was blocked in the presence of equal concentrations (100nM) of 
CID-2745687 and ML-145 (Figure 4-3.B.).  Closer inspection of the cytoskeletal 
architecture revealed that pamoic acid induced substantial actin filament rearrangement in 
comparison to serum free conditions, indicative of a migratory phenotype in HSV SMC 
(Figure 4-3.C). 
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Figure 4-2. CID-2745687and ML-145 block pamoic induced actin-cytoskeletal 
reorganisation in cells stably expressing hGPR35. 
Representative images of doxycycline (DOX) inducible Flp-In™ T-REx™ cells stably 
expressing FLAG-hGPR35-eYFP in the presence and absence of 100ng/mL doxycycline 
(i.e. +/- human GPR35eYFP).  24 hours later, cells were stimulated with 500nM pamoic 
acid (PAM) alone or 100nM PAM + 100nM CID-2745687 (CID) or ML-145 for 45 minutes. 
Cells were fixed with 4% PFA, stained for F-actin using TRITC actin phalloidin stain and 
mounted to glass coverslips with ProLong® Gold antifade with DAPI.  Slides were imaged 
via spinning disk illumination VivaTome™ microscopy. Visible actin reorganisation in the 
presence of pamoic acid is evident and this is blocked when co-administered with 
antagonists CID and ML-145. All images are representative of n=3 individual experiments. 
Scale bar represents 20µm. 
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Figure 4-3. Pamoic acid induces changes in HSV SMC morphology, cytoskeletal 
arrangement and size and this is blocked in the presence of antagonists CID-
2745687 and ML-145.   
A. A comparison of the morphological differences in quiescent human saphenous vein 
smooth muscle cells (HSV SMC) which were fixed and stained for F-actin following 
stimulation with 100nM of pamoic acid (PAM) +/- antagonists CID-2745687 (CID) or ML-
145 for 45 minutes. B. Quantification of HSV SMC size in the presence of 100nM pamoic 
acid +/- antagonists CID or ML-145. C. Comparative qualitative images, demonstrating 
cytoskeletal re-arrangement in response to stimulation with 100nM pamoic acid and 
serum free conditions, in HSV SMC fixed with 4% PFA, stained for F-actin using TRITC 
actin phalloidin stain and mounted to glass coverslips with ProLong® Gold antifade with 
DAPI. All data are representative of n=3-4 individual patient cells. Quantification of cell 
size was analysed using ImageJ software.  Statistical significance *** p<0.001.  Scale bar 
represents 100µm.  
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4.2.3 The effect of human-selective GPR35 ligands on HSV SMC migration  
To assess a possible functional role for GPR35 in vascular remodelling, migration of HSV 
SMC was next assessed via a scratch and wound healing assay in the presence of 
GPR35 ligands zaprinast or pamoic acid. Briefly, following a 48-hour exposure to serum 
free conditions, horizontal scratches were applied to a confluent monolayer of quiescent 
HSV SMCs using a 200µL pipette tip.  HSV SMCs were stimulated with ligands in serum 
free media and imaged at intervals of 6-8 hours in order to assess any effect of GPR35 
ligands on the migration of cells into the wounded area. Both zaprinast and pamoic acid 
significantly enhanced migration by up to 25% in comparison to serum free conditions 
(p<0.001) and this occurred in a concentration-responsive manner for concentrations of 
up to 500nM for zaprinast and 100nM for pamoic acid.  However, migration did not 
continue to increase following exposure above these concentrations for either agonist 
(Figure 4-4.B. and Figure 4-5.A., for zaprinast and pamoic acid respectively). Next, the 
effects of co-administering of GPR35 antagonists CID-2745687 and ML-145 at 100nM 
were assessed. Essentially, both antagonists completely abolished zaprinast and pamoic 
acid induced migration at 36 hours (p>0.05, compared to –serum) (Figure 4-4.C. and 
Figure 4-5.B., for zaprinast and pamoic acid respectively).  Pamoic acid-induced migration 
was also assessed at earlier time points of 20 and 30-hours (P<0.001) and the ability of 
GPR35 antagonists to effectively block this was also observed (Figure 4-5.C.). 
Importantly, neither antagonists had any effect on the basal migration of HSV SMC at 
these concentrations (p>0.05, compared to –serum) (Figure 4-6.A).  However, serum 
induced migration of HSV VSMC was inhibited at higher concentrations of 1µM and 10µM 
for both antagonists (Figure 4-6.B). These data suggest that physiological factors in 
normal serum might mediate HSV SMC migration via GPR35 activation and highlights that 
GPR35 antagonism may have therapeutic utility. 
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Figure 4-4. The migratory capacity of HSV SMC is increased following sustained 
incubation with zaprinast and this is blocked by co-administering CID-2745687 and 
ML-145. 
A. Representative images of invading migratory human saphenous vein smooth muscle 
cells (HSV SMCs) into the wound following zaprinast incubation over a time course of 36 
hours.  B. Migration of confluent, quiescent HSV SMC in the presence of increasing 
concentrations of the reference GPR35 agonist, zaprinast (100nM-1µM).  C. Migration of 
confluent, quiescent HSV SMC in the presence of agonist zaprinast and +/- CID-2745687 
or ML-145. All data were acquired via scratch-wound healing assay at 36 hours, 
expressed as a percentage of migration at time point 0 and are representative of n=3 
individual patient experiments.  Statistical significance; ** p<0.01, *** p<0.001 (compared 
to –SERUM control).   
177 
 
 
Figure 4-5. Pamoic acid induced HSV SMC migration is blocked in the presence of 
GPR35 antagonists CID-2745687 and ML-145. 
A. Migration of confluent, quiescent HSV SMC in the presence of increasing 
concentrations of hGPR35 agonist pamoic acid (PAM) (10-300nM). B. Migration of 
confluent, quiescent HSV SMC in the presence 100nM hGPR35 agonist pamoic acid 
(PAM) +/- CID-2745687 or ML-145. C. Comparative migratory response of confluent, 
quiescent HSV SMC in the presence 100nM hGPR35 agonist pamoic acid (PAM) +/- CID-
2745687 or ML-145 over a time course of 30 hours. All data was acquired via scratch-
wound healing assay at 30-36 hours, expressed as a percentage of migration at time point 
0 and are representative of n≥3 individual patient experiments.  Statistical significance; ** 
p<0.01, *** p<0.001 (compared to –SERUM control).   
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Figure 4-6.  Human GPR35 antagonists CID-2745687 and ML-145 block serum 
induced HSV SMC migration at high concentrations.   
A. Migration of confluent, quiescent HSV SMC in the presence of hGPR35 antagonists 
CID-2745687 and ML-145 at 100nM in the presence and absence of 15% serum. B. 
Migration of confluent, quiescent HSV SMC in the presence of hGPR35 antagonists CID-
2745687 and ML-145 at 100nM in the absence of 15% serum and 1µM and 10µM in the 
presence of 15% serum.  All data was acquired via scratch-wound healing assay at 36 
hours, expressed as a percentage of migration at time point 0 and are representative of 
n=2 individual patient experiments.  Statistical significance, based on 3 technical 
replicates, each with 10 cross-sectional wound measurements; *** p<0.001 (compared to 
–SERUM control).   
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4.2.4 GPR35-induced migration of HSV SMCs is mediated via the Rho A-
ROCK1/2 signalling axis. 
Given that GPR35 activation in HSV SMC leads to an alteration of the actin-cytoskeleton 
and subsequent increased migration, the involvement of the RhoA/ ROCK 1/2 signalling 
axis was next assessed. To test if pamoic acid directly induced RhoA activation, an 
immunoprecipitation RhoA pull-down assay was employed in HSV SMCs following a 
short, 5 minute exposure to 10-500nM pamoic acid.  Pamoic acid concentrations of 10-
100nM produced an increase in GTP-bound RhoA (activated RhoA) protein in HSV SMCs 
(Figure 4-7.A).  
To investigate the involvement of subsequent ROCK1/2 effectors on HSV SMC migration, 
pamoic acid was then co-administered alongside two distinct Rho A pathway inhibitors; Y-
27632 and Y16, in a wound-healing assay (Figure 4-7.C&D). Both inhibitors blocked 
pamoic acid induced migration in line with GPR35 antagonists (p<0.001), suggesting that 
GPR35 activation mediates effects on migration via the Rho A, ROCK1/2 signalling axis. 
HSV SMC viability was unaffected when exposed to high concentrations of the ROCK 
inhibitor Y-27632 (10µm), assessed via an MTS assay (Figure 4-7.B). 
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Figure 4-7. Pamoic acid induces RhoA activation in HSV SMC and pamoic acid 
induced migration is blocked in the presence of ROCK inhibitors Y-27632 and Y-16. 
A. Expression of total and active GTP-RhoA protein in human saphenous vein smooth 
muscle cells (HSV SMCs) following 5 mins incubation with increasing concentrations of 
pamoic acid (10-500nM), measured via a RhoA pull-down immunoprecipitation assay. B. 
The proliferative response of quiescent HSV SMC in the presence of increasing 
concentrations of the ROCK inhibitor Y-27632 (10nM - 10µM) in the absence of 5% 
serum, measured via MTS assay at 48 hours.  C&D. The migratory response of confluent, 
quiescent HSV SMC in the presence of hGPR35 agonist pamoic acid (PAM) +/- CID-
2745687, ML-145 (100nM) or 10µM ROCK inhibitors C) Y-27632 and D) Y16, measured 
by scratch-wound healing assay at 36 hours. Migratory experiments are representative of 
n=3-5 individual patients. For RhoA protein quantification, n=1.  Statistical significance; *** 
p<0.001 (compared to –SERUM control).   
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4.2.5 The effects of human-selective GPR35 ligands on HSV SMC 
proliferation.  
To account for the possibility that increased migration following GPR35 agonist stimulation 
was not simply due to an increased rate of cell proliferation, an MTS assay was employed.  
Essentially, the MTS assay is inclusive of both proliferation status and metabolic integrity 
via colorimetric measurement of formazan, a breakdown product of tetrazole, reduced 
enzymatically in healthy and proliferating cells (Wang et al., 2010). Neither zaprinast nor 
pamoic acid induced or prevented HSV SMC proliferation in concentrations equivalent to 
those used to assess migration (P>0.05) (Figure 4-8.). Moreover, it was also clear that 
neither CID-2745687 nor ML-145 had any effect on serum induced HSV SMC proliferation 
or cell-viability (Figure 4-8.D).  Taking these results together, GPR35 stimulation 
enhances the migration of HSV SMC without affecting proliferation. 
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Figure 4-8. HSV SMC proliferation is unaffected by the presence of GPR35 agonists 
and antagonists.   
A. Proliferation of HSV SMCs following exposure to increasing serum concentrations (0-
20%) at 48 hours. B&C. Increasing concentrations (100-500nM) of B) zaprinast or C) 
pamoic acid do not elicit a proliferative response in quiescent HSV SMC in the absence of 
serum.  D, E & F. Proliferation of HSV SMC induced by 5% serum is unaffected by D) 
500nM of GPR35 antagonists CID-2745687 (CID) or ML-145 or increasing concentrations 
(100-500nM) of E) zaprinast and F) pamoic acid. All data were acquired via MTS assay at 
48 hours and are expressed as absorbance at wavelengths of 490nm.  All data are 
representative of n=3-4.  Statistical significance; *** p<0.001 (compared to –SERUM 
control).  
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4.2.6 The effects of human-selective GPR35 ligands on HSV EC 
morphology, migration and proliferation.  
Impaired vascular endothelial cell integrity is implicated in the incidence of vein graft 
occlusion and, given that high expression levels of GPR35 have been demonstrated in 
these cells, the effects of the presence of GPR35 ligands on HSV EC were assessed.  In 
contrast to the effects of GPR35 on HSV SMCs; HSV EC morphology, actin-cytoskeletal 
architecture and migratory capacity remained unchanged following stimulation with 
increasing doses of pamoic acid (p>0.05, compared to –serum control) (Figure 4-9.A & B). 
Conversely, in assessing the proliferative capacity and viability of HSV EC via an MTS 
assay, a concentration-dependent increase in absorbance at 490nm following exposure to 
both zaprinast and pamoic acid was evident at 24 hours, p<0.001 (Figure 4-9.D & E). 
These results indicated that GPR35 agonists induced an increased metabolic response in 
HSV EC, suggestive of an increase in cell growth. 
For a more accurate measurement of cell proliferation, a second assay was employed to 
measure the incorporation of 5-Bromodeoxyuridine (BrdU) (a synthetic analogue of 
thymidine) into cells during the progressive growth cycle.  Essentially, results from BrdU 
incorporation directly correlated with those obtained via MTS. BrdU incorporation in HSV 
EC was significantly increased following exposure to concentrations of pamoic acid 
ranging from 50-500nM (Figure 4-10.B).  Moreover, the proliferative response induced by 
500nM of pamoic acid (p<0.001) was also examined in the presence of GPR35 
antagonists and was found to be completely abolished in the presence of two 
concentrations of either CID-2745687 (Figure 4-10.E) or ML-145 (Figure 4-10.F). This 
information indicates that GPR35 activation is involved in maintaining HSV EC integrity 
and cell cycle progression. Notably, 24-hour incubation with CID-2745687 alone did not 
induce HSV EC proliferation (Figure 4-10.C), however, this was not the case for ML-145, 
which increased proliferation at 500nM (p<0.01) (Figure 3-10.D). 
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Figure 4-9. GPR35 agonist stimulation induces HSV EC proliferation.    
A. Representative images of the human saphenous vein endothelial cells (HSV ECs) 
cytoskeleton, fixed and stained for F-actin (TRITC phalloidin) following stimulation with 
increasing concentrations of pamoic acid (PAM) (10nM-10µM) for 45 minutes.  B. The 
migratory response of confluent, quiescent HSV EC was unaffected in the presence of 
increasing concentrations of pamoic acid (PAM) (50-500nM) measured by a scratch-
wound healing assay at 12 hours. C, D & E. The increased proliferative response of HSV 
ECs following exposure to increasing concentrations of C) serum (0-20%), D) zaprinast 
(10-100nM) and E) pamoic acid (10-100nM). All data were acquired via MTS assay at 24 
hours, expressed as absorbance at 490nm.  All data are representative of n=3-5 individual 
patient experiments.  Statistical significance; * p<0.05, *** p<0.001 (compared to –SERUM 
control). Scale bar represents 20µm. 
185 
 
 
Figure 4-10. Pamoic acid-induced proliferation in HSV ECs is blocked by human-
selective GPR35 antagonists CID-2745687 and ML-145. 
The proliferative response of human saphenous vein endothelial cells (HSV ECs) exposed 
to increasing concentrations of A. serum (0-20%), B. pamoic acid, C. CID-2745687 (CID) 
and D. ML-145 (50-500nM). C & D. The response induced by 100nM pamoic acid was 
blocked by two concentrations of human selective GPR35 antagonists D. CID 
(100nM/500nM) and E. ML-145 (50nM/500nM). All data was acquired via BrdU 
incorporation at 24 hours, expressed as a ratio of the absorbance at 450/540nm.  All data 
are representative of n=2 individual patient experiments.  Statistical significance, based on 
3 technical replicates; * p<0.05, ** p<0.01, *** p<0.001 (compared to –SERUM control).  
186 
 
4.2.7 The effects of zaprinast and the novel high-potency agonist 
amlexanox in H9c2 cardiomyocytes. 
Results from this study have demonstrated that GPR35 activation leads to significant 
changes in the cytoskeletal architecture of vascular smooth muscle cells and given that 
previous studies indicate that GPR35 expression is up-regulated in the setting of heart 
failure and cardiac hypertrophy (Min et al., 2010, Ronkainen et al., 2014), it was important 
to assess the effect of GPR35 ligands in this setting.  Given that GPR35 over expression 
has been demonstrated to elicit a hypertrophic response, the incorporation of a transient 
transfection protocol into a cardiomyocyte hypertrophy assay was first optimised. Using a 
rat neonatal cardiomyocyte cell line (H9c2), an appropriate positive control for cell 
hypertrophy was of critical importance. Published reports demonstrate that 100nM of 
angiotensin II (AngII) elicits a significant hypertrophic response in H9c2 cardiomyocytes, 
following a 96-hour incubation period (Flores-Munoz et al., 2011).  However, as the aim 
was to transfect a GPR35 expression vector into the H9c2 cardiomyocytes first 
optimisation of the time-frame to enable transfection and AngII stimulation was performed.  
AngII at 200nM effectively induced significant hypertrophy in H9c2 cardiomyocytes at 48-
hours and this was measured by an increase in cell size by up to 44.8 ± 4.2µm (p<0.001), 
and this was not significantly different to H9c2 cell size following incubation with 100nM 
AngII at 96-hours (Figure 4-11.A).  To ensure efficient ratGPR35 transfection in H9c2 
cardiomyocytes, expression levels were assessed via real-time qRT-PCR.  Endogenous 
GPR35 expression in H9c2 cardiomyocytes was unchanged by the presence of serum or 
transfection reagent, x-fect (Figure 4-11.B.).  However, following exposure to 200nM 
AngII, endogenous expression of rat GPR35 increased by >2-fold in H9c2 cardiomyocytes 
(p<0.001, compared to – serum) (Figure 4-11.B.).  Most importantly, rat GPR35-eYFP 
transfection increased expression by >5000-fold, indicative of highly efficient transfection 
(Figure 4-11.B.).   
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With the exception of zaprinast, potent ligands to assess functional activation of GPR35 in 
rodent orthologs were previously lacking.  However, most recently, amlexanox was 
identified as a high-potency agonist at rat GPR35 (Mackenzie et al., 2014). Activation of 
GPR35 was confirmed via a β-arrestin-receptor interaction assay (Figure 4-12.), revealing 
similar potencies (EC50 = 4.5nM ± 0.173) to those previously reported for rat GPR35 
(Mackenzie et al., 2014). 
To assess the effects of GPR35 ligands on cardiac hypertrophy, quiescent H9c2 
cardiomyocytes expressing rat GPR35-eYFP remained in serum free conditions or were 
stimulated with 200nM of either zaprinast or amlexanox.  Non-transfected cells were 
exposed to 200nM AngII or maintained in serum free media alone.  After 48-hours, cells 
were fixed, stained for F-actin using TRITC-phalloidin and mounted on glass coverslips for 
subsequent fluorescence imaging and cell size quantification.  Conflicting with established 
reports, there were no differences in the H9c2 cardiomyocyte size in ratGPR35-eYFP 
transfected cells compared to non-transfected, non-stimulated cells (128.0 ±4.9µm and 
133.1 ±3.0µm, for transfected and non-transfected cells resepectively), and this was also 
true of cell morphology (Figure 4-13.A.).  However, this was not the case following 
exposure to GPR35 agonists and quantification of cell size revealed that ratGPR35-eYFP 
expressing cells stimulated with either zaprinast or amlexanox exhibited increased cell 
size of up to 44 ±8µm, compared to unstimulated H9c2 cells in serum free conditions and 
those transfected with ratGPR35-eYFP alone (Figure 4-13.B.).  Furthermore, distinct 
alterations in the cytoskeletal architecture in ratGPR35-eYFP expressing cells stimulated 
with either ligand were evident, including striated actin filaments aligning in a parallel 
fashion, indicative of a hypertrophic phenotype (Figure 4-13.A.).  These changes were not 
evident in unstimulated H9c2 cardiomyocytes transfected with rat GPR35-eYFP and 
therefore, this evidence suggests that GPR35 ligand exposure and thus activation is 
required to elicit a hypertrophic response in H9c2 cardiomyocytes. Notably, following 
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stimulation with either zaprinast or amlexanox, internalisation and clustering of rat GPR35-
eYFP is clear, representative of receptor activation (Figure 4-13.A.) 
 
Figure 4-11. Optimisation of the hypertrophy assay for AngII incubation and rat-
GPR35 transfection in H9c2 cells. 
A. H9c2 cardiomyocytes were incubated with 100nM or 200nM angiotensin II (AngII) for 
either 48 or 96 hours.  Cells were then fixed, using 4% PFA, stained for F-actin using 
TRITC-phalloidin and mounted on to glass coverslips with ProLong® Gold antifade with 
DAPI. Cell size was quantified using ImageJ software. B. H9c2 cells were plated in 6-well 
clear plates in serum free media. 24 hours later, cells were exposed to the following 
conditions; –serum, 10% serum or 200nMAngII. Alternatively, cells were transfected with 
ratGPR35-eYFP using X-fect reagent in serum free medium. After a 48 hour period, 
GPR35 expression was analysed via real-time qRT-PCR and was normalised for 
endogenous GAPDH expression, using respective TaqMan probes. Data are expressed 
as RQ, relative to serum free conditions. Data are representative of n=2 experiments.  
Statistical significance is based upon three technical replicates, with ten fields of view per 
replicate for the quantification of cardiomyocyte size; *** p<0.001, compared to – serum 
conditions. 
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Figure 4-12. Amlexanox is a novel high-potency agonist for rat GPR35. 
Representative concentration-response curves derived from a β-arrestin-2-receptor 
interaction assay in HEK293t cells transfected with β-Arrestin-2-Renilla-luciferase and 
either FLAG-humanGPR35-eYFP, FLAG-ratGPR35-eYFP or FLAG-mouseGPR35-eYFP 
in the presence of increasing concentrations of novel GPR35 agonist amlexanox. All data 
are representative of n=1 experiments, values are displayed as a mean % of maximal 
zaprinast response, +/- SEM and were performed in triplicate.   
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Figure 4-13. Zaprinast and amlexanox activate and internalise rat GPR35, inducing a 
hypertrophic response in H9c2 cardiomyocytes. 
A. H9c2 cells were plated on coverslips in serum free media. 24 hours later, cells were 
exposed to the following conditions; –serum, 200nM AngII, or were transfected with 
ratGPR35-eYFP +/- 200nM amlexanox or zaprinast. After 48 hours, cells were fixed using 
4% PFA, stained for F-actin using TRITC-phalloidin stain and mounted onto glass 
coverslips using Immu-Mount™.  Cells were then imaged on a conventional fluorescence 
microscope. B. Cell size was quantified using ImageJ software. All data are representative 
of n=3 experiments.  Statistical significance *** p<0.001, compared to – serum conditions. 
Scale bar = 50µm. 
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4.3 Discussion 
Here for the first time, an integrated investigation has assessed the role GPR35 activation 
may play in vascular and cardiac remodelling.  Recent literature has begun to highlight a 
potential role for GPR35 within numerous disease pathologies including hypertension and 
heart failure (Min et al., 2010, Ronkainen et al., 2014), asthma (Yang et al., 2010), pain 
(Zhao et al., 2010, Cosi et al., 2011), inflammatory bowel disease (Imielinski et al., 2009) 
and most recently; ulcerative colitis (Ellinghaus et al., 2013).  Even with these indications, 
research to define a role for GPR35 has been hampered by its challenging pharmacology, 
stemming from conflicting reports of the true endogenous agonist and subsequent 
detailing of its complicated species-selective pharmacology (Jenkins et al., 2010, Milligan, 
2011). Despite these difficulties, the identification of highly potent and human-selective 
agonists and antagonists has provided the opportunity to further dissect the functional role 
of GPR35 in an in vitro setting appropriate to vascular remodelling in cells of human origin 
(Jenkins et al,. 2012). 
Here, it was observed that primary vascular smooth muscle and endothelial cells 
demonstrate GPR35 expression levels comparative to those found in the colon, spleen 
and small intestine. Robust detection of GPR35 expression was also evident in HUVECs, 
but higher levels were quantified in primary saphenous vein vascular endothelial and 
smooth muscle cells. In some respects, these findings contrast those from a previous 
study which reported low expression of GPR35 in HUVECs via qRT-PCR (Barth et al., 
2009).  However, two robust positive controls for GPR35 expression were utilised in the 
study reported here, from a doxycycline inducible GPR35-stable cell line, and the colon 
adenocarcinoma cell line HT-29. The results in HT-29 cells are consistent with previous 
reports (Deng et al., 2012a, Deng and Fang, 2012b) giving confidence in our own findings.  
One caveat of these findings is that a direct comparison between gene expression from 
single isolated cell populations to those in a tissue containing many different origin cell 
types is difficult and does not necessarily enable conclusion that the expression levels in 
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the cells are biologically relevant. However, the work in this chapter has highlighted a 
potentially important functional role for GPR35 in the migration and proliferation of primary 
vascular cells. Not only is this the first study to assess the functional effect of GPR35 
activation in both primary vascular endothelial and smooth muscle cells, it is also the first 
to utilise human-selective antagonists to confirm endogenous activation.  To this end, 
results have shown that co-incubating a wounded monolayer of HSV SMCs with human 
GPR35 specific antagonists CID-2745687 and ML-145 abolished a GPR35-mediated 25% 
increase in migration following exposure to agonists, zaprinast and pamoic acid.  Given 
that these cells were isolated from human saphenous vein preparations used to surgically 
bypass multi-coronary artery occlusions, their subsequent physiological responses are 
relevant within the setting of vein graft remodelling, neointima formation and occlusion 
(Shukla and Jeremy, 2012).  In essence, the evidence discussed here reveals that 
activation of GPR35 might promote a pro-remodelling response, at least in an in vitro 
setting, suggestive of a therapeutic potential for GPR35 antagonists and this must be 
explored further.  
Whilst neither antagonist hindered the basal migratory capacity of HSV SMC in the 
absence of serum, preliminary findings demonstrated that serum induced migration of 
HSV SMCs was inhibited following exposure to higher concentrations (10-100-fold) of 
both antagonists.  Due to time constrictions, this effect was not investigated further here. 
However, serum-induced GPR35 activation may exist, given that LPA is a reported 
endogenous agonist at human GPR35 (Oka et al., 2010) and a well-known serum 
component, demonstrating micromolar concentrations (Kang et al., 2004).  Taking this 
together, it is possible to hypothesise that CID-2745687 and ML-145 might have blocked 
LPA mediated activation of GPR35 to inhibit migration in this study.  To address these 
potentially confounding factors, it would be useful to utilise dialysed serum in a migration 
assay and, assuming that serum components would be removed (Kang et al., 2004), it 
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may then be possible to ascertain if CID-274687 and ML-145 were blocking endogenously 
mediated GPR35 activation to inhibit a migratory response in serum treated HSV SMCs. 
Cellular morphology and cytoskeletal rearrangement in this primary vascular cell model 
were also assessed and results demonstrated significant architectural reorganization 
which elongated the cell following agonist stimulation.  This effect was also evident in a 
stably-expressing GPR35 cell line, for which GPR35 expression could simply be ‘switched 
on’ following exposure to doxycycline. Importantly, the exposure of non-GPR35 
expressing cells to pamoic acid had no effect on the actin cytoskeleton, further supporting 
that pamoic acid mediated its effects on the cytoskeleton via GPR35 activation.  Further to 
this, pamoic acid-induced changes were prevented by the co-addition of antagonists, CID-
2745687 and ML-145 in both cell types. This was quantified in endogenously GPR35 
expressing primary HSV SMCs, revealing cell elongation that was subsequently blocked 
in the presence of either antagonist.  It was hypothesised that the activation of ROCK1/2 
and subsequent myosin light-chain (MLC) phosphorylation were directly linked to the 
reorganization of the actin cytoskeleton, leading to vascular cell contraction and migration 
(Ai et al., 2001, Surma et al., 2011).  Results revealed that GTP-bound Rho A protein was 
up regulated in HSV SMCs, following pamoic acid exposure.  To examine this more 
closely, Rho A and ROCK 1/2 activation was assessed in migrating cells using two distinct 
Rho A pathway inhibitors; Y-27632, a molecule which directly inhibits ROCK 1/2 activation 
(Narumiya et al., 2000) and Y-16, a novel RhoGEF interfering compound (Shang et al., 
2013). As hypothesised, GPR35 agonist-stimulated migration was found to be blocked 
following exposure to either compound, confirming that GPR35 mediated HSV SMC 
mediated migration involved the Rho A: ROCK 1/2 signalling axis. Others have reported 
similar effects of ROCK1/2 inhibitors in smooth muscle cell migration induced by PDGF 
and LPA in a collagen matrix migration model (Wirth et al, 2010). Despite ongoing efforts 
to target Rho A and downstream mediators in a disease setting (Barandier et al., 2003, 
Zhou et al., 2011), consensus suggests that blocking this pathway across a broad 
194 
 
spectrum of cell types may not be attractive therapeutically.  Alternatively, compounds 
which mimic this effect – such as GPR35 antagonists, may have distinct therapeutic 
advantages in the setting of vascular injury and remodelling (Sawada et al., 2000). 
Therapeutic interventions which are carried out in ex vivo setting, as required by CABG, or 
have the opportunity to be modified out with the body, as with and stenting, might provide 
further opportunities to target GPR35 effectively.     
By further exploring the role of GPR35 in a proliferative capacity, it has been shown that at 
least in HSV SMC, neither GPR35 activation nor inhibition produced any effect on cell 
proliferation. Furthermore, assessment of migration was also carried out within a 48-hour 
time-frame within serum free conditions, so as to limit the proliferative capacity of 
migrating cells. Taking these together, the results clearly demonstrate that enhanced HSV 
SMC migration was not a consequence of increased cell number within the mono-layer 
wound.   Conversely, HSV EC demonstrated significantly enhanced proliferation in the 
presence of increasing concentrations of the agonists zaprinast and pamoic acid, whilst 
neither cytoskeletal organisation nor migration were affected.  It is well known that GPCRs 
often exhibit diverse effects amongst cell types (Wettschureck and Offermanns, 2005).  
However, such differential roles for vascular cell types was largely unexpected. Ruling out 
potential issues regarding receptor specificity, the proliferative response induced by 
pamoic acid was blocked in the presence of human selective antagonists CID-2745687 
and ML-145 in a secondary assay assessing BrdU incorporation, strongly indicating that 
this effect was GPR35-mediated.  Furthermore, it has been previously demonstrated that 
ML-145 displays >1000-fold selectivity for GPR35 over its most closely related receptor, 
GPR55 (Heynen-Genel et al., 2010). Given that both antagonists produced identical 
effects on HSV EC proliferation at low, nanomolar concentrations it is unlikely that the 
specificity of ML-145 for GPR35 was compromised. This suggests that GPR35 activation 
may play a role in maintaining integrity and cell cycle progression in HSV EC.  
Fundamentally, these results suggest that GPR35 activation might exert a protective 
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effect upon the endothelium whist encouraging a pro-migratory response in SMCs and 
therefore, is counterintuitive for progressive remodelling following vein grafting.  In going 
forward, it will be important to assess a role for GPR35 within an in vivo experimental 
setting that accounts for both EC and SMC function. For example, reports have recently 
detailed successful investigation of a role for endothelial and smooth muscle cell function 
within intact vessels, demonstrating that the regulation of microRNA-21 is essential for 
neointimal formation to occur following stenting (McDonald et al., 2013).  A similar setting 
might present an opportunity to further assess of a role for GPR35 activation within an ex 
vivo capacity in the future. 
Results from this study not only indicate a role for GPR35 in vascular remodelling but 
further support existing evidence that GPR35 has significant implications for the 
development of cardiac hypertrophy. Two other investigations have reported a role for 
GPR35 in cardiac hypertrophy and subsequent progressive remodelling (Min et al., 2010, 
Ronkainen et al., 2014). Whilst the first demonstrated that adenovirus-mediated 
overexpression of GPR35 induced a hypertrophic phenotype in rat neonatal 
cardiomyocytes (Min et al., 2010), the second highlighted that endogenous GPR35 
expression is regulated via HIF-1 activation following exposure to hypoxia in vitro and this 
was subsequently confirmed in the setting of acute MI in mice (Ronkainen et al., 2014).  
Indeed, these authors purported that GPR35 might be a novel, highly sensitive indicator of 
acute progressive cardiac remodelling (Ronkainen et al., 2014). H9c2 cardiomyocytes 
have been extensively characterised within the setting of cardiomyocyte hypertrophy and 
in recent years, authors have demonstrated that their ability to exhibit hypertrophic 
responses, comparative to primary neonatal cardiomyocytes, following the measurement 
of cell size and hypertrophic gene markers such as BNP and ANP (Flores-Munoz et al., 
2011, Watkins et al., 2011). Given that H9c2 cells revealed a limited capacity for 
endogenous GPR35 expression, it was necessary to transiently express GPR35 and, 
considering that they originate from rat neonatal cardiomyocytes, transfection of rat 
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GPR35-eYFP was most appropriate in this setting. This prohibited the use of CID-
2745687 or ML-145, which are human-selective (Jenkins et al., 2012).  However, results 
demonstrated that zaprinast and amlexanox induced a hypertrophic response in H9c2 
cardiomyocytes and they also clearly showed internalised rat GPR35-eYFP following 
ligand exposure.  GPR35 internalisation was previously reported in cardiomyocytes, 
confirming receptor activation following exposure to zaprinast (Ronkainen et al., 2014).  
Whilst the response in H9c2 cardiomyocytes in this study revealed alterations to the 
cytoskeletal architecture arrangement, it also increased cell size and this was not 
previously demonstrated in cardiomyocytes following ligand exposure (Ronkainen et al., 
2014). Of course, within a functional setting, cardiomyocyte hypertrophy is a resulting 
factor of an adaptive cardiac response to improve cardiac output and function following 
exposure to ischemia and increased total peripheral resistance (Keteyian, 2013). 
Ultimately, it cannot be sustained and leads to progressive remodelling of the cardiac 
tissue and heart failure (Maillet et al., 2013). 
It is possible that GPR35 might also mediate its effects via the Rho A: ROCK 1/2 
signalling axis and reports have previously detailed its central role in Gα13 mediated 
cardiac remodelling and heart failure (Takefuji et al., 2012). Whilst previous reports 
showed that GPR35 up regulation resulted in cardiac hypertrophy, over expression 
resulted in tonic activation of GPR35 (Ronkainen et al., 2014).  This effect was not 
demonstrated here and it is important to take into consideration that experiments were 
performed in serum free conditions, thus eliminating potential endogenous activation 
following exposure to serum components, such as LPA (Oka et al., 2010, Kang et al., 
2004). Consequently, this might explain the requirement for exogenous agonist exposure 
in this study.  
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4.3.1 Conclusions  
This is the first study to demonstrate considerable expression levels and a functional role 
for GPR35 in the setting of vascular remodelling. Future investigations which address the 
mechanism of GPR35s effects on vascular endothelial cell proliferation will be integral in 
our understanding of its true function in vascular disease. However, the current findings 
strongly suggest that antagonists of GPR35 may be of beneficial therapeutic effect with 
respect to attenuating vascular occlusion in the setting of vein graft failure. Furthermore, 
this is a Gα13 mediated response via the Rho A-ROCK1/2 axis.  Furthermore, results here 
also provide further evidence for a role for GPR35 in the development of cardiomyocyte 
hypertrophy; taking this together with reports of a role for GPR35 expression in 
cardiomyocyte hypertrophy and progressive remodelling (Min et al., 2010, Ronkainen et 
al., 2014), it is possible that GPR35 may also constitute a potential therapeutic target in 
this setting. 
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5 Pharmacological agonism of GPR35 modulates blood 
pressure in the stroke prone spontaneously 
hypertensive rat 
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5.1 Introduction 
According to the most recent data from the British Heart Foundation, ≥30% of Scottish 
men and women are hypertensive, with blood pressure readings exceeding 140/90mmHg 
(BHF, 2012).  Critically, these statistics are representative of the larger western population 
which further indicate that the mortality risk associated with uncontrolled hypertension is 
as high as 40.6% (Go et al., 2014).  Designed to target specific pathways which regulate 
peripheral vascular resistance, cardiac output and kidney function, medications prescribed 
to alleviate the burden of hypertension include ACE inhibitors, β-blockers and diuretics 
and practitioners most often prescribe a combination of these therapies to target a wider 
range of pathologies (Gradman et al., 2010). A recent meta-analysis of 44 individual 
clinical trials indicated that two combined therapies can provide a 5-fold improvement in 
hypertension control compared to doubling the dosage of a single medication (Wald et al., 
2009).  Despite this, it has been estimated that 20-30% of hypertensive patients remain 
resistant to combination therapies (Calhoun et al., 2008b). Furthermore, results from the 
National Health and Nutrition Examination Survey (NHANES) 2006-2008 have highlighted 
that only 50.1% of hypertensive cases are adequately controlled by the medications 
currently available (Egan et al., 2010). Hence, there remains an unmet clinical 
requirement for improved and novel therapeutics (Egan et al., 2010).  
A role for GPR35 in the development of hypertension was previously explored following 
results from a microarray screen of myocardial tissue from heart failure patients, 
demonstrating that GPR35 expression was significantly increased in comparison to 
myocardial tissue derived from healthy ‘controls’ (Min et al., 2010). This finding led 
authors to further investigate a role for GPR35 in vivo, subsequently assessing 
haemodynamic parameters and cardiac hypertrophy in a global GPR35 knock-out mouse 
model, (Min et al., 2010).  Whilst heart weight remained unchanged, authors reported an 
increase in systolic blood pressure of up to 37.5mmHg, assessed via Millar pressure 
catheterisation in GPR35 knockout mice compared to wild type (WT) litter mates (Min et 
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al., 2010).  The reasons for this elevation in blood pressure were unclear; however, 
authors went on to assess the effects of GPR35 overexpression in primary rat neonatal 
cardiomyocytes via adenoviral transduction and reported that GPR35 overexpression 
induced a hypertrophic phenotype (Min et al., 2010).  Taking these findings together, it is 
clear that the development of hypertension and cardiac dysfunction are both sensitive to 
GPR35 expression, however, its mechanism of action is unknown and thus far, a role for 
GPR35 has not been further examined in the setting of hypertension.   
A role for GPR35 in the heart was further investigated in a very recent report from 
Ronkainen and colleagues who suggested that GPR35 may be a prominent novel marker 
of early progressive cardiac remodelling (Ronkainen et al., 2014).  Here, authors explored 
the effect of hypoxia on GPR35 expression in cardiomyocytes in vitro and demonstrated 
time-dependent increases in GPR35 expression following exposure to hypoxic conditions 
which was concomitant with increased expression of the gold-standard hypoxic marker 
gene EGL nine homolog 3 (PHD3) (Ronkainen et al., 2014).  This effect was also 
confirmed in cardiac tissue from mouse models exposed to acute myocardial infarction via 
ligation of the left anterior descending (LAD) coronary artery.  Most interestingly, closer 
inspection revealed that the promoter region of GPR35 contained a binding site for HIF1α 
and this was responsible for increased expression levels of GPR35 in the setting of 
progressive cardiac remodelling (Ronkainen et al., 2014).  In vitro overexpression of 
GPR35 in cardiomyocytes altered actin-cytoskeleton formation, however, this did not lead 
to hypertrophy (Ronkainen et al., 2014). Essentially, the regulation of GPR35 expression 
within the heart is now better understood, and thus, an opportunity to further assess a role 
for GPR35 activation in the setting of hypoxia, remodelling and hypertrophy is evident. 
Amlexanox is one of the most potent agonists identified at GPR35 to date (Mackenzie et 
al., 2014). Like zaprinast, it has demonstrated potent activation at all three species of 
GPR35, however, it demonstrates substantial selectivity for rat GPR35, exhibiting 
potencies as high as 4.5nM (EC50) (Chapter 4-2-7).  However, at higher concentrations, 
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amlexanox has also been shown to target inflammatory pathways, as daily oral gavage 
administration of 25-100mg/kg amlexanox over 4-weeks resulted in rapid weight loss and 
improved insulin responses in mice fed a high fat diet (HFD) (Reilly et al., 2013). Though 
its mechanism of action was not fully elucidated, authors reported that the effect resulted 
from increased thermogenesis and involved the inhibition of inflammatory targets of the 
NF-κB pathways; IKK-ε and TBK1 (Reilly et al., 2013).  Importantly, it was clear from this 
investigation that the inflammatory alterations were evident only following exposure to 
high concentrations of amlexanox in an in vitro setting.  Furthermore, these effects were 
mimicked following exposure to similar concentrations in vivo, whereby the administration 
of 25-100mg/kg amlexanox equated to micromolar levels in serum (Reilly et al., 2013). 
Given that amlexanox has demonstrated extremely high potency for GPR35, it has utility 
to test GPR35 functional effects in vivo at much lower concentrations, however, it is clear 
that careful dose administration will be required to selectively target GPR35 in this 
capacity.   
The stroke prone spontaneously hypertensive rat (SHRSP) is a widely utilised, gold-
standard model for the study of essential hypertension and investigators have detailed its 
use for more than three decades (Yamori et al., 1976, Delles et al., 2010).  Its use has 
enabled researchers to explore pathologies relating to various pathologies of the 
cardiovascular system, including hypertension (McBride et al., 2005), stroke (McCabe et 
al., 2009) and cardiac hypertrophy (Flores-Munoz et al., 2012). Most advantageously, 
hypertension is established by 10-weeks of age enabling researchers to study the 
progression of end-organ damage from an early time-point and therefore, the SHRSP has 
become the most utilised rodent model in the assessment of cardiovascular disease 
pathologies (Hultstrom, 2012).  Furthermore, in recent years, researchers have begun to 
examine the differences in gene expression profiles in the SHRSP compared to the 
normotensive reference strain, the Wistar-Kyoto (WKY) rat (Yamamoto et al., 2013, 
McBride et al., 2003).  This has led to the identification of various positional candidate 
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genes which might be involved in the development of hypertension, including Glutathione 
S-transferase Mu 1 (Gstm1), Sphingolipid G-protein-coupled Receptor 1 (Edg1) and 
Vascular cell adhesion protein 1 (VCAM1 ) (Delles et al., 2010). Further exploration of a 
potential role for these genes has been carried out via manipulation of expression in the 
SHRSP, for example, a role for Gstm1 has been highlighted in pathophysiological 
development of hypertension with particular implications for oxidative stress in the renal 
system (McBride et al., 2005).   
 
5.1.1 Hypothesis and aims 
Given that GPR35 is hypothesised to play a role in multiple pathologies related to 
cardiovascular disease (MacKenzie et al., 2011), further investigation in an experimental 
model of essential hypertension, and related end organ damage, might help to elucidate 
its function. Reports of an elevation in blood pressure following the deletion of the GPR35 
gene in mice has been central in driving the hypothesis that GPR35 activation may alter, 
or even lower, the blood pressure response. It is also hypothesised that this may have a 
direct impact upon vital organs, inclusive of the vasculature, heart and kidneys.  
Therefore, the aim of this chapter was to assess the effect of GPR35 activation on blood 
pressure and end-organ damage in the vasculature, heart and kidney of the SHRSP 
following amlexanox administration.  The SHRSP is an excellent such model for this, 
since hypertension is established at an early age, providing the opportunity to assess if 
GPR35 activation offers a protective effect against the development of hypertension and 
progression of end-organ damage.  A time-line of the events are diagrammatically outlined 
in Figure 2-3 (see section 2.22.1) and a series of aims devised to investigate this 
hypothesis are outlined below: 
• To assess the effect of a low dose of amlexanox on body weight and fat deposition 
in the SHRSP. 
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• To assess the effect of amlexanox administration on blood pressure in the 
SHRSP. 
• To assess the effect of sustained amlexanox administration on large and small 
vessel reactivity, ex vivo. 
• To assess the effect of amlexanox administration on end-organ damage in the 
heart and kidney of the SHRSP. 
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5.2 Results 
5.2.1 The effect of amlexanox administration on body weight and adipose 
deposition in SHRSPs 
Since micromolar concentrations of amlexanox administered to mice have been reported 
to alter metabolism and hence body weight and fat distribution via targeting IκB kinases 
IKK
-ε and TANK binding kinase-1 1 (TBK1)  (Reilly et al., 2013), it was hypothesised that 
oral administration of amlexanox at >10-fold lower doses (2.5mg/kg/day) in a larger rodent 
would result in comparatively lower serum levels, effectively targeting GPR35 at relevant 
concentrations (EC50 =4.5 ±0.17nM).  To assess if low dose amlexanox administration in 
the SHRSP induced any changes in body weight (BW), this was carefully monitored and 
recorded daily throughout the duration of the study. Importantly, no differences between 
the body weight of SHRSPs in the amlexanox treatment group compared to vehicle 
control treated animals were observed (Figure 5-1.A).  Further to this, upon animal 
sacrifice retroperitoneal and epididymal fat pads were immediately excised, weighed and 
ratios were corrected for either tibia length (Figure 5-1.B) or body weight (Figure 5-1.C). 
Again, there were no significant differences in fat pad ratios derived from either 
anatomical area between conditions (Figure 5-1.C&B).  Taking this together, it is clear that 
2.5mg/kg/day amlexanox neither affected whole body weight nor adipose tissue 
deposition in the SHRSP.  
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Figure 5-1. The effect of amlexanox administration on body weight and fat ratio in 
the SHRSP.  
A. Average body weight of SHRSP following oral administration of 2.5mg/kg/day 
amlexanox or vehicle control, measured in grams (g) every 3 days from age 6-13 weeks 
B&C. Fat ratios derived from retroperitoneal (RETRO) and epididymal (EPIDYD) regions, 
normalised to tibia length (TIBIA) (B) or body weight (BW) (C) following sacrifice at 12-13 
weeks of age.  Values are expressed as grams (g), grams/millimetre (g/mm) or 
grams/grams (g/g). n=5 animals per group. 
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5.2.2 The effects of amlexanox administration on blood pressure and 
haemodynamics in the SHRSP 
Global knockdown of GPR35 expression has been implicated in an alteration in blood 
pressure, leading to increased SBP of up to 37.5mmHg in mice (Min et al., 2010). 
However, it was not clear from these results if GPR35 activation would offer a protection 
from the development of hypertension in the SHRSP.  Given that SHRSPs aged 6-weeks 
are too small for invasive radiotelemetry probe implantation, systolic blood pressure was 
measured via tail cuff plethysmography for the first 20 days (Figure 5-2.A). This enabled 
an immediate, non-invasive assessment of the effects of GPR35 agonist administration to 
a rodent model of hypertension at a young age. There were no immediate differences in 
SBP between groups using this method of assessment, however, hypertension was 
evident after day 10 in both groups at which point the age-matched SHRSPs were 7-8 
weeks old (amlexanox; 122.0 ± 6.1 mmHg, control; 134.5 ±9.6 mmHg, p>0.05). The 
development of hypertension (>110mmHg) was early in comparison to alternative reports 
which report established hypertension in SHRSPs at 10 weeks of age (Hultstrom, 2012). 
Wireless telemetry probes were surgically implanted on day 14 and following a 7-day 
period of recovery, measurements were collected from animals in both drug and vehicle 
groups at 5 minute intervals for the duration of the study. Blood pressure measurements 
were averaged for light- (12hrs) and dark-cycles (12hrs) (Figure 5-2 and Figure 5-3).  
Blood pressure measurements derived from SHRSPs administered with 2.5mg/kg 
amlexanox daily exhibited elevated SBP throughout the study, for which the overall drug 
effect was significantly higher compared to vehicle treated animals (amlexanox; 164.2 
±3.6 mmHg, control; 142.3 ±5.7 mmHg; p<0.001) (Figure 5-2.A).  Similarly, this was true 
for mean arterial pressure (MAP) (amlexanox; 144.8 ±2.5 mmHg, control; 134.3 ±3.5 
mmHg; p<0.001) (Figure 5-3.A) and pulse pressure (PP) (amlexanox; 47.3 ±6.6 mmHg, 
control; 24.6 ±10.3 mmHg; p<0.001) (Figure 5-3.B). Contrastingly, there were no observed 
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differences in diastolic blood pressure between groups at any point throughout the study 
(Figure 5-2.B). 
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Figure 5-2. The effect of amlexanox administration on haemodynamic pressures in 
the SHRSP. 
A. Average systolic blood pressure (SBP) and B. average diastolic blood pressure (DBP) 
following oral administration of 2.5mg/kg/day amlexanox or vehicle control. SBP was 
measured via tail cuff plethysmography on days 0-20 and following radiotelemetry 
implantation on day 21, both SBP and DBP measurements taken at 5-minute intervals 
were averaged for every 12-hours on day 27-47.   Values are expressed as millimetres of 
mercury (mmHg).  Statistical significance *** p<0.001.  n=4 animals per group. 
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Figure 5-3. The effect of amlexanox administration on haemodynamic pressures in 
the SHRSP. 
A. Averaged mean arterial pressure (MAP) and B. Pulse pressure (PP) following oral 
administration of 2.5mg/kg/day amlexanox or vehicle control, measured via radiotelemetry 
implantation.  Values are expressed as millimetres of mercury (mmHg).  Statistical 
significance *** p<0.001.  n=4 animals per group. 
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5.2.3 The effect of amlexanox administration on heart rate and activity in 
SHRSPs 
Another benefit of wireless telemetry implantation is its continuous measurement of heart 
rate and locomotive activity in an unrestricted, stress free environment. Unlike the induced 
changes in blood pressure, there were no significant differences in heart rate (amlexanox; 
301.1 ±2.9 bpm, control; 306.3 ±11.2 bpm) or activity (amlexanox; 1.6 ±0.2 A.U., control; 
2.1 ±0.37 A.U.) following drug administration (Figure 5-4.A&B).  However, a significant 
diurnal effect was evident in both amlexanox (HR night; 346 ±10.8 bpm, HR day; 308.7 
±11.5 bpm, p<0.001), (activity night; 4.1 ±0.38 A.U., activity day; 1.6 ±0.2 A.U., p<0.001) 
and vehicle treated (HR night; 337 ±6.5 bpm, HR day; 310 ±10.6 bpm, p<0.001), (activity 
night; 4.3 ±0.31 A.U., activity day; 1.61 ±0.22 A.U., p<0.001) SHRSPs. This information 
indicated that the SHRSPs were most active during dark-cycle periods (12h) and least 
active during light-cycle periods (12h), consistent with reported nocturnal behaviour in 
spontaneously hypertensive rats (van den Buuse, 1994).  
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Figure 5-4. The effect of amlexanox administration on heart rate and activity in the 
SHRSP. 
A. Averaged heart rate (HR) and B. activity following radiotelemetry implantation on day 
21 (measured from day 27-47) in SHRSPs administered either 2.5mg/kg/day amlexanox 
or vehicle control.   Values are expressed as beats per minute (BPM) for HR and arbitrary 
units (A.U.) for locomotion activity.  There were no significant differences between 
conditions.  n=4 animals per group. 
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5.2.4 The effect of amlexanox administration on the reactivity of large 
vessels and small resistance arteries 
Thus far, results from this study suggest a role for GPR35 in primary vascular endothelial 
and smooth muscle cell function and blood pressure regulation.  Next, vasoreactivity of 
small and large resistance arteries were assessed in an ex vivo setting.  Following animal 
sacrifice, the mesenteric artery and thoracic aorta were excised and prepared for small 
and large vessel wire myography. To test the effect of 6-weeks amlexanox administration 
on contractile vasoreactivity, isolated arteries were incubated with increasing 
concentrations of phenylephrine (PE) or noradrenaline (NA).  Importantly, following 
stimulation with respective vasoconstrictors both vessels produced a concentration-
response curve, indicating vessel contraction.  However, there were no differences in 
concentration-dependent vessel contraction between amlexanox treated animals or 
control animals (Figure 5-5.A&B.). 
To assess endothelium-dependent vasorelaxation, vessels were then incubated with 
cumulative concentrations of carbachol, which induces the release of nitric oxide from 
endothelial cells to initiate vessel dilatation (Furchgott, 1999). Contrastingly, 
concentration-dependent inhibition curves demonstrated impaired relaxation in both aortic 
and mesenteric vessels from amlexanox treated animals compared to vehicle treated 
controls (Figure 5-6).  However, this effect was only significant in the aorta (amlexanox; 
41.56 ±6.14%, control 18.13 ±5.7%, p<0.01), not in mesenteric arteries (amlexanox; 67.8 
±15.6%, control 53.04 ±3.1%, not significant) (Figure 5-6). These results suggest that 
continuous amlexanox administration together with an increase in blood pressure in the 
SHRSP might have significantly impaired endothelial function in large vessels. 
Interestingly, the data also suggest that this effect may also be true for mesenteric vessels 
and future investigation to test this effect may require a larger number of animals per 
condition in order to improve statistical power. 
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Smooth muscle cell-mediated vasodilatation was assessed following exposure to 
cumulative concentrations of sodium nitroprusside (SNP), an endothelium-independent 
vasodilator (Morris et al., 2001). Both vessels exhibited a concentraion-dependent 
inhibition in vessel contraction to reach basal tension levels, however, there were no 
significant differences between vessel relaxation in amlexanox treated SHRSPs compared 
to vehicle treated SHRSPs (Figure 5-7). This data indicated that smooth muscle cell 
dependent vasoreactivity remained unaffected by amlexanox administration and 
subsequent increased SBP in the SHRSP.  
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Figure 5-5. The effect of amlexanox administration on the contractile response in 
aortas and mesenteric arteries of the SHRSP.  
A. Contractile concentration-response curve in the presence of increasing concentrations 
of phenylephrine (PE) in aortic rings derived from SHRSP animals upon sacrifice following 
6 weeks oral administration of 2.5mg/kg/day amlexanox or vehicle control B. Contractile 
concentration-response curve in the presence of increasing concentrations of nor-
adrenaline (NA) in mesenteric arteries derived from SHRSP upon sacrifice following 
exposer to 6 weeks oral administration of 2.5mg/kg/day amlexanox or vehicle control. 
Measurements were derived via wire-myography at 37°C. Values are expressed as 
percentage of maximal contractile response.  There are no significant differences between 
conditions.  n=4 animals per group (aorta) and n=3 animals per group (mesenteric artery). 
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Figure 5-6. The effect of amlexanox administration on endothelial cell mediated 
relaxation of aortas and mesenteric arteries of the SHRSP. 
The alteration of endothelial cell mediated relaxation in the presence of increasing 
concentrations of carbachol in aortic rings (A) and mesenteric arteries (B) derived from 
SHRSP upon sacrifice following 6 weeks oral administration of 2.5mg/kg/day amlexanox 
or vehicle control.  Measurements were derived via wire-myography at 37°C. Values are 
expressed as percentage of maximal contractile response.  Statistical significance * 
p<0.05, ** p<0.01. n=4 animals per group (aorta) and n=3 animals per group (mesenteric 
artery). 
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Figure 5-7. The effect of amlexanox administration on smooth muscle cell mediated 
relaxation of aortas and mesenteric arteries of the SHRSP. 
The alteration of smooth muscle cell mediated relaxation in the presence of increasing 
concentrations of sodium nitroprusside (SNP) in aortic rings (A) and mesenteric arteries 
(B) derived from SHRSP upon sacrifice following 6 weeks oral administration of 
2.5mg/kg/day amlexanox or vehicle control.  Measurements were derived via wire-
myography at 37°C. Values are expressed as percentage of maximal contractile 
response.  There are no significant differences between conditions. n=4 animals per 
group (aorta) and n=3 animals per group (mesenteric artery). 
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5.2.5 The effect of amlexanox administration on cardiac tissue mass and 
cardiomyocyte size in the SHRSP 
In Chapter 4-2-7, it was demonstrated that 200nM amlexanox and zaprinast-induced 
GPR35 activation mediated a hypertrophic phenotype in H9c2 cardiomyocytes, given that 
GPR35 expression has been most recently implicated in the development of heart failure 
in vivo (Ronkainen et al., 2014), the effects of continuous amlexanox administration on 
cardiac tissue and cell size were also assessed here. Following animal sacrifice at 12-13 
weeks of age, whole heart tissue mass was measured and upon cardiac dissection, left 
ventricle + septum mass were also measured.  As with fat pads, cardiac tissue weight was 
then normalised for either BW or tibia length. The first observation was that distribution of 
cardiac tissue weight following amlexanox administration exhibited a more variable mass 
in comparison to tissue from vehicle control animals (Figure 5-8). However, amlexanox 
administration did lead to significantly higher whole heart weight following independent 
normalisation for body weight (amlexanox mean; 3.82 ±0.08 g/g, control mean 3.61 ±0.01 
g/g, p<0.05) (Figure 5-8.C).  Histological analysis of the myocardium to image cross-
sectional areas of cardiomyocytes within the LV wall, stained using TRITC conjugated 
wheat germ agglutinin (WGA) was performed (Figure 5-9). Cardiomyocyte size was 
quantified by measuring the cell diameter using ImageJ software.  Cardiomyocyte cross-
sectional area revealed that amlexanox treatment induced a tendency for an increase in 
individual cardiomyocyte size, compared to vehicle controlled animals, however, the effect 
did not reach significance (p=0.067).  
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Figure 5-8. The effect of amlexanox administration on cardiac mass in the SHRSP. 
Average heart weight (HW) (A) or left ventricle + septum (LV+S) (B) normalised to tibia 
length in SHRSPs following oral administration of 2.5mg/kg/day amlexanox or vehicle 
control upon sacrifice at 13 weeks of age.  C&D. Average HW (C) or LV+S (D) normalised 
to body weight (BW) in SHRSP rats following oral administration of 2.5mg/kg/day 
amlexanox or vehicle control upon sacrifice at 13 weeks of age.  Values are expressed as 
milligrams/millimetre (mg/mm) or milligrams/grams (mg/g). Statistical significance * 
p<0.05. n=5 animals per group. 
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Figure 5-9.  The effect of amlexanox administration on cardiomyocyte size in the 
SHRSP. 
Average cardiomyocyte size in SHRSP rats following oral administration of 2.5mg/kg/day 
amlexanox or vehicle control. Upon sacrifice at 13 weeks of age, hearts were excised, 
weighed and left ventricle plus septum were fixed using paraformaldehyde embedded in 
paraffin and stained using TRITC conjugated wheat germ agglutinin (WGA) 
(representative images). Cardiomyocyte diameter was determined using ImageJ software 
and expressed as micrometres (µm).  n=4 animals per group. Scale bar = 50µm. 
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5.2.6 The effect of amlexanox administration on renal fibrosis in the SHRSP 
Hypertension is understood to contribute to end-organ damage in the SHRSP (Gelosa et 
al., 2009), and given that amlexanox treated SHRSPs revealed elevated systolic blood 
pressures compared to vehicle-only treated animals, the kidney was also assessed for 
damage histologically.  There were no significant differences in kidney weight between 
treatment conditions, normalised to both tibia length and BW (Figure 5-10). Histological 
analysis of picosirius red staining, specific for collagen type I and III to assess fibrosis, 
suggested that collagen deposition in kidneys from amlexanox treated SHRSPs was more 
uniform in comparison with vehicle-treated controls (Figure 5-11.).  This was confirmed 
following fibrosis quantification using Image ProPlus software.  Quantitative analysis of 
fibrosis in multiple cross-sections, specific for both interstitial and perivascular collagen 
deposition, revealed that amlexanox treatment significantly increased collagen deposition 
in both interstitial and perivascular regions (p<0.05 and p<0.001, respectively). 
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Figure 5-10. The effect of amlexanox administration on kidney mass in the SHRSP. 
Average kidney weight (A) normalised to tibia (TIBIA) length in SHRSP rats following oral 
administration of 2.5mg/kg/day amlexanox or vehicle control upon sacrifice at 13 weeks of 
age.  B. Average kidney weight normalised to body weight (BW) in SHRSP rats following 
oral administration of 2.5mg/kg/day amlexanox or vehicle control upon sacrifice at 13 
weeks of age.  Values are expressed as milligrams/millimetre (mg/mm) or 
milligrams/grams (mg/g). There were no statistical differences between conditions.  n=5 
animals per group. 
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Figure 5-11. The effect of amlexanox administration on renal fibrosis in the SHRSP. 
Representative images and quantification of kidney fibrosis derived from kidney tissue 
sections in SHRSP rats following oral administration of 2.5mg/kg/day amlexanox or 
vehicle control. Upon sacrifice at 13 weeks of age, kidneys were excised, weighed and 
were fixed using neutral buffered formalin, embedded in paraffin and sections were 
stained using picosirius red specific for collagen type I and III.  Interstitial and perivascular 
collagen deposition was quantified using Image ProPlus software and values are 
expressed as a percentage of non-stained sections. Statistical significance * p<0.05, ** 
p<0.01.  n=3-4 animals per group. Scale bar = 500µm. 
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5.2.7 The effect of amlexanox administration on gene expression in the 
heart and kidney of the SHRSP 
Given the effect of elevated blood pressure on end-organ damage in both heart and 
kidney tissue following amlexanox administration to the SHRSP, we next assessed the 
expression of both GPR35 and Gα13, its G-protein coupling partner, via real-time qRT-
PCR. Spleen tissue was used as a positive control for GPR35 expression, owing to its 
high expression (Wang et al., 2006a). Results demonstrated that neither GPR35 nor Gα13 
expression were altered in kidney (or spleen) following administration of amlexanox in 
comparison to vehicle-only control (Figure 5-12.A&B). Interestingly, GPR35 expression in 
the heart was elevated 2.7-fold (p<0.001) following drug treatment.  The mRNA 
expression of collagen type I and III genes were further assessed via quantitative RT-PCR 
in heart and kidney, revealing that collagen I and III expression were down-regulated in 
kidneys from amlexanox treated SHRSPs, compared to vehicle treated controls, and this 
effect was significant for collagen I expression  (P<0.001) (Figure 5-12.). This finding was 
unexpected, given that fibrosis was increased in kidney tissue following amlexanox 
treatment.  
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Figure 5-12. The effect of amlexanox administration on gene expression in tissues 
of the SHRSP. 
Expression of GPR35 (A) and Gα13 (B) in freshly isolated heart, kidney and spleen from 
SHRSP rats following oral administration of 2.5mg/kg/day amlexanox or vehicle control via 
real-time qRT-PCR and normalised to endogenous ribosomal 18s expression using 
respective TaqMan probes.  C&D. Expression of collagen type I and III in freshly isolated 
heart (C) and kidney (D) tissue from SHRSP rats following oral administration of 
2.5mg/kg/day amlexanox or vehicle control via real-time qRT-PCR and normalised to 
endogenous β-actin (heart) or ribosomal 18s expression (kidney) using respective 
TaqMan probes. Values are expressed as RQ, relative to control.  Statistical significance 
** p<0.01, *** p<0.001.  n=5 animals per group. 
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5.2.8 The expression of GPR35 in the heart and kidney in experimental 
models of hypertension 
To assess if GPR35 expression was altered in experimental models of hypertension 
compared to normotensive strains, expression levels were assessed at three ages (5, 16 
and 21 weeks of age) in Wistar Kyoto (WKY; the reference strain for the SHRSP) and 
SHRSP in the heart and kidney. GPR35 expression in the heart was significantly reduced 
after 5 weeks of age (p<0.001), however, this was not different between strains (Figure 5-
13.B).  GPR35 expression was increased with age (>16 weeks) in the kidney and this was 
significantly higher in the SHRSP compared to the WKY strain (p<0.05).  Therefore, this 
suggests that GPR35 expression in the kidney increases with age and is further 
exacerbated by hypertension.  Next it was assessed whether changes in GPR35 
expression were common in other experimental models with a hypertensive phenotype.  
Expression levels were assessed in heart, kidney and spleen (positive control) tissue 
derived from 12 week old C57BL/6 mice which have undergone continuous infusion of 
angiotensin II (AngII) at a dose of 400µg/kg/hr for 2-weeks via osmotic minipump 
compared to vehicle (dH2O) control infused C57BL/6 mice. Results demonstrated that 
GPR35 expression was not significantly different between conditions (Figure 5-13.A).  
Given that AngII-induced hypertension is established 2-weeks following infusion 
(Zimmerman et al., 2004, Clarke et al., 2013), temporal differences in gene regulation may 
be difficult to measure here. Ultimately, these results suggest that GPR35 expression is 
regulated differently, depending on the mechanism of hypertension involved. 
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Figure 5-13. Assessment of GPR35 expression in rodent models of hypertension 
A) Expression of GPR35 in freshly isolated spleen, heart and kidney tissue derived from a 
mouse model of hypertension, induced via angiotensin II (AngII) infusion or in control 
animals, assessed via real-time qRT-PCR and normalised to endogenous ribosomal 18s 
expression.  B&C) Expression of GPR35 in freshly isolated heart (B) and kidney (C) 
derived from WKY and SHRSP rats at 5, 16 and 21 weeks of age, assessed via real-time 
qRT-PCR and normalised to endogenous ribosomal 18s expression.  Values are 
expressed as RQ, relative to sham or vehicle control animal gene expression.  Statistical 
significance * p<0.05.  AngII/control n=5, WKY/SHRSP n=3 
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5.3 Discussion 
This study has assessed the effects of stimulating GPR35 pharmacologically in a model of 
essential hypertension. Most evidently, results have demonstrated that low doses of the 
novel, highly potent GPR35 agonist amlexanox exacerbated hypertension, increasing 
SBP by up to 20mmHg, compared to vehicle treated controls.  Furthermore, this study has 
also demonstrated that amlexanox administration affected end-organ damage, resulting in 
increased cardiac mass and renal fibrosis, and diminished endothelium-dependent 
vascular reactivity in the SHRSP.  Thus far, confirmation of the true endogenous ligand for 
GPR35 has been challenging given that KYNA demonstrates extreme species-selectivity 
between GPR35 orthologues with low potency for rat GPR35 (Jenkins et al., 2011). To 
this end, previous investigations as to the role GPR35 might play in the development of 
hypertension and cardiac hypertrophy predominantly focussed on the modulation of 
GPR35 expression, as opposed to its activation (Min et al., 2010, Ronkainen et al., 2014).  
However, recent advances in the identification of novel ligands for GPR35 have included a 
selection of mast cell stabilising compounds as high-potency agonists at GPR35 (Neetoo-
Isseljee et al., 2013, Mackenzie et al., 2014).  From this, the identification of amlexanox as 
a highly potent, surrogate agonist at rat GPR35 has provided an opportunity to examine 
the effect of GPR35 activation in the development of hypertension in a well-established 
model, the SHRSP (Mackenzie et al., 2014, Delles et al., 2010). 
It was important to note, however, that alternative targets for amlexanox within the NFКB 
pathway were recently reported, demonstrating that at serum concentrations higher than 
1-2µM (IC50), amlexanox inhibited IKK-kinases, IKK-ε and TBK1 (Reilly et al., 2013).  In a 
complex and extensive investigation, authors demonstrated that this led to an improved 
response to insulin sensitivity, reduced adipose inflammation and induced significant 
weight loss in mice fed a HFD (Reilly et al., 2013). These findings have attracted 
considerable scientific interest since, in recent years, modulators of IKK-kinases have 
emerged as attractive therapeutic targets in the treatment of chronic inflammation and 
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tumour progression via their interaction with NFКB and subsequent modulation of gene 
transcription (Clement et al., 2008). Importantly, the potency of amlexanox for rat GPR35 
is within the nanomolar concentration range and to selectively target GPR35, a 
comparatively lower concentration of amlexanox would be adequate (Mackenzie et al., 
2014). To assess if administration of 10-fold lower dosages of amlexanox (2.5mg/kg) 
reflected some of the findings described by Reilly et al, SHRSP body weight and fat mass 
were measured and results clearly demonstrated that both parameters remained 
unchanged throughout drug administration.  Consequently, the effects of amlexanox 
administration on the SHRSP could be better attributed to GPR35, which remains its only 
other reported target to date (Neetoo-Isseljee et al., 2013, Mackenzie et al., 2014).  
Whilst tail-cuff plethysmography was able to detect a time-dependent increase in SBP in 
SHRSPs for both groups, there were no observed differences between conditions before 
day 20. However, following implantation of the radiotelemetry probe, pressure readings 
were sensitive enough to identify an increase in SBP of up to 20mmHg in amlexanox 
treated SHRSPs.  Upon reflection, it is clear that radiotelemetry provided a more accurate 
blood pressure measurement than the tail-cuffing procedure owing to a less stressful and 
unrestrained environment.  Given this, it is unsurprising that this method remains the most 
widely utilised in small studies of rodent hypertension (Kurtz et al., 2005).  First developed 
over two decades ago (Brockway et al., 1991), radiotelemetry implantation has provided 
investigators with an extremely useful tool to assess the progressive development of 
hypertension and alternative parameters including heart rate and locomotion (Greene et 
al., 2007). In this study, given a period of recovery following surgical implantation, 
radiotelemetry was sensitive enough to determine diurnal blood pressure variations 
related to circadian rhythms in light- and dark-cycles and this is a commonly reported 
effect in the SHRSP (Calhoun et al., 1994). Whilst amlexanox administration did not 
appear to affect heart rate or locomotion in the SHRSPs, a substantial diurnal effect was 
clear when analysing the data for both measurements one week following surgical 
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implantation and this provided sufficient indication that the animals had recovered well 
(Greene et al., 2007). 
As discussed, the ambiguity related to the true endogenous agonist for GPR35 has 
hampered investigations to assess a role for GPR35 activation in a functional setting and 
therefore, the majority of studies have focused upon the regulation of its expression thus 
far (Min et al., 2010, Sun et al., 2008, Ronkainen et al., 2014). Prior to this study, a role for 
GPR35 in the development of hypertension was highlighted for the first time in a GPR35 
knock-out mouse model (Min et al., 2010).  Though investigators did not extensively 
dissect the phenotype of GPR35 KO mice, two parameters; blood pressure and cardiac 
mass were accounted for and via invasive Millar pressure catheter measurement in the 
right carotid artery, GPR35 KO mice had  up to 37.5mmHg higher SBP than WT 
littermates (Min et al., 2010).  Authors did not comment on a role for GPR35 here, 
however, it could be hypothesised that GPR35 expression and presumably, endogenous 
activation provided protection against the development of hypertension or, that GPR35 
might be involved in the maintenance of myogenic tone. In the current study, the SHRSP 
offered an excellent model to explore this hypothesis, given that hypertension is fully 
established at 10-weeks of age and therefore, any protection offered following GPR35 
activation following amlexanox administration may well be evident from an early time 
point. However, results here demonstrated that GPR35 activation is not protective against 
the development of hypertension in the SHRSP, but rather exacerbated its development 
resulting in an elevated SBP which was >20mmHg higher in amlexanox treated SHRSPs, 
compared to vehicle treated controls and this effect was evident throughout the study. 
In light of these contrasting indications, it is important to question the mechanism whereby 
GPR35 activation via amlexanox might lead to an increase in blood pressure.  One major 
contributing factor stems from the uncertainty of a true endogenous ligand(s) for GPR35 
or its potential concentrations in an in vivo setting (Milligan, 2011). It is possible that 
endogenous activity at GPR35 has been affected by the addition of a synthetic ligand, 
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altering its confirmation and thus physiological response.  Allosteric modulation is 
understood to either potentiate or inhibit endogenous activation via receptor interaction at 
a distinct binding position from the orthosteric (endogenous) site (Conn et al., 2009, 
Milligan and Smith, 2007). Given that amlexanox is a partial agonist at GPR35 and this is 
a common feature of allosteric agonists for class A GPCRs (Schwartz and Holst, 2007), it 
is possible that amlexanox is interfering with endogenous activation of GPR35 and this 
might promote signalling via alternative pathways to exacerbate hypertension. This mode 
of allosteric modulation is true for a number of GPCRs and a classic example relates to 
allosteric modulation of the chemoattractant receptor-homologous molecule (CRTH2) 
which can lead to functional selectivity resulting in the potentiation of G-protein 
independent β-arrestin signalling in T-helper cells (Mathiesen et al., 2005). To assess if 
amlexanox or indeed any other agonist at GPR35 displays allosteric modulation it is 
essential to assess their cooperativity alongside the true endogenous ligand in a wide-
range of primary and secondary endpoint assays in vitro, thereby identifying the mode of 
its potential allosterism (Smith et al., 2011).  Jenkins and colleagues have identified 
multiple overlapping binding sites belonging to KYNA and zaprinast (Jenkins et al., 2011).  
Given this, zaprinast could theoretically provide a robust substitute for KYNA in the 
required assays, however, evidence that KYNA is the true endogenous ligand at GPR35 
remains conflicted (Jenkins et al., 2011, Milligan, 2011). 
Mechanistically, peripheral resistance and vascular tone are modulated by vascular 
smooth muscle cell reactivity and a role for various GPCRs, including AT1R and ET-1 R, 
has been well characterised in the setting of vasoreactivity following acute vascular injury 
and exposure to increased shear stress (Touyz and Schiffrin, 2000).  Whilst Gαq activation 
and subsequent modulation of Ca2+ release is understood to be a major contributor to 
vasoconstriction, the activation of Rho A and subsequent ROCK1/2 signalling has also 
been implicated in the development of hypertension following the inhibition of MLCP via 
phosphorylation of MYPT-1 (Seko et al., 2003, Wirth, 2010). Given that results in an 
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earlier chapter from this study demonstrate that GPR35 activation in primary human 
smooth muscle cells led to a contracted phenotype mediated via Rho A/ ROCK1/2 
signalling (Chapter 4-0), it is possible that amlexanox administration has resulted in similar 
vascular effects to alter vascular tone in the SHRSP.  Taking this together with results 
demonstrating increased pulse pressure following amlexanox administration, it is possible 
that sustained GPR35 activation mediated its vasoconstrictive effects, at least in part, via 
vascular SMCs.  Importantly, studies have shown that pulse pressure is a precise, 
independent risk factor for coronary artery disease, vessel stiffness and end-organ 
damage, with particular implications for the renal system (Franklin et al., 1999, Safar et 
al., 2012).   
Despite an increase in pulse pressure following amlexanox exposure, arterial stiffness 
was not fully reflected in ex vivo experiments as results indicated that SMC-dependent 
vasorelaxation remained uncompromised in large and small resistance arteries derived 
from amlexanox treated SHRSPs. However, endothelium-dependent relaxation was 
reduced by more than 20% following exposure to maximal concentrations of carbachol in 
aortic preparations derived from amlexanox treated animals compared to vehicle controls.  
However, given that amlexanox administration promoted further elevations in SBP, MAP 
and PP in the SHRSP, increased shear stress within the vasculature may have resulted in 
endothelial cell loss and dysfunction, in turn compromising signalling between vascular 
endothelial and smooth muscle cells (Chiu and Chien, 2011). It is well understood that 
vascular endothelial cell dysfunction is able to perpetuate the hypertensive response and 
promote vascular disease via a reduction in nitric oxide (NO) release and enhanced 
recruitment of inflammatory mediators (Cai and Harrison, 2000). This remains to be 
studied in detail in the future. 
A role for GPR35 in cardiac hypertrophy was also explored in this model and while results 
indicated that amlexanox administration may promote an enlargement in cardiomyocytes 
situated within cross-sections of the LV wall, the effect was only significant for cardiac 
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mass at a whole tissue level. It is hypothesised that with larger sample numbers, this 
effect may have proved significant and future investigations may benefit from the 
application of a power calculation to judge the optimum sample size required to detect an 
effect. However, with regard to GPR35 expression, the small sample size was adequate 
to highlight a significant up regulation in the myocardium. Interestingly, these findings 
correlate with recent reports of HIF-1 mediated GPR35 expression in cardiac tissue 
undergoing progressive remodelling following ligation of the LAD coronary artery 
(Ronkainen et al., 2014). Importantly, HIF-1 activation has also been implicated in the 
early stages of pressure overload induced cardiac dysfunction and hypertrophy (Sano et 
al., 2007). An existing limitation of this study is that simultaneous HIF-1 activation was not 
assessed and therefore, it is impossible to draw parallels between HIF-1 activation and 
GPR35 expression directly in the SHRSP.  However, taking this information together, it is 
possible to hypothesise that GPR35 up regulation is a result of HIF-activation following 
pressure overload presented by an increased SBP in the SHRSP and this would be 
important to investigate in future studies.  Given that GPR35 expression has been 
repeatedly implicated in heart failure (Min et al., 2010), progressive remodelling and 
cardiomyocyte hypertrophy (Ronkainen et al., 2014) further investigation to dissect a 
mechanistic role for GPR35 in this setting will be required. 
Amlexanox treatment also resulted in significantly increased kidney fibrosis and this was 
highlighted within interstitial and perivascular regions of the kidney via collagen I and III 
staining. Renal blood flow accounts for up to 20% of cardiac output and therefore it is 
understandable that kidney reperfusion apparatus is highly sensitive to alterations in blood 
pressure (Nangaku and Eckardt, 2007).  This has been confirmed by reports of glomerular 
hyperperfusion and hypertrophy within juxtamedullary regions of the kidney following 
exposure to increased systolic blood pressure in the SHRSP (Hultstrom, 2012).  
Therefore, as with the heart, it is possible that exacerbated hypertension led to a 
progressive reduction in glomerular filtration and the resulting tubular atrophy and 
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apoptosis presented as increased interstitial fibrosis and perivascular remodelling in 
amlexanox treated SHRSP kidneys (Hultstrom, 2012). Remarkably, interstitial fibrosis is 
considered to be a significant hallmark in end-stage renal failure and given that both 
interstitial and perivascular fibrosis was evident at 12-weeks of age, GPR35 activation 
seems to have provoked a particularly aggressive response (Nangaku and Eckardt, 
2007).  There was no evidence of an alteration in GPR35 expression in the kidney 
following amlexanox administration.  However, GPR35 expression was also assessed in 
the heart and kidney of alternative models of hypertension and, whilst there were no 
significant alterations in expression following Ang II infusion in mice for either tissue, 
GPR35 expression was elevated at in the kidney of the SHRSP and the WKY at 21-weeks 
of age, and this was significantly higher in the SHRSP strain.  Though kidney damage is 
not often evident in the SHRSP before 30-weeks of age, it is understood that glomerular 
filtration starts to decline at 20-weeks as a result of sustained hypertension and therefore, 
this is often the earliest indicator of renal damage (Hultstrom, 2012). Given that this study 
has demonstrated sensitive regulation of GPR35 expression in suggested early stages of 
renal damage, it is possible that GPR35 may also be a highly sensitive gene-biomarker for 
progressive remodelling in the kidney, as well as the heart (Ronkainen et al., 2014) 
5.3.1 Conclusions 
In conclusion, this chapter has defined a novel role for GPR35 activation in both 
hypertension and its related end-organ damage to the vasculature, kidney and heart. 
Although more work is required to dissect whether end-organ damage is a result of 
increased peripheral resistance or GPR35 activation (or both), this can be realistically 
explored and compartmentalised within individual disease models in the future.  Most 
importantly, to fully examine a therapeutic potential for GPR35 antagonists in the setting 
of hypertension and progressive remodelling in the heart and kidney, a better 
understanding of GPR35’s endogenous agonist will be required. 
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6 General Discussion 
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6.1 Summary of main findings 
In this thesis I have undertaken an integrated analysis of a role for GPR35 in the 
progression of various pathologies related to cardiovascular disease. In the first results 
chapter, this study aimed to provide an in-depth characterisation of existing surrogate and 
endogenous GPR35 ligands, relating to their species-selectivity for both human and 
rodent orthologues of GPR35. In focusing on the species pharmacology of ligands, we 
have identified optimal tools to realistically explore a role for GPR35, both in vitro and in 
vivo, for the first time. In results chapter 4.0, a role for GPR35 mediated signalling was 
evident in the progression of vascular remodelling of primary endothelial and smooth 
muscle cells islolated from human saphenous veins. The final results chapter investigated 
pharmacological activation of GPR35 in vivo in the setting of hypertension and related 
end-organ damage in the SHRSP. The results of this research support the assertion that 
there is therapeutic potential for GPR35 antagonists in the setting of vascular remodelling, 
hypertension and end-organ damage in the heart and kidneys.  
Whilst previous studies have reported low level GPR35 expression in HUVECs (Barth et 
al., 2009), the results presented in this thesis suggest that GPR35 is robustly expressed in 
various vascular cell types, including HUVEC’s, HSV EC and SMCs.  Importantly, 
expression levels within HSV EC were comparable to those demonstrated in the colon, a 
tissue previously reported to express GPR35 highly (Taniguchi et al., 2006).  Previously, 
expression analysis of GPR35 has primarily focused upon gastrointestinal tissue, 
however, this investigation is the first to compare and contrast expression within tissue 
and individual primary cell populations to explore a potential role for GPR35 within the 
vasculature. 
Taking this together with the characterisation of novel, highly potent and human-selective 
GPR35 ligands; the agonist pamoic acid, and two distinct, competitive antagonists CID-
2745687 and ML-145 (Jenkins et al., 2012), an opportunity to assess a role for GPR35 
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within functional cell culture models relevant to vascular remodelling and vein graft 
occlusion in cells of a human origin was evident. In the assessment of the migratory and 
proliferative capacity of vascular endothelial and smooth muscle cells, results 
demonstrated that GPR35 activation altered the arrangement of cytoskeletal actin 
filaments to promote a migratory phenotype in HSV SMCs, and this was blocked in the 
presence of either of the human-selective GPR35 antagonists. Importantly, co-incubation 
with either antagonist provided confirmation for endogenous GPR35 activation in primary 
cells. This thesis is the first to assess these novel GPR35 antagonists in a 
pathophysiologically relevant functional model.  Moreover, the findings were further 
consolidated, as selective coupling of GPR35 to Gα12/13 following pamoic acid stimulation 
was observed in both the molecular pharmacological assays and the functional assays in 
primary HSV SMCs. Our results demonstrated that GPR35 mediated migration was 
completely abolished in the presence of two distinct Rho A and ROCK pathway inhibitors, 
Y-16 and Y-27632, respectively. Whilst Rho A signalling has broader implications for the 
maintenance and regulation of vasoconstriction, atherosclerosis and vascular remodelling, 
their current inhibitors have displayed questionable target specificity in vivo (Budzyn et al., 
2006). Therefore, blocking this pathway might not be advantageous in a wider therapeutic 
sense. Given that GPR35 antagonists are not reported to target elsewhere, the use of 
these compounds to inhibit GPR35 mediated Gα12/13 signalling and subsequent activation 
of Rho A and ROCK1/2 may prove beneficial for clinical applications whereby a window of 
opportunity exists for local delivery, such as those presented during CABG surgery or 
PTCA strategies (Conte, 2007). Currently, intervention strategies have explored the use of 
polymer coated DES and adenoviral-mediated gene therapy.  However, the patency rates 
of grafts and stents remain potentially compromised due to endothelial dysfunction and 
loss of the intact endothelial layer (Rienstra et al., 2008, Otsuka et al., 2012). 
Moreover, results from this study have highlighted a potential role for GPR35 activation in 
the maintenance of endothelial cell integrity and cell-cycle progression.  Using two distinct 
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assays, GPR35 activation produced a concentration-dependent increase in EC 
proliferation which was blocked upon co-administration with either GPR35 antagonist.  
Importantly, there remains a requirement for novel therapeutic targets which enhance re-
endothelialisation following stenting; for example, DES are subject to severe late stenosis 
due to a 50% reduction in re-endothelialisation following deployment (Joner et al., 2006). 
However, further research is required to truly delineate the role for GPR35 agonism/ 
antagonism in human ECs and SMCs. To assess if GPR35 antagonists might be useful in 
this setting, it would be relevant to assess if they also inhibited serum induced proliferation 
of HSV EC as this might reflect inhibition of endogenous GPR35 ligand mediated 
agonism. Of course, as with the results derived from the migratory capacity of HSV SMCs 
following serum stimulation, without knowledge of a true endogenous agonist, such as 
LPA (Oka et al., 2010), these results are challenging to interpret.  To understand the 
implications of simultaneously targeting GPR35 activation in both vascular cell types, 
further investigation is required.  As previously noted, it would be advantageous to assess 
this in an assay whereby neointimal formation is quantified within intact vein tissue 
following exposure to ligands (McDonald et al., 2013). Moreover, this setting would also 
be conducive to assess the effect of GPR35 mediated improvement in endothelial cell 
integrity and smooth muscle cell migration in the presence of hypoxia and/ or exogenously 
added inflammatory mediators, such as IL-β and TNF-α.  These are of particular 
relevance, since a very recent publication demonstrated that HIF-1α activation is able to 
directly up-regulate GPR35 expression in myocardial tissue in a time-dependent manner 
following exposure to hypoxic conditions (Ronkainen et al., 2014).  Additionally, it has 
been reported that GPR35 activation in monocytes promoted firm arrest to an endothelial 
cell monolayer under vascular flow conditions, suggestive of a role for GPR35 in acute 
vascular inflammation (Barth et al., 2009).   
Whilst the application of basic pharmacological approaches has provided us with a degree 
of certainty and specificity in targeting endogenously expressed GPR35 in cells of human 
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origin, the varied potency of ligands at multiple species orthologues has presented distinct 
challenges for the use of GPR35 agonists and antagonists within rodent models of 
disease.  Moreover, they also highlight implications for the conclusions of a role for 
GPR35 activation and nociception derived from a previous study employing the use of 
human-selective agonist pamoic acid in a mouse model which demonstrated that 
increasing dosages of pamoic acid reduced nociception following an acetic acid induced 
abdominal constriction test (Zhao et al., 2010). However, following reports that blood 
pressure readings in mice lacking GPR35 were significantly increased by up to 37.5mmHg 
(Min et al., 2010), it was hypothesised that GPR35 expression, and theoretically 
endogenous activation, might offer a protective effect against the development of 
hypertension or play a role in the maintenance of myogenic tone.  One experimental 
paradigm available to test this hypothesis was to assess the effect of GPR35 activation in 
the SHRSP, which at 10-weeks of age develops established hypertension 
(SBP>110mmHg) (Hultstrom, 2012).  The lack of an appropriate rodent specific antagonist 
was a limiting factor here, by which a reversal of the effects of GPR35-mediated signalling 
could not be fully dissected. In light of this, it was imperative to utilise an agonist with high 
potency and specificity for GPR35.  The identification of amlexanox resulted from a screen 
of mast cell stabilising compounds at GPR35 and therefore, it was already a marketed 
compound with known safety and bio-availability characteristics (Mackenzie et al., 2014, 
Neetoo-Isseljee et al., 2013). However, amlexanox was also recently reported to be an 
inhibitor of IKK-ε and TBK1 in mice, and its administration in rodent models induced a 
rapid reduction in body weight and improved insulin control at serum concentrations 
exceeding 1-2µM following administration at doses ranging from 25-100mg/kg/day (Reilly 
et al., 2013). Given that pharmacological assessment demonstrated that amlexanox has 
an EC50=4.5nM for rat GPR35, we hypothesised that 10-100-fold lower doses 
(2.5mg/kg/day) would be optimal to target GPR35 at relevant serum concentrations. In 
contrast to the observations reported by Reilly et al. we observed no change in body 
weight throughout the study or fat deposition following animal sacrifice (Reilly et al., 2013). 
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We were therefore confident that this low dose of amlexanox was sufficient to target 
GPR35 in the SHRSP and assess its effects on cardiovascular haemodynamics. To fully 
assess circulating concentrations of amlexanox within serum, it would have been optimal 
to carry out quantitative mass spectrometry in serum samples following exposure to 
increasing dosages of amlexanox and though serum samples were collected upon 
sacrifice, time constraints did not permit further exploration here (Lietz et al., 2013). 
Rather than exerting protection against the development of hypertension, pharmacological 
agonism of GPR35 exacerbated the hypertensive response and related end-organ 
damage in the heart and kidneys of the SHRSP.  Whilst this finding disproved our original 
hypothesis, upon further consideration, it was clear that these results reflected our 
findings from functional characterisation of HSV SMCs, given that a contractile phenotype 
was evident following a rearrangement in F-actin filaments in HSV SMCs following GPR35 
stimulation.  Essentially, SMCs are integral in vasoconstriction and together, the evidence 
suggests that an elevation in SBP and MAP may have been mediated, at least in part, via 
SMC contraction (Wang et al., 2009).  In future studies, it might also be interesting to 
investigate the arrangement of cytoskeletal filaments in arterial SMCs derived from larger 
resistance vessels, or even cells of the microvasculature, following exposure to GPR35 
ligands. Importantly, whilst there have been differences reported between ET1R subtype 
Ca2+ handling in excitation-contraction coupling in venous SMCs compared to arterial 
SMCs (Claing et al., 2002), there is no information to suggest that there might be any 
differences in the regulation of cytoskeletal architecture following ROCK1/2 mediated 
inhibition of MLCP between SMC subtypes. 
Importantly here, PP was also increased following amlexanox administration and studies 
have indicated that this is a robust independent marker of arterial stiffness and end-organ 
damage (Safar et al., 2012). These indications were partially reflected following the 
examination of vasoreactivity in small and large vessels and results demonstrated that 
endothelium-dependent relaxation in aortic samples from amlexanox treated SHRSPs 
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was significantly reduced by 20%, compared to vehicle treated control samples.  Despite 
a lack of evidence for compromised SMC dependent vasoconstriction in these 
experiments, the results indicate a degree of endothelial damage or dysfunction in the 
vasculature and this may have resulted from increased shear stress to induce endothelial 
cell loss and dysfunction (Chiu and Chien, 2011).  To further clarify this issue, it would be 
advantageous to directly assess the effect of ligand exposure on isometric tension in 
intact small and large arteries derived from normotensive animals. Whilst the SHRSP 
provided an excellent model to test our original hypothesis, it would now be relevant to 
assess if GPR35 activation also promotes hypertension in otherwise normotensive 
counterparts, such as the WKY, in future studies.  In doing this, it may also be possible to 
ascertain if an elevation in SBP, and thus total peripheral resistance, is responsible for the 
cardiac and renal related end-organ damage observed here. Findings within this study 
remain difficult to dissect in this sense, given that end-organ damage is established in the 
SHRSP from an early age time point - regardless of ligand exposure (Camargo et al., 
1993). 
In addition to an increase in SBP, MAP and PP, our findings suggest that amlexanox 
administration exacerbated damage to the heart and kidneys.  This was evident following 
whole heart mass assessment, which was significantly larger in SHRSPs treated with 
amlexanox compared to vehicle controls. Moreover, GPR35 expression was elevated by 
2.7-fold in the heart. Whilst there was no evidence of an alteration of GPR35 expression in 
the kidney, it was clear that amlexanox administration increased fibrosis in the kidney in 
both the interstitial and perivascular regions and these are suggested hallmarks of late-
stage renal damage (Nangaku and Eckardt, 2007). While the implications of 
pharmacologically targeting GPR35 in the heart or kidney are currently unclear, it is 
possible that this effect was primarily mediated by an elevation in SBP, however, results 
here may also be suggestive of a role for GPR35 as a primary mediator of remodelling, at 
least within the myocardium. This is particularly relevant given that we also demonstrated 
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that H9c2 cardiomyocytes underwent hypertrophy following transient transfection of rat 
GPR35 and stimulation with amlexanox or zaprinast.  Moreover, the elevation in GPR35 
expression reported here is concurrent with a recent publication which demonstrated HIF-
1α mediated up-regulation of GPR35 expression in the myocardium undergoing 
progressive remodelling in response to acute and chronic hypoxia (Ronkainen et al., 
2014) and an investigation which reported an up-regulation of GPR35 in the myocardial 
tissue derived from patients with heart failure (Min et al., 2010). Whilst authors have 
recently concluded that GPR35 expression might be a sensitive biomarker for progressive 
remodelling in the heart, results here suggest that GPR35 expression, and subsequent 
signalling via the Gα12/13 – Rho A – ROCK 1/2 axis, has broader implications for 
remodelling within the vasculature, myocardium and possibly, the kidney.  Essentially, all 
of the functional studies conducted thus far, in vitro and in vivo, suggest a therapeutic 
value for GPR35 antagonists within this setting and providing that screening to identify 
these at rodent orthologues continues, future experimental applications to define a role for 
GPR35 within these systems will be of enhanced value.  
Fundamentally, many of the findings reported here raise important questions relating to 
the ambiguity of endogenous activity of GPR35. While results from this study have 
confirmed previous findings of orthologue selectivity for the endogenous agonist KYNA, in 
that it demonstrates little efficacy or potency at human GPR35 (Jenkins et al., 2010), it 
has also highlighted that this was similar for KYNA activity at mouse GPR35.  Taking 
these findings together, evidence for a role for KYNA as the true endogenous agonist at 
GPR35 remains unconvincing.  Given that GPR35-mediated signalling following 
endogenous activation also remains uncharacterised, as does the possibility of allosteric 
modulation via surrogate synthetic ligands, the interpretation of the specific effect of an 
exogenous, synthetic agonist on hypertension and end-organ damage is challenging. This 
also has implications for a role for GPR35 activation in serum induced migration, which 
was inhibited following exposure of high concentrations of either human-selective GPR35 
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antagonist. The findings described here and their relationship to each other are illustrated 
with relevance to the published literature (Figure 6.1).  
In conclusion, this study has employed multiple approaches to pharmacologically target 
GPR35 in both human and rodent tissues of the cardiovascular system. Importantly, this 
translational approach has highlighted a role for GPR35 within a range of 
pathophysiological settings with relevance to cardiovascular disease and results suggest 
that inhibition of GPR35 mediated signalling may be therapeutically relevant in the 
treatment of vascular remodelling, hypertension and progressive remodelling of the heart 
and renal system.  In the future, it will be important to assess the effect of GPR35 
mediated signalling within individual disease models, however, to gain a better 
understanding of endogenous GPR35 activation, the identification of the true endogenous 
ligand for GPR35 will be key. 
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Figure 6-1. Summary of a role for GPR35 in the pathology of CVD. 
GPR35 activation promoted a contracted, migratory phenotype in HSV SMCs mediated via 
selective Gα12/13 activation of Rho A and ROCK 1/2, suggestive of a role for GPR35 in vascular 
remodelling and vasoconstriction. A resulting elevation in systolic blood pressure (SBP) following 
pharmacological GPR35 agonism in vivo has direct implications for renal and cardiac function 
following pressure overload and reports also suggest that activation of hypoxia inducible factor-1 
(HIF-1) may enhance GPR35 expression in these tissues (Ronkainen et al., 2014). GPR35 
activation induced a proliferative response in HSV ECs, which might offer vascular protection. 
Others have reported an increase in monocyte adhesion to vascular ECs following GPR35 
activation and together with increased SMC migration, a role for GPR35 in acute vascular 
inflammation and neointimal formation may also be evident (Barth et al., 2009). Literature also 
suggests that Rho A/ ROCK 1/2 signalling is implicated in cardiomyocyte hypertrophy, which was 
also evident in H9c2 cells and at the whole heart level in the SHRSP following GPR35 activation. 
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